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ABSTRACT. 
The interaction of the 2,3-diazanaphthalene, phthalazine and its 
1-substituted derivatives with the molybdenum hydroxylases, aldehyde 
oxidase and xanthine oxidase, has been investigated both in vivo and /Ok in vitro. 
Metabolic studies, carried out by treating rabbits with both cold 
and 
14C-labelled phthalazine, have shown that this compound is extensiv- 
ely metabolised in vivo, the major metabolite being a glucuronide con- 
jugate. Very little unchanged phthalazine or its molybdenum hydroxylase 
mediated oxidation product 1-hydroxyphthalazine were excreted in the 
urine. 
Pretreatment of rabbits with phthalazine or 1-hydroxyphthalazine 
had no effect upon the activity of the microsomal monooxygenases but 
caused a significant increase in the specific activities of both 
aldehyde oxidase and xanthine oxidase. 
Determination of the molybdenum content of purified aldehyde 
oxidase fractions using electrothermal atomic absorption spectroscopy 
has confirmed that an increase in the molybdenum content of the enzyme 
fraction accompanies the increase in activity. 
A qualitative assessment of purified aldehyde oxidase fractions 
using iso-electric focusing has indicated that this enzyme may be 
composed of 2 or 3 active variants and following pretreatment with 
either phthalazine or 1-hydroxyphthalazine a further band of enzyme 
activity is apparent on the electropherogram. 
The Km value for phthalazine is significantly reduced with enzyme 
prepared from phthalazine treated rabbits, indicating that a form of the 
enzyme with a high affinity for phthalazine may have been induced. 
1-Hydrazinophthalazine (Hydralazine) and two other hydrazine 
substituted N-heterocycles, endralazine and 1-hydrazinoisoquinoline have 
been shown to exert a potent progressive inhibition of aldehyde oxidase 
in vitro, effective only in the presence of substrate, but are inactive 
towards xanthine oxidase. 
In addition, administration of hydralazine to rabbits results in a 
significant reduction in liver aldehyde oxidase activity. Investigations 
into the interaction of some of the metabolites of hydralazine with 
aldehyde oxidase in vitro suggest that hydralazine is also the 
inhibiting species in vivo. 
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SECTION I 
GENERAL INTRODUCTION. 
0 
Compounds containing nitrogen heterocyclic rings are widely distri- 
buted throughout nature and often play an important role in biochemical 
processes. In addition, a large number of drugs in use today contain 
such ring systems. 
Oxidative reactions predominate in the Phase I metabolism of 
nitrogen heterocycles, which normally result in the hydroxylation of 
ring carbon atoms, although the heteroatom may serve as an alternative 
site for oxidative attack, leading to N-oxide formation. 
Two enzyme systems are responsible for oxidation of the carbon 
atoms of heterocyclic rings: - 
i) The microsomal monooxygenase system catalyses electrophilic attack 
involving molecular oxygen and requires NADPH as a cofactor. 1 The 
reaction catalysed takes the form: - 
rRH 
+ 02 + NADPH + H+ ºR- OH + H2O + NADP+ 
ii) The molybdenum hydroxylases, which are a group of cytosolic enzymes 
catalyse a. reaction which involves attack by a nucleophile, the oxygen 
introduced into the substrate being derived from water. 
2 
These enzymes, which include aldehyde oxidase and xanthine oxidase, 
catalyse the reaction: - 
-2e- -H+ 
RH R- OH 
+0H- 
2 
In contrast to the microsomal monooxygenases which play a major 
role in the oxidation of many carbocyclic compounds, the molybdenum 
hydroxylases require the presence of a nitrogen atom in the ring system 
0 of the substrate for activity. 
The difference between the groups of enzymes is exemplified by a 
comparison of the in vitro oxidation of several bicyclic ring systems. 
The simplest bicyclic ring structuret, naphthalene,, is oxidised via the 
microsomal monooxygenase system to an unstable epoxide intermediate 
which may isomerise non-enzymically to produce a mixture of 1-naphthol 
and 2-naphthol. 3' 4 Naphthalene is not a substrate for the molybdenum 
hydroxylases. 
naphthalene 
microsomes OH 
0 1-naphthol 
isomerisation 
0% 
epoxide - OH 
2-naphthol 
1-Azanaphthalene, quinoline, is'a substrate for both enzyme systems 
2-naphthol 
giving rise to three major metabolites when it is incubated with rabbit 
liver fractions. 5 
3 
0 
\IN 
quinoline 
aldehyde 
oxidase 
microsomes 
OH 
3-hydroxyquinoline 
microsomes 
HO 
II 
NONO 
HH 
2-hydroxyquinoline 2,6-dihydroxyquinoline 
(carbostyril) 
C 
2-Hydroxyquinoline, which exists preferentially as the non-phenolic 
tautomer carbostyril, is produced by the aldehyde oxidase mediated 
attack on quinoline, 3-hydroxyquinoline arises from microsomal oxida- 
tion of the parent compound, and 2,6-dihydroxyquinoline is produced by 
the microsomal oxidation of carbostyril. 
As the number of nitrogen atoms in the molecule increases, the 
molybdenum hydroxylases begin to play a predominant role in the 
oxidative biotransformation of these compounds. Consequently, the 
diazanaphthalene, quinazoline is a good substrate for-the molybdenum 
hydroxylases, being oxidised to 4-hydroxyquinazoline by both aldehyde 
/ 
oxidase and xanthine oxidase. Furthermore, this product is subsequently 
converted to 2,4-dihydroxyquinazoline by aldehyde oxidase, whereas only 
a small amount of microsomal product can be detected. 
6 
4 
0 
xanthine aldehyde 
oxidase oxidase 
0 
NH 
i J. N 
4-hydroxyquinazoline 
quinazoline 
aldehyde 
oxidase 
0 
NH 
llo N 
H 
2,4-dihydroxyquinazoline 
Finally,, pteridine, containing two nitrogen atoms in each ring, is 
6 
oxidised exclusively via the molybdenum hydroxylases, being converted to 
2,4-dihydroxypteridine by aldehyde'oxidase and '2,4,7-trihydroxypteridine 
by xanthine oxidase. 
7 
pteridine J NN 
xanthine aldehyde 
oxidase oxidase 
O 
N 
NH 
J NN 
4-hydroxypteridine 
aldehyde oxidase 
xanthine oxidase 
oN 
NH : 
ü, 
2,4-dihydroxy-7 
pteridine 
H 
xanthine 
oxidase 0 
N 
, NH I 
2,4,7-trihydroxy= 
NN0 pteridine 
HH 
5 
Although it is relatively easy to study the metabolism of these 
compounds in vitro, using isolated or partially purified enzyme systems, 
it becomes more difficult in vivo where Phase II metabolism may also 
occur producing water soluble conjugates which cannot easily be isolated 
using traditional extraction techniques. The three major metabolites 
isolated from the in vitro incubation of quinoline with, liver fractions 
have also been identified as products of the in vivo metabolism of the 
compound along with other metabolites, including 8-hydroxyquinoline, 
6-hydroxyquinoline and 5,6-dihydroxyquinoline. 8 The phenolic metabo- 
lites, which all arise from the microsomal monooxygenase mediated 
hydroxylation of quinoline, are further metabolised by conjugation to 
produce water soluble glucuronides and sulphates. 
9 
When additional groups are introduced into a heterocyclic molecule 
alternative sites become available for metabolic biotransformations 
mediated by other enzyme systems. For example, substitution of an amino 
group in the 2 position of quinoline means that N-acetyltransferase 
mediated acetylation of the amino group becomes an important metabolic 
route for this compound-10 
N-acetyl transferase 
I/ 
acetyl coenzyme A ý. / 
NH2 N NHCOCH3 
Induction or repression of enzyme activity by the foreign compound 
or its metabolites may add a further complication to the study of in 
vivo metabolism. For example, phenobarbitone is an effective inducer of 
6 
the microsomal monooxygenase system. 11 Conversely, alloxanthine, a 
metabolite of the drug allopurinol, is a potent inhibitor of xanthine 
oxidase, but is unreactive towards aldehyde oxidase. 12 
0 This thesis is primarily concerned with the interaction of phthal- 
azine (2,3-diazanaphthalene) and its derivatives with the molybdenum 
hydroxylases, both in vivo and in vitro. Consequently, the remainder of 
this section will describe the properties of the molybdenum hydroxy- 
lases, with a brief review of the microsomal monooxygenases being 
included to enable comparison between the two enzyme systems. 
THE MOLYBDENUM HYDROXYLASES. 
The group of enzymes known as the molybdenum-iron-sulphur-flavin 
hydroxylases includes aldehyde oxidase (EC. 1.2.3.1 ), xanthine oxidase 
(EC. 1.2.3.2) and xanthine dehydrogenase (EC. 1.2.1.37). 
These enzymes form a closely related group with very similar 
properties, but differ somewhat in their substrate specificities. Two 
of these enzymes, aldehyde oxidase and xanthine oxidase, are studied in 
this thesis, with the emphasis on the former enzyme. 
The term 'aldehyde oxidase' is a misnomer which arose because the 
enzyme was first identified by its ability to oxidise aldehydes. 13 
However, more recent work has demonstrated that a large number of' 
nitrogen containing non-aldehydic compounds are better substrates for 
the enzyme than aldehydes. 
14 
The reaction catalysed by the molybdenum hydroxylases can be 
expressed as: - 
7 
0 
H 
-2e- -H+ 
OH 
R-C=X R-COX 
+0H- 
0 
II 
R-C -XH 
where X-0 ,N or even C in rare cases. 
The enzymes function by being alternately reduced by substrate and 
reoxidised by either oxygen, NAD+, or an artificial electron acceptor. 
The oxygen incorporated into the enzyme is ultimately derived from 
water. 2 
Distribution. 
The existence of the molybdenum hydroxylases was acknowledged as 
early as 1891 and xanthine oxidase has been one of the most extensively 
studied of all enzymes. 
However, the existence of an 'aldehyde oxidising' enzyme, as 
distinct from xanthine oxidase, was not discovered until 1940 by Gordon 
et a1.13 This finding was later confirmed by Knox15 who related the 
'quinine-oxidising' enzyme from rabbit liver to aldehyde oxidase, 
showing that the enzyme was also capable of hydroxylating the quinoline 
nucleus. 
0 No detailed studies on the distribution of the molybdenum hydroxy- 
lases were carried out until thirty years later, when Wurzinger and 
Hartenstein16 investigated the occurrence of the enzymes in 79 species 
and Krenitsky et a117 looked at their tissue distribution among 8 
individual phyla. They found that although both enzymes were widely 
8 
distributed throughout most of the animal kingdom, being found in 
species as diverse as the sea anemone and man, the species differences 
in the levels of aldehyde oxidase activity were much more pronounced 
0 
than those of xanthine oxidase, especially among mammals. Compared to 
other mammals, the level of both enzymes appears to be low in humans, 
although other carnivores, e. g. dog and cat also have low levels of 
aldehyde oxidase. 
A study of bacteria shows that they contain both xanthine oxidase 
and xanthine dehydrogenase18 and Drosophila melanogaster contains 
aldehyde oxidase and xanthine dehydrogenase. 
19 Two isoenzymes of 
aldehyde oxidase have also been isolated from the potato tuber (Solanum 
tuberosum). 20 
. Both enzymes are most abundant in the liver and intestine of 
mammals, 17' 21 although bovine milk is a rich and commonly used source 
of xanthine oxidase. Rabbit liver has a high aldehyde oxidase activity, 
but very little xanthine oxidase17 and consequently is frequently used 
as a source of the former enzyme. 1 
Regulation of Activity In Vivo. 
In common with other enzymes, the activity of the molybdenum 
hydroxylases may be regulated in a variety of ways, including changes in 
the rate of synthesis or degradation, alteration in molecular activity 
and inhibition by products of reaction. The levels of these enzymes are 
also under genetic and hormonal control. 
The genetic control over mouse liver aldehyde oxidase is exerted by 
9 
a pair of autosomal alleles, one of which determines the high level and 
the other the low level of activity. 
22 Similarly, a locus which 
controls the level of xanthine oxidase has been identified. 23 In rat 
liver hepatomas, the activity of a key purine biosynthetic enzyme, 
glutamine phosphoribosyl pyrophosphate amidotransferase is increased at 
the expense of the purine catabolising enzyme xanthine oxidase. 
24 This 
shows a reprogramming of gene expression to favour purine synthesis over 
degradation and thus confers selective advantages to the cancer cell. 
Although interstrain differences are genetically controlled, the 2 
to 4 times higher activity in males than females of the same strain of 
mice indicates that the level of activity is also under hormonal 
control. This control is believed to be exerted by the androgen 
testosterone, which acts by induction of aldehyde oxidase synthesis, 
rather than activation of pre-existing molecules. 
25 
The level of enzymic activity may alter during adaptation to nutri- 
tional change. Rowe and Wyngaarden26 found that rat liver xanthine 
oxidase activity decreased during periods of protein insufficiency and 
increased on feeding a high protein diet. This increase in activity was 
ascribed to an increase in 'de novo' protein synthesis. 
Although increased protein synthesis is one means of alteration of 
® enzyme activity, a variation in the proportion of active and inactive 
enzyme can also effect a change. 
Itoh et a127 concluded that diet induced changes in molecular 
activity could result from a change in the proportion of an inactive 
form of the enzyme, known as 'desulpho' enzyme. 
10 
Johnson et a128 demonstrated that apoenzyme can be synthesised in 
the absence of dietary molybdenum and the metal later incorporated into 
the enzyme molecule, indicating that this is also a means by which the 
activity of the molybdo-enzyme could be regulated. 0 
When micro-organisms are grown on a purine rich medium, an increase 
in-the levels of both xanthine oxidase and xanthine dehydrogenase 
results. Studies show that this increase is due to the induction of 'de 
novo' protein synthesis, rather than activation of pre-existing non- 
functional enzyme. 29 Although purines can, to some extent, act as 
inducers of xanthine oxidase and xanthine dehydrogenase in the micro- 
organisms, it is believed that the end product of purine oxidation, uric 
acid, is the true inducer. 30 There appear to be no reports of similar 
substrate mediated induction of aldehyde oxidase. 
Biological Role. 
Despite the wealth of information accumulated on the structure and 
function of the molybdenum hydroxylases, their true biological 
significance is still unclear. 
In contrast to the microsomal monooxgenases, which are now generally 
regarded as detoxication enzymes because of the wide range of foreign 
compounds upon which they act, most of the work on xanthine oxidase and 
subsequently on aldehyde oxidase has been carried out under the assump- 
tion that the molybdenum hydroxylases exist solely to oxidise endo- 
genous substrates. 
The role of xanthine oxidase in the conversion of xanthine to 
uric acid is well known, but a genetic deficiency of xanthine oxidase, 
11 
termed xanthinuria does not appear to have any detrimental effect upon 
the health of those individuals suffering from the disease. 
31 Likewise, 
reduction of xanthine oxidase levels in rats, by treatment with tungsten 
0 evokes no change in the physical well-being of the animals. 
32 Thus, it 
appears that the presence of a xanthine oxidising enzyme in these 
species is not essential. 
Because of the close structural and functional similarity between 
aldehyde oxidase and xanthine oxidase, it has been suggested that they 
both arose from a common progenitor by gene duplication and 
subsequent modification. 
33 Although it had been previously postulated 
that aldehyde oxidase preceded xanthine oxidase phylogenetically, 
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Krenitsky33 suggested that the primordial enzyme was xanthine oxidase, 
based upon its presence in procaryotes. In comparison, the most primi- 
tive aldehyde oxidase is found in the sea anemone (Sagartia luciae). 
Both enzymes will oxidise'a large number of compounds, but the 
specificity and position of hydroxylation varies with each enzyme. 
Consequently, the enzymes can detoxify a wide range of pyrimidines, 
pteridines and related compounds. 
Although both enzymes are detected throughout most of the animal 
kingdom, the species differences in the levels of aldehyde oxidase are 
much more pronounced than those of xanthine oxidase. 
17 As the highest 
levels of aldehyde oxidase are present in herbivores, it has been 
suggested that the evolution of certain plants capable of synthesising 
toxic heterocycles, which xanthine oxidase was incapable of detoxifying, 
led to the development of a second enzyme, aldehyde oxidase, 
specifically to metabolise these compounds. The high levels of enzyme 
f 
12 
present in the small intestine and liver appears to constitute a 
protective barrier against ingested nitrogen heterocycles and confirm 
the above hypothesis-17 
0 
More recently, several other biological roles have been suggested 
for the molybdenum hydroxylases, in particular xanthine oxidase. Fried 
et a134 suggested that the main function of xanthine oxidase may not be 
oxidation of xanthine or hypoxanthine, but as a source of oxidising 
agents, e. g. hydrogen peroxide or superoxide anion in other coupled 
reactions. This was questioned by Bray2 in view of the fact that most 
xanthine, oxidase exists as a dehydrogenase in vivo. However, the 
finding by Krenitsky and Tuttle35 of two catalytically distinct types of 
xanthine oxidase, one of which exists as an oxidase in vivo may support 
the finding of Fried., 
An increase in xanthine oxidase levels in polymorphonuclear 
leucocytes of infected mice suggests that the enzyme may play a role in 
the bactericidal activity of the cells. 36 It is known that the 
destruction of bacteria by phagocytes is mediated by hydrogen peroxide 
or superoxide and thus it is believed that xanthine oxidase, a producer 
of these species, might participate in the oxidative process during 
phagocytosis. 37 
® Similarly,, an aldehyde oxidase isolated from guinea pig neutrophils 
is thought to detoxify aldehydes arising from phagocytosed amino acids, 
at the same time producing hydrogen peroxide and superoxide. 38 
There is some evidence for the participation of intestinal xanthine 
oxidase in the mucosal processing of iron in rats by oxidising and 
13 
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incorporating it into the mucosal transferritin. 39 It has also been 
suggested that rat liver xanthine dehydrogenase may participate in the 
liberation of iron from ferritin stores, by promoting reductive release 
of iron from the liver ferritin. 40 
Xanthine oxidase shows an ability to detoxify certain purine 
N-oxides, which are known to be oncogenic, 41 by reducing them to their 
free bases under anaerobic conditions and in the presence of an electron 
donor. 42 Guinea pig aldehyde oxidase has also been shown to function as 
a sulphoxide reductase under anaerobic conditions. 43 
Conversely, the enzyme has also been found to catalyse the binding 
of 1-nitropyrene to DNA. 44 As mutagenicity increases in the presence of 
liver homogenates and is dependant upon the presence of-hypoxanthine, it 
is believed that xanthine oxidase provides the necessary step in the 
metabolic activation of 1-nitropyrene to a bacterial mutalten. 
However, it is apparent from these studies, that overall, both 
aldehyde oxidase and xanthine oxidase play an important role in detoxi- 
cation processes. The probability that this is their prime function is 
supported by the wide substrate specificity exhibited by these enzymes. 
Substrate Specificity. 
AMý Both aldelde oxidase and xanthine oxidase catalyse the 
hydroxylation of a wide range of purines, pyrimidines, pteridines and 
aldehydes. However, despite the structural similarity of the two 
enzymes, the specificity for each substrate and the position of 
hydroxylation can vary greatly. 
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Krenitsky et a114 systematically compared the specificities of 
xanthine oxidase and aldehyde oxidase towards a wide range of sub- 
strates. Table 1 shows an extract of this work as an example of the 
diversity of the compounds hydroxylated and the difference in specifici- 
ty between the two enzymes. - 
Minor changes in a molecule can totally alter its specificity 
towards the two enzymes. For example, 2,4-dihydroxypurine i. e. 
xanthine, the 'classic' substrate for xanthine oxidase, is not 
hydroxylated by aldehyde oxidase, whereas 6-methylpurine is a good 
substrate for aldehyde oxidase but not xanthine oxidase. 
However, the enzymes differ not only in their substrate specifici- 
ties, but also with respect to the position of hydroxylation of the 
substrate. This is apparent when substrates have more than one site 
available for hydroxylation e. g., pteridines and purines. While 
xanthine oxidase converts purine to uric acid via the intermediates 
hypoxanthine and xanthine, aldehyde oxidase catalyses hydroxylation of 
purine in the 8 position only, although it can slowly convert hypo- 
xanthine to xanthine. Similarly, xanthine oxidase catalysed oxidation 
of pteridine produces 2,4,7-trihydroxypteridine, whereas aldehyde 
oxidase mediated conversion of this compound yields 2,4, -dihydroxy- 
pteridine (lumazine). 7 
The possibility that some substrates may be oriented in more than 
one way at the active site of the enzyme was suggested by Felsted and 
Chaykin, 45 who studied the oxidation of the quaternary compound, 
N1-methylnicotinamide, an intermediate in the in vivo metabolism of 
nicotinic acid. 
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Table I. Comparison of the Structure-Substrate Activity Relationships 
of Bovine Milk Xanthine Oxidase and Rabbit Liver Aldehyde 
Oxidase. 
Rate 
Substrate Structure Xanthine Aldehyde 
Oxidase Oxidase 
iH 
Acetaldehyde CH'0 <43 80 
Pyridine -1 
N 
CONH2 
N1-Methylnicotinamide <3 34 
CH3 
2-Hydroxypyrimidine 28 280 
HON: 
ýN 
OH 
4-Hydroxypyrimidine 130 134 
`N 
N 
100 100 Purine 
L 
N 
IC 
H 
CH3 
6-Methylpurine 
N 
<3 82 
NH 
. OH 
Hypoxanthine 130 3 N 
ýN N 
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Table 1. continued 
Rate 
Xanthine Aldehyde 
Substrate Structure Oxidase Oxidase 
to 
OH 
Xanthine 170 <1 
HO NH 
Pyrazolo [3,4d] 39 36 N 
pyrimidine N H 
Quinoline 1 <3 9 
N-Methyl- 
\IN <3 80 quinolinium 
CH3 
Pteridine 56 240 
OH 
N 
Pterin 
1 
100 <1 
NH= NN 
Initial rate at 24°C - pH 6.8 using potassium fericyanide as electron 
acceptor. - Rates relative to purine (100). 
Substrate concentrations 0.07mM for xanthine oxidase and 2.1mM for 
aldehyde oxidase. 
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Aldehyde oxidase catalyses the oxidation of this compound to two 
products, the 2- and 4-pyridones. 
CONH2 
1I N1-methylnicotinamide + N 
CH3 
O 
jycoNH2. 
CONH2 
II 
ONN 
CH3 CH3 
N1-methyl-2-pyridone- NI-methyl-4-pyridone- 
5-carboxamide 5-carboxamide 
Although the ratio of the 2 to the 4 pyridone is constant within 
one species, the ratio varies considerably in different mammals. 
N1-methylnicotinamide is not oxidised by xanthine oxidase at physiological 
pH, but at pH 9 to 11, where xanthine-oxidising activity is low, the 
enzyme acquires the ability to oxidise this compound to the 2-pyridone. 
46 
The quaternary compound phenazine methosulphate, which is often 
IV 
used as an electron acceptor for the enzymes, can also, under some 
conditions be oxidised by aldehyde oxidase to the 3-hydroxy derivative. 
47 
Hydroxylation of phenazine methosulphate, in common with the production 
of the 4-pyridone of N1-methylnicotinamide, is unusual in that oxidation 
does not occur at the carbon adjacent to the ring nitrogen. 
18 
0 
Ný 
CH3 
10-methylphenazine 
N 
\N0 
1 CH3 
10-methylphenazine-3-one 
Although Krenitsky et a114 compared the rates of oxidation of 
numerous compounds by aldehyde oxidase and xanthine oxidase, they did 
not investigate the nature of the oxidation products and in only a few 
cases did they calculate the kinetic constants for the oxidation 
reaction. The. majority of the substrates investigated by these workers 
are based on a two ring system containing nitrogen in both rings. Apart 
from quinoline, very few compounds consisting of a six membered carbo- 
cyclic ring fused to an N-heterocyclic ring had been studied, until 
Stubley6 undertook such an investigation. A number of simple mono and 
diaza-heterocycles were investigated in the presence of either aldehyde 
or xanthine oxidase in order to determine their substrate specificity 
by calculation of kinetic constants and to identify their oxidation 
products. 
The compounds studied were the monoazanaphthalene isoquinoline and 
qu 
the diazanaphthalenes quinoxaline, quinazoline, phthalazine and 
cinnoline. 
Calculation of the Michaelis Menten constants for these compounds 
indicated that they are among the best substrates so far discovered for 
aldehyde oxidase. However, only two of the compounds, phthalazine and 
quinazoline appear to be substrates for xanthine oxidase. 
19 
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Table 2. Simple Mono and Diazanaphthalenes, their Oxidation Products 
and Kinetic Constants. 
Apparent Michaelis-Menten 
constants (M) pH7.0,30°C. 
SUBSTRATE OXIDATION PRODUCT Aldehyde oxidase Xanthine oxidase 
54 
1- hydroxy- 1.96 x 10-4 
isoquinoline 
7 
(isocarbostyril) 
6 
0)2 
81 
Isoquinoline 
ý ýN 
ýI /N 
1-hydroxyphthalazine 9.9 x 10-5 2.55 x 10-3 
Phthalazine 
Quinazoline 
4-hydroxy- 
quinazoline 
2,4-dihydroxy- 
quinazoline 
1.46 x 10-5 2.50 x 10-4 
1.07 x 10-4 - 
N/ 
\ý 
N 
2-hydroxy- 
quinoxaline 
2,3-dihydroxy- 
quinoxaline 
%9i 
Quinoxaline 
Cinnoline 
4-hydroxycinnoline 
1.76 x 10-4 - 
5x 10-4 - 
1.39 x 10-4 - 
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As the corresponding monocyclic azines, eg. pyrazine, pyridazine 
and pyrimidine do not show any reaction with either aldehyde or xanthine 
oxidase, the presence of the fused benzene ring appears to be necessary 
for enzyme activity. 48 
0 
With one exception, these compounds are oxidised at the carbon 
adjacent to the ring nitrogen. This position is. normally the site of 
lowest electron density, thus facilitating nucleophilic attack on the 
substrate. In the case of cinnoline, the oxidation product was- 
identified as 4-hydroxycinnoline, oxidation occurring one carbon away 
from the nitrogen. However, electron density calculations indicate that 
this position is more susceptible to nucleophilic attack than carbon 3 
in cinnoline. 
Incubation of either quinazoline or quinoxaline with rabbit liver 
aldehyde oxidase gives rise to two oxidation products, but in the case 
of phthalazine, the third diazanaphthalene for which a dihydroxy product 
is theoretically possible, only 1-hydroxyphthalazine has been isolated. 
Drugs acting as-substrates. 
i) Folic acid and its analogues. 
NH2 rN N 
R COOH I2 01N 
N CH2 N/C HZCOOH 
R, 
R, - OH R2 =H Folic acid 
R, = NH2 R2 = CH3 Methotrexate 
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The folic acid analogue methotrexate (4-amino-4-deoxy-N10-methyl- 
pteroylglutamate), which is extensively used in the treatment of neo- 
plastic disease, is a very good substrate for rabbit liver aldehyde 
oxidase (Km =10-4M). 49 It is rapidly hydroxylated at position 7 of the 
40 
pteridine ring by the enzyme to produce 7-hydroxymethotrexate. This 
metabolite is two orders of magnitude less efficient than methotrexate 
as an inhibitor of dihydrofolate reductase50 and consequently, in 
rabbits, toxic levels of the drug are difficult to achieve. 
In humans methotrexate was believed to be excreted unchanged in the 
urine. However, since the introduction of 'high dose' regimens of 
methotrexate (>50mg/kg) for the treatment of osteogenic sarcoma, 51 the 
presence of 7-hydroxymethotrexate, in amounts of up to 10% of the total 
dose, has been detected in the urine. 52_ 
The proposal that folic acid is an effective agent in the treatment 
of hyperuricaemia has led to a study of the interaction of folic acid 
and its analogues with xanthine oxidase. 
53 Interestingly, it was found 
that both folic acid (Ki = 1.2 x 10-7M) and methotrexate 
(Ki = 2.5 x 10-5M) were extremely good competitive inhibitors of the 
enzyme in vitro. However, unless very high intracellular levels of 
folic acid are achieved, it is unlikely that the compound would be an 
effective chemical agent for the inhibition of xanthine oxidase in vivo. 
MM Similarly, although methotrexate levels in excess of 2.5 x 10-5M are 
achieved in 'high dose' chemotherapy, it is a transient state and 
unlikely to be of clinical significance. 
ii) Quinine. 
The antimalarial drug quinine contains both a quinoline and a 
22 
quinuclidine ring available for metabolic oxidation. 
0 
CH 
I% 
Quinine 
In rabbits, the major metabolite is 2'-hydroxyquinine, produced by 
aldehyde oxidase mediated hydroxylation of the quinoline ring. 
54 This 
is in contrast to the metabolism of quinine in humans, where the major 
metabolite arises from microsomal oxidation of the 3 position of the 
quinuclidine ring and only a small amount of the 2'-hydroxyquinine is 
produced. 55 
The antiarrhythmic drug quinidine, an isomer of quinine, is metabo- 
lised in a similar manner to quinine, although in man the major metabo- 
lite of this compound is the non-phenolic 2'-hydroxyquinidine. 56 
iii) 5-fluorouracil. 
Oxidation of the precursors of the antineoplastic drug 
5-fluorouracil-emphasises the differences in substrate specificity 
between aldehyde oxidase and xanthine oxidase. The compound 4-hydroxy- 
5-fluoropyrimidine can be oxidised to 2,4-dihydroxy-5-fluoropyrimidine 
23 
(5-fluorouracil) by xanthine oxidase but not aldehyde oxidase. 
57 
Conversely, whilst aldehyde oxidase can catalyse the conversion of 
2-hydroxy-5-fluoropyrimidine to 5-fluorouracil, this compound does not 
appear to be a substrate for xanthine oxidase. 
0 
FNF 
NH 
N0 LN 
-H 
2-hydroxy-5-fluoropyrimidine. 
aldehyde o: 
N 
H 
4-hydroxy-5-fluoropyrimidine. 
xanthine oxidase 
5-fluorouracil. 
Although it has been suggested that xanthine oxidase is responsible 
for the conversion of 4-hydroxy-5-fluoropyrimidine to 5-fluorouracil in 
human subjects, studies indicate that metabolic alteration of 2-hydroxy- 
AM\ to 5-fluorouracil does not occur in man. 
i 
iv) Nicotine. 
The conversion of nicotine to its major metabolite cotinine occurs 
via an unusual two step mechanism involving the oxidation of an iminium 
ion by aldehyde oxidase. 58 
1]") 
qu 
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The initial step in the metabolic process is the hydroxylation of 
the saturated ring system by an NADPH-dependant mixed function oxidase. 
The oxidation product, a carbinolamine, is thought to exist mainly in 
the form of an iminium ion at physiological pH. The second stage is the 
aldehyde oxidase catalysed hydroxylation of this iminium ion to produce 
the lactam metabolite cotinine. 
59 
mixed 
N fuction 
oxidase 
N CH3 
Nicotine 
N CH3 
iminium ion aldehyde 
oxidase 
1L N 
Cotinine 
H 
OH 
N: 
ý CH3 
Carbinolamine 
This mechanism of oxidation, whereby. the lactam metabolite of an 
unsaturated N-heterocyclic ring system is obtained is not unique to the 
metabolism of nicotine. It is. believed that the biotransformation of 
the a-adrenergic blocking agent azatepine to oxazatepine60 and the 
conversion of the anti-tumour drug cyclophosphamide to 4-keto- 
cyclophosphamide6l both proceed by a similar mechanism with the 
involvement of aldehyde oxidase. 
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0 
CHZ N\ 
ýO 
NCH2CH=CH2 CH2 p 
CH2-0 
. N(CH2CH2CI)2 
Azatepine Cyclophosphamide 
Molecular Properties 
Both aldehyde oxidase and xanthine oxidase consist of two identical 
sub-units, each with an active site, but with the dimeric structure 
being. necessary for activity. 
62. They have an approximate molecular 
weight of 300,000 and contain 2 atoms of, molybdenum, 8 atoms - of non-haem 
iron and 2 molecules of FAD per molecule of enzyme. 
63 
Examination of the absorption spectrum of xanthine oxidase (see 
figure 1) which, is very similar to, the spectrum from aldehyde oxidase, 
shows that the contribution of the flavin moiety only accounts for 35% 
of the total absorption at 450nm. 
64 
The difference spectrum of either aldehyde oxidase or xanthine 
oxidase, produced by subtraction of a stoichiometric amount of flavin 
from the oxidised enzyme, is very similar to the spectra of other iron 
qJ containing enzymes. For example, an essentially identical absorption 
spectrum characterises the non-haem iron of enzymes from the 
mitochondrial electron transport chain. 
63 
Deflavo aldehyde oxidase and xanthine oxidase, prepared by the, 
treatment of the enzymes with calcium chloride and calcium acetate , 
26 
I 
have absorption spectra which very closely resemble the difference 
spectra produced as above. 
65,66 
® The use of deflavo enzyme has permitted closer investigation into 
the site of reoxidation of the enzyme. As removal of flavin prevents 
oxygen-reductase activity, this indicates that the reduced Flavin 
chromophore is the site of interaction with molecular oxygen. However, 
the site of interaction with other acceptors, such as ferricyanide and 
2,6-dichlorophenolindophenol must be located elsewhere on the molecule, 
as they can function in the absence of the flavin component. 
65 
Anaerobic reduction of aldehyde oxidase by N1-methylnicotinamide 
results in the bleaching not only of the flavin portions of the 
spectrum, but of the iron contribution as well (see figure 2) suggesting 
that the iron participates in the, catalytic functioning of the enzyme,, 
presumably by undergoing reversible reduction and reoxidation. 
63 
A feature common to iron-protein complexes in which non-haem iron 
undergoes cyclic reduction and reoxidation is the presence of acid 
labile sulphur in an amount stoichiometric to iron. 
63 Treatment of 
aldehyde oxidase and xanthine oxidase with hydrochloric acid results in 
the evolution of hydrogen sulphide in an amount approximately stoichio- 
metric to the iron present. 
Table 3 summarises the composition and spectral properties of some 
of the molybdenum hydroxylases. 
The A280/A450 ratio gives 'an indication of the purity of the 
enzyme. If the preparation is spectrally good in the visible region, a 
ratio greater than 5 indicates contamination with a colourless protein 
27 
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Figure 1. Comparison of the Absorption Spectra of Native and Deflavo 
Aldehyde Ozidase. 
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Figure 2. Spectrophotometric Changes on Anaerobic Reduction of Aldehyde 
Oxidase by N1-Methylnicotinamide. 
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(4.8 is the best value obtained in the literature). As there is no 
contribution from flavin at 550nm, the absorbance in the 500 - 700 nm 
region is due solely to the iron constituent. The A450/A550 ratio gives 
® an indication of the iron-sulphur to flavin ratios. A value of 3 
represents a ratio of 4: 1. 
The Molybdenum Cofactor. 
The possibility that molybdenum may exist in the form of a cofactor 
was postulated by Nason et al67 who found that when extracts of a mutant 
(nit-1) of the fungus Neurosporra crassa, which lacked nitrate reductase 
activity (a molybdenum containing enzyme) were incubated with extracts 
from wild' type Neurosporra, the nitrate reductase activity was 
recovered. This activity could also be recovered by incubation of the 
mutant extracts with various acid-treated molybdenum containing enzymes, 
including milk or intestinal xanthine oxidase, rabbit liver aldehyde 
oxidase and chicken liver xanthine dehydrogenase. 
68 Similarly, it has 
been found that demolybdo sulphite oxidase, purified from the livers of 
tungsten treated rats can be reconstituted by a factor present in rat 
liver, human liver and Escherichia coli. 
69 
This suggests that the molybdenum containing enzymes may share a 
highly similar sub-unit. More recently,, there have been reports of the 
isolation of this cofactor in both inactive70 and partially active , 
AOL\ 0 
forms. 71 It has been shown to-'contain a novel pterin component with a 
sulphur bound at position 7 in the ring, 
72 possibly complexed with the 
molybdenum and covalently bound to the rest of the enzyme molecule. It 
has been suggested that the pterin component exists biologically in the 
reduced form, possibly playing a role in the oxidation-reduction state 
30 
of the molybdenum during catalysis. 70 However, the cofactor is very 
labile and upon attempted isolation is degraded, the molybdenum atom is 
lost and the pterin component is oxidised producing a concomitant 
characteristic fluorescence. 71 
0 
Hon Functional Forms of the Enzyme. 
As enzyme purification procedures improved, with the production of 
a virtually homogeneous preparation, 73 it became apparent that ordinary 
preparations of the molybdenum hydroxylases contained considerable 
amounts of non-functional enzyme. 
74 
i) Demolybdo Enzyme. 
Felsted et al, 75 after purifying rabbit and hog liver aldehyde 
oxidase to homogeneity, showed that although the enzyme contained a full 
complement of FAD and iron-sulphur groups the molybdenum content varied 
from 0.66-1.14 g. atoms of molybdenum per mole of enzyme, which is 
considerably less than the 2 g. atoms of molybdenum per mole previously 
found by other workers. 
63 Similar observations were noted by Hart et 
a176 who succeeded in producing milk xanthine oxidase of high specific 
activity by selectively decomposing the demolybdo enzyme with salicylate 
during the purification procedure. These workers investigated the 
origin of the demolybdo enzyme and concluded that it was also present in 
to 
milk prior to preparative procedures it must, be secreted together with 
active enzyme. 
It has been suggested that the amount of demolybdo enzyme is under 
nutritional control, as milk xanthine oxidase can be prepared with a 
high or low specific activity, depending upon the source of the milk. 
77 
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This was confirmed by the finding that treatment of rats with tungsten 
caused a decrease in xanthine oxidase and sulphite oxidase activity, by 
inhibiting the incorporation of molybdenum into the apoenzyme. 32 
ii) Desulpho Enzyme 
Following a purification procedure which involved removal of 
demolybdo enzyme from milk xanthine oxidase, a second modification of 
the enzyme was observed, characterised by the variability of enzyme 
activity relative to molybdenum content or absorbance at 450nm. 76 The 
existence of this form was confirmed when affinity chromatography 
separated a non-functional and a functional form of xanthine oxidase 
from enzyme possessing a full complement of molybdenum, FAD and iron- 
sulphur groups. 73 
The difference spectrum derived from non-functional and functional 
enzyme closely resembles that obtained following treatment of the enzyme 
with cyanide. It has been shown that this inactive form of enzyme, 
which arises spontaneously during preparation or storage, is identical 
to the 'desulpho' enzyme produced by cyanolysis of an essential sulphur 
present at the molybdenum centre of the enzyme. 78' 79 
Electron Acceptors. 
0 
The 'molybdenum hydroxylases may vary in their physiological 
electron acceptor. Those that preferentially utilise oxygen are termed 
'oxidases' and those for which oxygen is not an efficient electron 
acceptor are classified as 'dehydrogenases'. 
Purified preparations of mammalian enzymes are therefore classed as 
32 
'oxidases' because of their efficient use of oxygen as an electron 
acceptor. The enzyme from an avian source utilises NAD+ as its 
physiological electron acceptor and is termed a 'dehydrogenase', 80 as is 
the enzyme from Micrococcus lactilyticus for which ferredoxin is the 
most efficient electron acceptor. 81 
Xanthine oxidase has been-found to exist in many mammals as a 
NAD+-dependant dehydrogenase. 82- During purification and storage of the 
enzyme, interconversion from dehydrogenase (Type D) to oxidase (Type 0) 
activity occurs. This conversion, which can also-be effected by 
proteolysis, heating, organic solvents and sulphydryl modifying groups, 
involves either the removal or oxidation of specific thiol groups in 
the vicinity of the flavin chromophore, which are essential for NAD+- 
linked dehydrogenase activity-83,84 
Most oxidase forms, except when prepared by proteolysis, can be 
reconverted to the dehydrogenase form by incubation with dithio- 
erythritol, presumably by reduction of disulphide bonds to sulphydryl 
moieties. 83 
There have been no reports of a dehydrogenase form of aldehyde 
oxidase. 
Removal of the flavin group from aldehyde oxidase or xanthine 
0 
oxidase leads to the loss of oxygen-reductase activity, indicating that 
flavin is the site of interaction with molecular oxygen. 
65,66 
The reaction of the reduced enzyme with oxygen occurs in two 
distinct kinetic phases, the, rate of the first phase being approximately 
ten times that of the second phase. 
85 
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Olson et a186 proposed a mechanism for the biphasic reoxidation of 
xanthine oxidase, based on a combination of one electron and two 
electron transfers from the enzyme to oxygen. Reduction of the oxygen 
to produce the superoxide anion and hydrogen peroxide respectively can 
be represented by the following equations: - 
FADH2 + 202 FAD + 2H+ + 202 
FADH2 + 02 FAD + H202 
Xanthine oxidase can take up to six electrons to produce fully 
reduced enzyme. The fast phase of the reoxidation process corresponds 
to the removal of all but the last electron from the fully or partially 
reduced enzyme. The slow step represents the removal of the last 
electron. 
H202 H2O2 02 02- 
%0(6) 
y 
o-- %0(4) %0(2) 
- 
Ko(1) x0(0) 
K, K1 Ký K2 
H202 H2O2 Ki 
ao(5) ao(3) 
KI 
Each step in the fast phase involves complex formation between 
fully reduced flavin and oxygen. An electron is then transferred to 
the oxygen to produce superoxide. If the enzyme contains more than 2 
electrons, fully reduced flavin is rapidly regenerated by intra 
molecular electron transfer and another electron transferred to the 
superoxide anion to produce hydrogen peroxide. 
This sequence continues until 2 electron reduced enzyme is 
produced. At this stage, fully reduced flavin cannot be regenerated 
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after transfer of the first electron to oxygen and subsequently 
superoxide is rapidly produced. 
The final phase of the reoxidation process is second order and ý" 
involves the reaction of oxygen with the flavin semiquinone to produce 
the superoxide radical. 
In addition to the physiological electron acceptors, oxygen or 
NAD+, both enzymes are capable of transferring electrons to a number of 
oxidising agents, including ferricyanide, cytochrome C, methylene blue, 
2,6-dichlorophenolindophenol, phenazine methosulphate and nitro blue 
tetrazolium. 87' 83 
Although the electron acceptor specificity is very similar for both 
aldehyde oxidase and xanthine oxidase, one noticeable difference is that 
the quinone, menadione, is an electron acceptor for xanthine oxidase, 88 
but a potent inhibitor of aldehyde oxidase. 
87 
Information about the interaction of each electron acceptor with 
the enzyme is largely derived from results obtained from modification of 
the'prosthetic groups eg. removal of flavin and the use of inhibitors of 
the electron transport process. 
89 
The electron acceptors can be-divided into four groups: " 
a) Those that interact'with the molybdenum centre, in particular 
2,6-dichlorophenolindophenol (DCI). - This compound forms a spectro- 
photometrically detectable complex with the enzyme bound molybdenum and 
can competitively inhibit the enzyme catalysed oxidation of a reducing 
substrate-90 f 
b) Those that interact with an iron-sulphur centre. Included in this 
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group are ferricyanide, methylene blue (MB) and possibly phenazine 
methosulphate (PMS). 
c) Those that interact directly with flavin. Nitro blue tetrazolium 
(NBT), oxygen and NAD+ fall into this category. 
d) Those that react with reduced forms of oxygen. The reduction of 
cytochrome C is mediated by the superoxide anion produced during 
turnover and can be inhibited by the addition of superoxide dismutase, 
which catalyses the reaction: 
88 
02 + 02 + 2H+ º H202 + 02 
In aldehyde oxidase there is a strict requirement for molecular 
oxygen and deflavo enzyme is devoid of cytochrome C reductase 
activity. 
65 However, it has been reported that deflavo xanthine oxidase 
can reduce cytochrome C anaerobically or aerobically, presumably by 
interacting at the iron-sulphur centre-91 Similarly, it appears that 
the nitro blue tetrazolium reductase activity of xanthine oxidase is 
mediated via the superoxide radical, or by direct interaction with the 
iron-sulphur centre whereas in aldehyde oxidase the dye is reduced by 
superoxide or by direct interaction with the flavin chromophores. 
92 
It has been demonstrated that in the absence of a conventional 
electron acceptor, the purine N-oxides can serve as slow oxidising 
agents, being reduced back to the parent base. 
42 Nicotinamide N-oxide 
1 
can also be reduced in a similar manner, but this compound is of 
particular interest since Murray et a193 demonstrated that xanthine 
oxidase can catalyse the direct transfer of 
180 from nicotinamide- 
180 N-oxide to xanthine, in the course of uric acid formation. This is in 
direct contrast to the normal reaction of xanthine oxidase, whereby the 
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oxygen incorporated into the reducing substrate is derived from water. 
A number of nitro compounds eg. nitrofurazone have also been found 
to act as electron acceptors for aldehyde oxidase94 and xanthine 
oxidase95 being reduced to the corresponding hydroxyamino derivative. 
Whilst the nitro-reductase activity of xanthine oxidase requires 
absolute anaerobic conditions, the aldehyde oxidase system is less 
susceptible to inhibition by molecular oxygen and therefore may be more 
likely to occur at physiological oxygen tension. 
Mechanistic Studies on the Molybdenum Hydroxylases. 
Although a limited amount of information on the oxidation states of 
molybdenum, iron and PAD has been derived from optical spectroscopy, the 
use of electron paramagnetic resonance (e. p. r. ) spectroscopy, potentio- 
metric titrations and extended X-ray absorption fine structure spectro- 
scopy (EXAFS) has provided much of the recent information on the 
structure and function of the molybdenum hydroxylases. 
i) Flavin. 
Enzyme bound flavin can exist in 3 oxidation states, each of which 
may have different states of protonation, although only the semiquinone 
is paramagnetic and so used for e. p. r. studies. 96 The partially reduced 
a flavin semiquinone provides an e. p. r. signal at g=2.004 in both aldehyde 
oxidase97 and xanthine oxidase. 98 
(N. B. The g value is determined by the ratio of the magnetic field 
H, to the microwave frequency at which resonance occurs). 
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The signal has a peak line width of 19.4 gauss in xanthine 
oxidase, 99 suggesting that the flavin is present as a blue or neutral 
semiquinone. 10° In aldehyde oxidase, the peak line width of 16.4 
gauss97 is characteristic of absorption in-the red part of the spectrum 
and indicative of the anionic form of the semiquinone. 10° Following 
reduction of aldehyde oxidase by substrate, less than 5% of the total 
flavin occurs in the semiquinone form and the e. p. r. signal is 
resultantly weak-101 Potentiometric titrations of aldehyde oxidase also 
show that the FAD is more easily reduced than in either xanthine oxidase 
or xanthine dehydrogenase. 
102 
ii) Iron-Sulphur Centres. 
E. p. r. studies of reduced enzyme indicates the existence of two 
different iron-sulphur systems present in both aldehyde oxidase97 and 
xanthine oxidase. 99 
The first system, referred to as Fe/SI, has a signal at gs1.95, 
is very similar in both enzymes102 and resembles a typical plant 
ferredoxin. 103 The appearance of the low field component Fe/SII, with a 
signal at g=2.02 is temperature dependent and although the centre is 
apparently similar in both aldehyde oxidase and xanthine oxidase, it is 
distinctly different from the Fe/SI centre. 104 
10 Integration of the e. p. r. signals indicates that Fe/SI and Fe/SII 
each account for one electron per half molecule in a fully reduced- 
enzyme99 and by analogy to the ferredoxins they may both consist of 
2 iron-2 labile sulphur units, one of each being present in each enzyme 
sub-unit. 
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As molybdenum makes no contribution to the absorption spectrum, the 
spectrum of deflavo enzyme results from the Fe/S chromophore. 
Determination of the individual contributions of each of the Fe/S 
centres shows that in xanthine oxidase, the Fe/SI system accounts for 
80% and the Fe/SII system the remaining 20% of the absorption at 
550nm. 104 
While e. p. r. work has shown that magnetic interactions exist 
between molybdenum and the Fe/SI and FAD and Fe/S centres in both 
enzymes, 102 there is no interaction between molybdenum and FAD or 
between molybdenum and Fe/SII in xanthine oxidase. 
105 
It has also been reported that there is no interaction between the 
two reduced Fe/S centres in aldehyde oxidase, "although some interaction 
is apparent in xanthine oxidase. 
106 Oxidation-reduction studies have 
also shown that whereas in xanthine oxidase Fe/SII has a greater 
affinity for electrons than Fe/SI, the opposite appears to be true for 
aldehyde"oxidase. 106 Consequently, there appear to be differences in 
the structure and possibly the environment of the Fe/S centres in 
aldehyde oxidase compared to xanthine oxidase. 
iii) Molybdenum. 
As molybdenum makes no contribution to the absorption spectra of 
the molybdenum hydroxylases, knowledge about the reduction and 
reoxidation of the metal comes almost entirely from e. p. r. studies. 
Although molybdenum can theoretically exist in any valency from six 
downwards, only the trivalent and pentavalent states are paramagnetic 
and in the molybdenum hydroxylases, the e. p. r. spectra are derived from 
the pentavalent state. 
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The molybdenum signal has 'a g value of 1.97 and there appear to be 
at least five major types of the signal produced from the pentavalent 
metal in these enzymes. 2 
Oxidised xanthine oxidase does not normally give an e. p. r. signal 
and is assumed to contain only Mo(VI). In contrast, a small signal is 
obtained from oxidised aldehyde oxidase, corresponding to approximately 
4% of the molybdenum present in the pentavalent state. This signal, 
termed the 'Resting' signal does not appear to be derived from 
functional enzyme as it is not affected by oxidising agents and is 
unchanged in`intensity when the active enzyme is reduced. 97 
On reduction of xanthine oxidase with some substrates, two signals 
are produced, termed 'Rapid' and 'Very Rapid'. 
107 The 'Rapid' signal is 
believed to be due to reduced enzyme alone, whereas the 'Very Rapid' 
signal is due to the reduced enzyme with substrate bound-108 The 'Rapid' 
signal shows splitting due to the presence of a proton and the 
relationship between the two signals appears to be pH dependant-109 
110 
Aldehyde oxidase produces a 'Rapid' signal which can be resolved 
into two individual signals 'Rapid Type I' and 'Rapid Type, II'. 
11 1 The 
'Type I' e. p. r. spectrum `is comparable to the 'Rapid' signal in xanthine 
oxidase and potentiometric titrations provide similar values for the 
'Rapid' species in both enzymes. 
102 
The 'Inhibited' signal arises from the treatment of active enzyme 
with methanol. It is a stable signal, not involved in enzyme turnover 
and arises from the coupling of a single non-exchangeable proton, 
derived from the reaction product, with pentavalent molybdenum-112 
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A furthur type of inhibited signal has been produced by both 
aldehyde and xanthine oxidase. This contains molybdenum in a 
pentavalent state, resistant to oxidation and reduction. The species 
can be derived from native enzyme in a two step process, firstly, 
conversion to 'desulpho' enzyme and secondly reaction with ethylene 
glycol. This species gives a characteristic Mo(V) e. p. r. signal, 
designated 'Resting II' or 'Desulpho Inhibited' and is virtually 
identical to the species occurring naturally in non-treated rabbit liver 
aldehyde oxidase. 113 
The final type of signal is the 'Slow' signal, present in both 
aldehyde oxidase111 and xanthine oxidase. 
114 This signal arises by 
reduction of 'desulpho' enzyme with dithionite. 
Reduction of active xanthine oxidase, labelled with 
33S in the 
cyanide labile site of the molybdenum centre shows strong coupling from 
the 33S. to the molybdenum, providing evidence that in the signal giving 
species, a sulphur atom is present as a ligand to molybdenum-114 
Originally, it was thought that the cyanide labile sulphur was 
present in a persulphide group. 79 However, more recent e. p. r. 
spectroscopy and extended X-ray absorption fine structure work115 
supports the proposal of Gutteridge et al116 that in the active enzyme 
the sulphur is present as a terminal sulphur of the molybdenum ie. 
(Enz)-Mo=S and in the desulpho form the sulphur is replaced by oxygen to 
give. (Enz)-Mo=O. Protonation of these groups would give (Enz)-Mo-SH for 
functional and (Enz)-Mo-OH for desulpho enzyme respectively. Besides 
this terminal sulphur atom it has been suggested that other ligands to the 
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molybdenum may be sulphur atoms from two cysteine and one methionine 
residue and there is some question as to the presence of a terminal 
oxygen group in the active enzyme. 117 
0 Electron Transfer Sequence. 
The exact arrangement of the redox groups within an enzyme sub-unit 
is not known, but a study of the magnetic interactions between the 
groups has provided some information. 
The finding that removal of flavin has no effect upon the e. p. r. 
signal of molybdenum or the iron-sulphur: centres indicates that it is 
not directly bound to either of these groups and is possibly located 
some distance from them. 66 Lowe et all 18 estimated the distance between 
molybdenum and Fe/SI to be between 10A and 25A. More recent studies105 
have measured interactions between all the prosthetic groups in xanthine 
oxidase and postulated distances-between the groups of-the same order of 
magnitude as those quoted by Lowe'et "al". 'A study of aldehyde oxidase106 
shows similar interactions between the groups, the molybdenum centre 
appearing to be very similar in all of the molybdenum hydroxylases. 
However, slight alterations in the magnetic interactions indicate that 
some differences may exist in the structure and the environment of other 
prosthetic groups compared to xanthine oxidase. The differences between 
the groups leads to questions as to how the electrons are transported 
within the enzyme. 
Bray et ai107 suggested a linear sequence of electron transport 
from substrate to molybdenum to flavin to Fe/S. Subsequent studies have 
shown that this is not the case and the redox centres are now accepted 
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as being arranged in a non-linear fashion, with reversible electron 
transfer taking place between the groups. 
Figure 3. Postulated Non-Linear Electron Transfer Sequence and Site of 
Electron Egress to Acceptors. 
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Mechanism of Hydroxylation. 
E. p. r. studies have shown that during catalysis a hydrogen atom AVVk 
V 
from the carbon undergoing hydroxylation is transiently coupled with 
molybdenum. 2 Although no mechanism of hydroxylation has been postulated 
recently for aldehyde oxidase, several have been suggested for xanthine 
oxidase. 
I 
It was originally proposed that hydroxylation occurred by removal of 
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a hydride ion from the substrate and replacement by a hydroxyl ion. 
119 
The investigators suggested that this attack would be facilitated if 
the enzyme provided a group to act as a Lewis acid, ligating the 
'nitrogen adjacent to the carbon to be hydroxylated. 
Several years later, however, Stiefel11° postulated that following 
attack of a nucleophile at carbon 8 of xanthine, coupled electron and 
proton transfer occurred, two electrons being transferred to molybdenum, 
producing the Mo(IV) state and the proton transferred. to a nitrogen 
ligand of the molybdenum atom. 
Olson et a186 proposed a mechanism for the hydroxylation of 
xanthine based upon these hypotheses. 
Figure 4. Mechanism of Hydroxylation as proposed by Olson et al. 
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The initial step involves binding of xanthine to the active site of 
the enzyme, followed by attack by a persu lphide 'group, causing splitting 
0 of the carbon-hydrogen bond, accompanied by the donation of 2 electrons 
to molybdenum. The rate of the reaction is dependent upon the fraction 
of molybdenum (VI) present. 
The hydrogen atom at position 8 of xanthine is taken up by a basic 
group, possibly nitrogen, liganded to the molybdenum. The final rate 
determining step involves attack by a water molecule, hydrolysing the 
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sulphur-xanthine linkage with the release of product. 
These proposals have been questioned by Gutteridge et a1116 who 
® argue 
that the proton accepting group at the molybdenum centre cannot be 
nitrogen, based on the lack of nitrogen hyperfine splitting of the Mo(V) 
signal. These workers also postulate that the cyanolysable sulphur, 
present at the molybdenum centre, is a terminal sulphide of the 
molybdenum, rather than a persulphide group. Based on these findings 
they suggest that coupled proton and electron transfer occurs, with the 
terminal sulphur acting as a proton acceptor and an unidentified nucleo- 
phile binding at carbon 8 of the substrate-110 
H 
ij, C_He 
N X, 
Mo S 
The suggested mechanism results in the coordination of xanthine via 
the N9 atom to the molybdenum. The reaction consists of the transfer 
of 2 electrons to the molybdenum atom (probably via the N9 atom) and of 
the proton to the sulphide while the xanthine C8 carbonium ion reacts 
with the nucleophile X. Subsequent hydrolysis of the covalently_bound 
intermediate yields. uric acid and reduced enzyme. 
Recently Davis, 120 working under the auspices of Olson, has 
proposed a new mechanism for xanthine oxidase catalysed hydroxylation 
reactions. Unlike previous mechanisms, which have been solely concerned 
with the oxidation of xanthine, this mechanism has arisen from a study 
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e 
of the hydroxylation of 2,4-dihydroxypteridine (lumazine). 
In contrast to the original mechanism proposed by Olson et x186 in 
which the-cyanolysable sulphur was present as-a persulphide group, these 
workers, in agreement with Gutteridge et al1t6 now represent the sulphur 
in the form of a terminal ligand to the molybdenum., The existence of an 
oxo ligand to the molybdenum is"also important for the proposed 
mechanism of hydroxylation. 
The mechanism is based upon the principle-that the initial step in 
the reaction is hydrogen bonding between the enzyme and the substrate 
(unlike the other proposed mechanisms where the initial step is reaction 
between molybdenum and substrate). This proposal is based upon the 
finding that there is very little alteration in the optical properties 
of the enzyme or the substrate during the rapid equilibrium of the 
enzyme-lumazine binding step. 
Figure 5. Proposed Mechanism for the Binding of Lumazine to Xanthine 
Ozidase. 
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After hydrogen bonding has taken place, a conformational change of 
the enzyme brings the bound substrate into the coordination sphere of 
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the molybdenum, so that the oxoligand can form a loose charge, transfer 
complex with the substrate. It is proposed that this interaction 
produces covalent hydration across the carbon-nitrogen double bond, 
hydroxylating C7 and protonating N8. A proton and 2 electrons are then 
abstracted as a hydride ion by the terminal sulphur, the electrons being 
subsequently transferred to molybdenum, reducing it from Mo(VI) to 
Mo(IV). A covalent bond is formed between the oxo ligand and C7 of the 
substrate and the terminal sulphur is converted'to'a mercaptide. 
The final step in the reaction involves reformation of the carbon- 
nitrogen double bond, the severing of the covalent connection and the 
subsequent dissociation of the enzyme-product complex. 
Inhibitors. 
Based upon their mode of action, inhibitors of aldehyde and 
xanthine oxidase may be divided into two broad categories. 
The first category contains those compounds which exert an 
inhibitory effect upon the internal electron transport chain of the 
enzyme. Aldehyde oxidase is particularly susceptible to this type of 
inhibition. 87 
The inhibitors include non-ionic detergents, e. g. Triton X100 and 
steroids such as oestradiol, progesterone and diethyistilboestrol. As 
2,6-dichlorophenolindophenol activity is unaffected by these compounds, 
they must exert their inhibitory effect at a site after the molybdenum 
centre in the electron transport sequence. 89 
In addition to the steroids, aldehyde oxidase is susceptible to 
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other inhibitors of mitochondrial respiration. For example, Amytal 
produces an immediate inhibition of the rate of oxidation and as this 
compound prevents the enzymic reduction of phenazine methosulphate, 
e ferricyanide and methylene blue, it is believed to block electron 
transfer from molybdenum to the Fe/S centres. Antimycin A, another 
Table 4. Effect of Inhibitors on Rabbit Liver Aldehyde Oxidase. 
Addition Concentration (M) % Inhibition' 
Menadione 2 x 10-7 85* 
Menadione diphosphate 1 x 10-4 0 
Benzoquinone 1 x 10-5 100 
Hydroquinone I x 10-4 40 
Coenzyme Q10 1 x 0-5' 0 
Amytal 1 x 10-3 69 
Antimycin A 2 x 10-6 62* 
Oestradiol 2 x 10-6 62* 
Progesterone, 6.7 x 10-5 45* 
2.4-Dinitrophenol 3.3 x 10-4 50$ 
Dicoumarol 1 x 10-4 36$ 
Triton X100 2 x 10-4% 61 
Apr\ 
Sodium cholate 1 x 10-4% 0 
Quinacrine 1 x 10-4 83 
* At the end of 5 minutes. 
$ At the end of 10 minutes. 
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potent inhibitor of mitochondrial respiration only inhibits the reduc- 
tion of oxygen, cytochrome C and nitro blue tetrazolium, indicating that 
it exerts its inhibitory effect by blocking electron transfer from the 
Fe/S groups to flavin. The inhibition produced by this compound is 
progressive in nature and as it occurs solely in the presence of sub- 
strate, it appears that it only binds to the reduced form of the 
enzyme 89 
All quinones, except Co-enzyme Q10, inhibit aldehyde oxidase to 
some extent and menadione is a particularly potent inhibitor of the 
enzyme, effective at concentrations of 10-7M. 87 
O 
II 
Menadione 
CH3 
0 
In contrast, xanthine oxidase is not inhibited by amytal, 
antimycin A, progesterone, oestradiol or Triton X100, even at much higher 
concentrations and the quinones, including menadione, are efficient 
electron acceptors for the enzyme. 
The second group of inhibitors interact with the active site of the 
enzyme. This group includes reagents which chemically modify the 
molybdenum centre, eg. cyanide, arsenite, methanol and sulphydryl 
agents, acting either as reversible competitive inhibitors or tight 
binding stoichiometric inhibitors. Substrate analogues, which competi- 
tively inhibit the enzyme also belong to this category. 
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i) Cyanide. 
It was originally believed that cyanide exerted its inhibitory 
effect by binding to the active centre of aldehyde oxidase and xanthine 
® 
oxidase. 121 However, more recent work demonstrates that the inactiva- 
tion is accompanied by abstraction of sulphur in the form of 
thiocyanate. 78 The inactive enzyme so produced is identical to the 
'desulpho' form isolated from purified enzyme preparations. 
109 
Incubation of the inactive enzyme with sodium sulphide leads to partial 
recovery of enzyme activity 
78 
As previously reported (see page 40), the sulphur is believed to 
exist as a terminal sulphur of the molybdenum atom116 and may be 
replaced by oxygen upon treatment of the enzyme with cyanide. 
(Enz)-Ko=S + CN- + H2O -º (Enz)-Xo=O + CNS- + 2e + 2H+ 
Certain substrates, eg. those that can produce substrate inhibi- 
tion, can protect against cyanide inhibition, as can the inhibitor 
quinacrine, when incubated with enzyme and cyanide. 119 
It has been proposed that the cyanolysable sulphur is not 
necessary for the binding of the reducing substrate to the molybdenum 
locus, but is'essential for hydroxylation to occur. 122 
ii) Arsenite. 
The observations that arsenite does not interact with 'desulpho' 
enzyme and that cyanide inhibition is markedly reduced by prior comple- 
xing with arsenite indicates that cyanolysable sulphur is essential for 
reaction of arsenite with the enzyme. 
123 Arsenite will interact with 
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both oxidised and reduced enzyme124 and the inhibition is believed to 
produce a specific stabilisation of the Mo(V) oxidation state of the 
enzyme-125 
In comparison to the inhibition of xanthine oxidase, which is non- 
competitive with respect to reducing substrate and essentially 
irreversible, the arsenite inactivation of aldehyde oxidase is very 
rapid, competitive and readily reversible by arsenite dilution. 
125 
iii). Methanol. 
The inhibition of aldehyde and xanthine oxidase by methanol and 
formaldehyde gives rise to the 'Inhibited' e. p. r. signal. This air 
stable signal is produced by interaction of a single non-exchangeable 
proton with molybdenum. 
112 The origin of the proton is believed to be a 
formyl residue, 'derived directly from formaldehyde, or produced by 
enzymic oxidation of methanol to'formaldehyde. The formyl group 
interacts with an essential residue in the vicinity of the molybdenum, 
stabilising the metal in the pentavalent state and preventing enzyme 
turnover. Interaction with the molybdenum centre has been confirmed by 
Coughlan et al, 
123 
who demonstrated that cyanide does not bind to the 
methanol inactivated enzyme. The inhibition is, turnover dependent and 
progressive, which presumably indicates a requirement for partially 
reduced enzyme ie. Mo(V). 
V 
iv) Allopurinol. 
Oxidation of the hypoxanthine isomer allopurinol (4-hydroxy- 
pyrazolo L 3,4d ] pyrimidine) is catalysed by both aldehyde oxidase and 
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xanthine oxidase. 125 The 6-hydroxylated product, alloxanthine, is a 
potent inhibitor of xanthine oxidase but is unreactive towards aldehyde 
oxidase. 12 Alloxanthine has no inhibitory effect upon xanthine oxidase 
in the absence of substrate, thus it is believed that the inhibitor 
forms a very tightly bound complex with a partially reduced form of the 
enzyme, in particular enzyme-bound molybdenum in the tetravalent 
state-126 The tight binding of alloxanthine to xanthine oxidase allows 
its use as a functional site titrant to determine the proportion of 
inactive enzyme present'in an apparently homogeneous preparation. 
Reoxidation of the molybdenum prosthetic groups Mo(IV) -+ Mo(VI) effects 
the release of the bound alloxanthine with the concomitant regenera- 
tion of activity. Such reactivation is slow in air and is best achieved 
by the use of ferricyanide or phenazine methosulphate. 
126 
By virtue of its powerful inhibitory activity towards xanthine 
AOPJI% 
T. O') 
oxidase, allopurinol is a widely used drug, effective in the control of 
hyperuricaemias associated with gout. 127 
Purification. 
i) Aldehyde Oxidase. 
Gordon et a113 first prepared aldehyde oxidase by treatment of hog 
liver brei with 25% alchohol, followed by basic lead acetate precipita- 
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tion and repeated ammonium sulphate fractionation (20-35% saturation). 
The authors estimated the preparation to be approximately 50% pure. 
However, when Knox15 prepared rabbit liver aldehyde oxidase in an essen- 
tially similar manner, he found the preparation to be only 5% pure. 
Rajagopalan et a187 later prepared rabbit liver aldehyde oxidase to 
a higher degree of purity. Their method comprised the following steps: 
a) Homogenisation of liver and centrifugation. 
b) Heat treatment of the supernatant at>55-60°C for 15 minutes 
followed by cooling and centrifugation. 
c) Ammonium sulphate precipitation (0-50% saturation). 
d) Acetone fractionation (43-50%). >., 
e) Adsorption onto and subsequent elution from calcium phosphate 
gel. 
f) Alumina gel treatment followed by ammonium sulphate 
precipitation. 
g) Dialysis. 
According to the authors this method resulted in a 400 fold 
purification and provided a virtually homogeneous preparation. Later 
methods of preparation tend to be based on this procedure. For-example, 
Felsted et a175 followed the same method as far as stage (e), but ,I 
produced a more stable enzyme by the incorporation of two different 
stages: 
i) DEAE-cellulose chromatography. 
ii) Preparative acrylamide gel electrophoresis. 
Similarly, Johns128 prepared human liver aldehyde oxidase by modifying 
the procedure of Rajagopalan. He eliminated the-acetone fractionation 
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and rather than using dialysis, which result in a marked loss of enzyme 
activity, the enzyme was passed down a Sephadex G75 column to remove 
small molecules and salts. 
Sax and Lynch, 129 in their investigation of the oxidation products 
of quinoline, used 100,000xg supernatant as their source of aldehyde 
oxidase. However, Subryan5 later reported that 10,000xg supernatant 
was adequate for studies relating to product identification and metabo- 
lite isolation. Stubley6 isolated partially purified aldehyde oxidase 
by ammonium sulphate precipitation using a similar procedure to 
Rajagopalan. This preparation is more stable than highly purified 
aldehyde oxidase and is suitable for most experimental work, except 
where high purity samples are required. 
ii) Xanthine Oxidase. - 
Rabbit liver, the richest source of aldehyde oxidase only contains 
a small amount of xanthine oxidase, which is normally removed during 
preparation of aldehyde oxidase of high purity. 
75 
Xanthine oxidase can however, be isolated from the liver of a 
number of different mammals, using similar techniques to those described 
for the preparation of aldehyde oxidase. Separation of aldehyde oxidase 
and xanthine oxidase can be effected by chromatography on DEAE- 
AOTII 
cellulose. 
Highly purified xanthine oxidase can be isolated in good yield from 
bovine milk, using a series of preparative steps which may include a 
pancreatic digest of the milk, butanol-ammonium sulphate fractionation 
and the use of sodium salicylate as a selective denaturant. 
76,77 
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Bovine milk xanthine oxidase is commercially available and is 
consequently the most commonly used source of the enzyme for in vitro 
study. 
THE CYTOCHROME P-450 MONOOXYGENASE SYSTEM. 
The enzymes known as the 'mixed function oxidases' or 'mono- 
oxygenases' play an important role in the detoxication of many foreign 
compounds, including drugs and pesticides and also in the oxidative 
metabolism of steroids and other endogenous substrates. The oxidative 
mechanisms involved include dealkylation, epoxidation, N and S oxide 
formation and most commonly aliphatic and aromatic hydroxylation. 130 
These enzymes, which consist of haemoprotein cytochromes, are 
associated with the microsomal fraction of cells-131 The microsomes are 
derived from the endoplasmic reticulum of the intact cell and can be 
separated from soluble fraction enzymes such as the molybdenum 
hydroxylases by centrifugation at-100,000xg. 
The, microsomal monooxygenase system can be resolved into three 
major components all of which are essential for enzyme activity. 
132 
i) Phospholipid. Phosphatidyl choline is an integral part of the 
monooxygenase system both in vitro and in vivo. It is thought 
to facilitate interaction between the lipophilic substrate and 
the polar protein. 
ii) NADPH-cytochrome P-450 reductase is a flavoprotein 
instrumental in transferring electrons from NADPH to 
cytochrome P-450. 
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iii) Cytochrome P-450. This is the terminal oxidase and consists 
of an unusual b type cytochrome. It derives its name from the 
fact that in the reduced form it combines with carbon 
monoxide to form a complex with a characteristic absorbance at 
450nm. 
The system also requires NADPH and molecular oxygen. 
Substrate Interaction with Cytochrome P-450" 
Haemoproteins can undergo spectrophotometrically observable 
transitions associated with the various changes in the electronic 
configuration of their iron-porphyrin group. 133 Remmer et a1134 
reported the formation of two types of spectral change following 
addition of drug substrates to liver microsomes. Both types of spectral 
change are reversible and dependent upon the presence and amount of 
added substrate. The initial step in the cytochrome P-450 catalysed 
oxidation is the formation of an enzyme-substrate complex. The spectral 
change associated with the formation of the oxidised cytochrome P-450 
substrate complex is characterised by a difference spectrum with an 
absorption peak at 385-390nm and a trough at 420nm and is termed a 
'Type I' spectral change. This spectral change is believed to be due to 
the lipophilic substrate binding to the hydrophobic region of the enzyme 
and displacing the sixth ligand of the ferric cytochrome, to produce a 
5 co-ordinated high spin state. 133 Compounds combining with oxidised 
cytochrome P-450 to produce this Type I difference spectrum include 
drugs, pesticides and steroid hormones from many chemical classes. "35 
Many lipophilic nitrogenous bases interact with the oxidised liver 
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microsomes to produce a 'Type II' spectral change, characterised by a 
trough at 400nm and a peak between 420-430nm in the difference spectrum. 
This spectral change is attributed to the donation of a lone pair of 
# 
electrons by the substrate, binding the lipophilic compound to the sixth 
co-ordination position of the iron and retaining the low spin state. 136 
The Type II difference spectrum is produced mainly by aromatic and 
aliphatic amines, but isocyanides, steroids and alcohols can also elicit 
this type of spectral change. It is of interest to note that whereas 
quinoline gives a typical Type I spectrum, isoquinoline produces a 
Type II spectrum. 72 It has been suggested that the terms 'Type I' and 
'Type II' binding should be replaced by 'substrate' and 'ligand' binding 
respectively136 and that enzymic carbon hydroxylation is probably 
mediated primarily via Type I binding of the substrate. 137 
The first compound for which a Type II spectral change was reported 
was aniline, although an underlying Type I component was also discovered 
in the binding spectrum. As both spectra can exist together, it appears 
that some lipophilic compounds are substrates for one cytochrome P-450 
and ligands for another, resulting in superimposed Type I and Type II 
binding spectra. It is also evident that substrates and ligands can 
compete for an active site and displace each other. 136 
A third type of spectral change, originally described as 'Modified 
Type II, ' but later designated 'Reverse Type I' appears as a mirror 
image of the Type I spectral change, with an absorption maximum at 
420nm and a trough at 390nm. This type of spectral change is exhibited 
by compounds such as alcohols, albumin and phenacetin. 138 It has been 
suggested137 that in the neutral state, cytochrome P-450 is weakly bound 
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Figure 6. A Comparison of Type I and Type II Binding Spectra. 
Type I Interaction - Hexobarbital. 
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to an endogenous Type I substrate and that normal Type I interactions 
occur by replacement of the endogenous substrate by a more strongly 
bound exogenous substrate. If, however, the exogenous substrate binds 
more weakly than the endogenous compound, but is added in higher 
concentrations, it will replace some of the binding sites to produce a 
weaker Type I interaction in the substrate cuvette, with a resultant 
'Reverse Type I' difference spectrum. 
TnA.. n +4 an 
In contrast to the molybdenum hydroxylases, a large number of 
compounds are known to induce cytochrome P-450 dependant monooxygenases. 
The term 'induction' is loosely used, to mean the mechanism whereby an 
increased rate of substrate oxidation is obtained139. The induction of 
the monooxygenase system influences the in vivo disposition of a number 
of drugs, with an increased rate of oxidation leading to decreased 
pharmacological activity. Similarly, changes in the metabolism of endo- 
genous compounds, eg. steroids, may produce an altered physiological 
state. 
The properties necessary for inductive activity are: 
i) Lipophilicity. 
ii) An ability to interact with the enzyme molecule. 
iii) A prolonged biological half life-140 
The biochemical changes observed during enzyme induction can be 
used to divide the inducing agents into two main categories. 
141 
The first group, exemplified by phenobarbitone, contains a large 
number of drugs and insecticides, which produce an increase in the 
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levels of cytochrome P-450 with a resultant increase in the metabolism 
of a wide variety of substrates. 
HN 
O1 
Phenobarbitone 
The second group largely comprises the polycyclic hydrocarbons e. g. 
3-methylcholanthrene. These compounds produce an increase in the level 
of a second form of cytochrome P-450, (known as cytochrome P-448) and 
stimulate the metabolism of a limited number of substrates. 
CH 3-methylcholanthrene. 
It is now apparent that other groups of inducers, which stimulate 
metabolism by completely different mechanisms also exist. 139 
Multiplicity. 
The mechanism by which the microsomal system catalyses such a wide 
variety of reactions with so many diverse substrates is partly explained 
by the existence of multiple forms of cytochrome P-450, varying in their 
60 
catalytic, spectral and immunological properties. 
The existence of the multiple forms is supported by the finding 
that certain compounds induce different forms of cytochrome P-450. For 
example, treatment of the animals with 3-methylcholanthrene results in 
the appearance of the spectroscopically distinct cytochrome P-448, 
accompanied by a change in the catalytic activity of the resultant 
microsomes. 142 Although only the two major forms of the cytochrome 
system have been studied in any detail, there appear to be a number of 
other forms. These multiple forms, which exist within the same tissues, 
each catalyse a limited but overlapping spectrum of oxidation reactions 
with a variety of substrates and have varying sensitivity to different 
inducing agents. 143 A difference in the proportion of these forms may 
explain species, strain, age and tissue differences. 
114i\ r-jf 
SECTION II 
AIMS AND SCOPE OF THE PRESENT INVESTIGATION. 
The in vitro oxidation of simple mono and diazanapthalenes has been 
studied in some depth and results indicate that these compounds are 
among the best substrates so far identified for the liver cytosolic 
enzyme aldehyde oxidase. 
6 Although this enzyme plays a key role in the 
overall metabolism of quinoline in vivo, there is very little 
information pertaining to the in vivo biotransformation of the other 
simple azanaphthalenes. In view of the fact that these compounds are 
oxidised much more rapidly than quinoline by aldehyde oxidase under 
experimental conditions, it would be of interest to see whether this is 
reflected in their metabolic fate in vivo. 
Consequently, ' it is proposed to investigate the metabolic fate of 
the 2,3-diazanaphthalene phthalazine in'vivo. 
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This compound has been chosen on the basis that it is a very good 
substrate in vitro for-aldehyde oxidase (Km - 10-4M. ), being rapidly 
converted in high yield to the oxo derivative, 1-hydroxyphthalazine. 
6 
Furthermore, unlike the other diazanaphthalenes, quinoxaline and 
quinazoline, phthalazine gives rise to only one oxidation product with 
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purified aldehyde oxidase and appears to be inactive towards the 
microsomal monooxygenase system. 
Rabbits, which are to be used throughout the study, will be treated 
0 
with 14C-labelled phthalazine. Any metabolites present in the urine are 
to be investigated using solvent extraction techniques, followed by thin 
layer chromatography and auto radiography. High performance liquid 
chromatography is to be employed to separate and isolate the 
metabolites, which may then be characterised by the use of microdisc 
infra-red spectroscopy and mass spectrometry. 
It is also the intention to establish whether treatment of the 
rabbits with phthalazine alters the levels of oxidative enzymes present 
in the liver. This will be determined by preparing enzyme fractions 
from the livers of pretreated rabbits and comparing the enzyme 
activities associated with these fractions with those from control 
animals. It is also proposed to assess aldehyde oxidase levels by 
measuring the molybdenum content of highly purified enzyme fractions 
using electrothermal atomic absorption spectroscopy and to compare the 
electrophoretic properties of aldehyde oxidase from treated and control 
rabbits using isoelectric focusing. 
A substituted phthalazine, the antihypertensive drug hydralazine, 
is extensively metabolised in vivo, 144 the majority of the metabolites ® 
being derived from biotransformations of the hydrazine group. However, 
both phthalazine and 1-hydroxyphthalazine have been identified as minor 
metabolites and it has been suggested that hydralazine may be a 
substrate for aldehyde oxidase. 
6 
In view of these findings, it is also proposed to examine the 
63 
interaction of hydralazine and related compounds with the molybdenum 
hydroxylases. 
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SECTION III 
INTERACTION OF PHTHALAZINE AND ITS HYDROZYLATED DERIVATIVES 
WITH THE MOLYBDENUM HYDROXYLASES IN VITRO. 
0 
INTRODUCTION. 
The 2,3-diazanaphthalene phthalazine (benzo[d]pyridazine) has been 
reported to be rapidly and quantitatively converted to its 1-hydroxy- 
lated derivative when incubated with rabbit liver aldehyde oxidase. 
6 
Phthalazine is also oxidised to 1-hydroxyphthalazine by xanthine 
oxidase but is a much poorer substrate for this enzyme than for aldehyde 
oxidase. 
N 
cc 
N 
aldehyde xanthine 
oxidase oxidase 
N 
OH 
1-hydroxyphthalazine 
(lactim) 
N 
0 
1-(2H)-phthalazinone 
(lac tam) 
00 The oxidation product, 1-hydroxyphthalazine is capable of existing 
in two tautomeric forms. Examination of the infra-red spectrum, which 
shows absorption in the NH (3,292 and 3,240cm-1) and C=0 (1,658cm-1) 
stretching vibration regions145 and evidence from UV spectroscopy146 
indicates that this compound exists almost entirely in the lactam form 
as 1-(2H)-phthalazinone. 
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Theoretical calculations of the TTelectron densities in phthalazine 
by Longuet-Higgins and Coulson147 gave the following charge distribution 
pattern: - 
0.972 0.817 
0.960 rN1.308 
0.960 
I 
N1.308 
0.972 0.817 
The electron densities are closely correlated with the chemical 
behaviour of phthalazine, which upon electrophilic substitution eg. 
nitration, gives rise to the 5-substituted product. 
148 
Similarly, carbon 1 (or-carbon 4) is the most susceptible to 
nucleophilic attack. However, the effect of the amide bond in 1-hydroxy- 
phthalazine on the electron density at carbon 4 has, not been determined 
and although phthalazine is rapidly converted to 1-hydroxyphthalazine by 
the molybdenum hydroxylases no 1,4-dihydroxyphthalazine has been 
isolated from in vitro incubations. This is in contrast to the other 
diazanaphthalenes, quinoxaline and quinazoline which are both 
sequentially oxidised to the corresponding dihydroxy product by aldehyde 
oxidase. 48 
This chapter describes the determination of kinetic constants for 
phthalazine as a substrate for both aldehyde oxidase and xanthine 
oxidase under conditions comparable to those in vivo (previous 
determinations have been carried out at 30°C) and an investigation into 
the interaction of 1-hydroxyphthalazine and 1,4-dihydroxyphthalazine 
with these enzymes. 
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EXPERIMENTAL. 
Preparation of Partially Purified Aldehyde Oxidase. 
The livers of mature, female New Zealand White rabbits were 
routinely used as the source of aldehyde oxidase. 
Centrifugation was carried out using an MSE High Speed 18 
centrifuge fitted with an angled rotor and all apparatus and solutions 
were cooled to 4°C, prior to use. 
A rabbit was killed by cervical dislocation and the liver 
immediately excised. After removal of the gall bladder the liver was 
weighed, washed with ice cold 1.15% potassium chloride solution 
containing 10-4M. 'EDTA and then transferred to a Waring blender along 
with two to three times by volume of the 1.15% potassium chloride 
solution. The liver was liquidised at high speed for two minutes and 
the suspension divided equally between two 500ml Erlenmeyer flasks. 
The suspension was heated on a steam bath at 55-60°C for eleven 
minutes, cooled in ice to 100C and then centrifuged at 15.000xg for 
forty-five minutes at 4°C. 
The resultant supernatent was decanted through glass wool into a 
measuring cylinder and the volume of the clear red solution noted. 
Precipitation of'the enzyme was accomplished by adding solid ammonium 
sulphate to 50% saturation (35.3g/100ml at 4°C) and agitating the 
suspension using a magnetic stirrer. 
Finally, the precipitate was collected by centrifugation at 6,000xg 
for twenty minutes and then redissolved in approximately 20m1 of 10-4M 
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EDTA. solution. 
This partially purified enzyme was used for determination of 
Michaelis-Menten constants, or stored in liquid nitrogen in the form of 
small beads until required for qualitative studies. 
Spectrophotometric Determination of the Rate of Oxidation of Substrate 
using Potassium Ferricyanide as Electron Acceptor. 
All determinations were carried out using a Pye Unicam SP8-250 
UV/Visible Spectrophotometer in the fixed wavelength mode and fitted 
with a Pye Unicam cell temperature controller. 
Solutions were normally made up in 0.067M potassium phosphate 
buffer (pH 7.0) and maintained at 370C in the constant temperature unit 
to obviate any temperature effects upon mixing. 
The enzyme solution was kept in ice. 
The rate of oxidation was monitored by following spectrophoto- 
metrically the decrease in absorbance at 420nm resulting from enzymic 
reduction of potassium ferricyanide at 37°C. 
All substrates were tested initially for non-enzymic interaction 
with potassium ferricyanide before enzyme was added. 
The conditions for assay were as follows: - 
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0 
Sample Cuvette. (1cm pathlength) 
Substrate 
Ethylene diamine tetraacetic acid 
(disodium salt) (EDTA) 
Potassium ferricyanide 
varying concentrations 
1x10-4M. 
1x10-3M. 
Sufficient enzyme to provide a suitable reaction rate and thus a 
spectrophotometrically discernable absorbance change during the 
observation period. 
0.067M Potassium Phosphate buffer to provide a total cell volume of 
3. Om1. 
Reference Cuvette. (1cm pathlength) 
As for the sample cuvette with the exception of substrate. 
Determination of Michaelis-Menten Constants. 
The rate of oxidation of varying concentrations of substrate was 
monitored over the first two minutes of reaction. The enzyme was 
diluted to provide suitable reaction rates over an appropriate range of 
substrate concentrations. Typically 0.1 ml of diluted enzyme solution 
was added to each cuvette. 
The initial velocity V, corresponding to each substrate 
concentration [S] was determined by measurement of the gradient of the 
line recorded on the chart paper and expressed as the change in 
absorbance/time. 
Two different graphical representations of the results have been 
used: - 
i) V versus [S] 
ii) 1/V versus . 1/[S] 
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The double reciprocal plot, known as a 'Lineweaver Burk' plot was 
used to determine the Michaelis-Menten constant for the reaction, which 
corresponds to the negative reciprocal of the x intercept. 
0 
The line of best fit through the points was calculated using 
simple linear regression by the least squares method on a Commodore 
Series 2001 Microcomputer. The goodness of fit of the line was 
expressed by-the 'coefficient of determination'. 
Determination of the Mode of Inhibition and Inhibitor Constant. 
The effect of an inhibitor upon the rate of oxidation of a 
substrate can also be investigated spectrophotometricälly. 
Determination of the mode of inhibition and subsequently the 
inhibitor constant was achieved by use of the method described for the 
determination of Michaelis-Menten constants with the addition of 
inhibitor to each cuvette. 
The'initial rate of oxidation at varying substrate concentrations 
was measured alone and in the presence of a fixed concentration of 
inhibitor. This procedure was normally repeated in the presence of a 
second inhibitor concentration. 
The type of inhibition was determined by examination of double 
reciprocal plots of both non-inhibited and inhibited data and the 
inhibitor constant (Ki) was calculated by the use of information derived 
from these plots. 
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RESULTS AND DISCUSSION. 
As the absorbance spectra of phthalazine and 1-hydroxyphthalazine 
are similar, it is not possible to monitor the rate of oxidation of 
phthalazine by following a change in the absorbance of this compound at 
a particular wavelength. Consequently, all kinetic determinations were 
carried out using the artificial electron acceptor potassium ferri- 
cyanide and monitoring a decrease in the absorbance at 420nm which 
occurs upon reduction of ferricyanide to ferrocyanide. This technique 
is described in the experimental section (page 67). 
All Km determinations and inhibitor studies were carried out at 
37°C in order that direct comparisons could be made with the results of 
the subsequent in vivo studies. 
Partially purified rabbit liver aldehyde oxidase (see page 66 for 
details of the preparative procedure) and commercially available bovine 
milk xanthine oxidase, were used for the kinetic determinations. 
Determination of the Michaelis-Renten Constants (Km) for Phthalazine. 
i) Km of Phthalazine using Aldehyde Oxidase. (Figure 7) 
Enzyme dilution = 1: 20 
Km = 1.14 x 10-4M 
Oh 
Toýl 
coefficient of determination = 0.999 
ii) Km of Phthalazine with Xanthine Oxidase. (Figure 8) 
Enzyme dilution = 1: 20 
(initial protein concentration = 24mg/ml. ) 
Km = 3.36 x 10-3M 
coefficient of determination = 0.997 
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It was interesting to note that although the rate of oxidation 
curved off rapidly with aldehyde oxidase, using xanthine oxidase the ' 
rate was linear for at least ten minutes. 
The Km values obtained for phthalazine with both aldehyde oxidase 
and xanthine oxidase at 370C are very similar to the values quoted by 
Stubley. 6 The Km using xanthine oxidase was approximately thirty times 
greater than the value with aldehyde oxidase, confirming that 
phthalazine is a much poorer substrate for xanthine oxidase than 
aldehyde oxidase. 
Interaction of 1-Hydroxyphthalazine with Aldehyde Ozidase and Xanthine 
Oxidase. 
When 1-hydroxyphthalazine was incubated with either aldehyde 
oxidase or xanthine oxidase in the presence of potassium ferricyanide, 
there was no detectable change in absorbance at 420nm, thus confirming 
that 1-hydroxyphthalazine is not a substrate for the molybdenum' 
hydroxylases. 
However, when the rate of oxidation of phthalazine by either 
aldehyde oxidase or xanthine oxidase was monitored in the presence of 
1-hydroxyphthalazine a decrease in the initial rate was observed, 
AM indicating that 1-hydroxyphthalazine was exerting an inhibitory effect. 
upon the reaction. 
Inhibition studies were carried out as described in the 
experimental section (page 69) using two different concentrations of 
1-hydroxyphthalazine. 
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It can be seen from the Lineweaver Burk plots (Figures 9 and 10) 
that 1-hydroxyphthalazine acts as a competitive inhibitor of phthalazine 
oxidation by both aldehyde oxidase and xanthine oxidase. 
Using the information derived from these plots the inhibitor 
constant (Ki) for 1-hydroxyphthalazine with each enzyme was calculated 
using the following formula: - 
Km. a Km(1+[I]/Ki) 
where: [I] = inhibitor concentration 
Km' apparent Km 
Km - uninhibited Km value 
i) Determination of Ki of 1-Hydroxyphthalazine with Aldehyde Oxidase. 
(Figure 9 
Enzyme dilution = 1: 20 
L1J 
3x 10-3M 
6x 10-3M 
Km phthalazine = 1.14 x 10-4M 
Km 
1.93 x 10-4M 
2.78 x 10-4M 
Ki 
4.34 x 10-3M 
4.19 x 10-3M 
coefficient 
of determination 
0.994 
0.999 
ii) Determination of Ki of 1-Hydroxyphthalazine with Xanthine Oxidase. 
Figure 10 
e 
Enzyme dilution = 1: 20 
Km phthalazine = 3.36 x10-3M 
coefficient 
Kris Ki of determination 
3x 10-3M 5.9 x 10-3M 4.22 x 10-3M 0.999 
6x 10-3M 8.4 x 10-3M 4.18 x 10-3M 0.999 
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Although phthalazine is a much better substrate for aldehyde 
oxidase than xanthine oxidase, calculation of the inhibitor constants 
indicates that the product of the oxidation reaction, 1-hydroxy- 
0 phthalazine, 
is an equally effective inhibitor of both enzyme systems. 
However, as an inhibitor constant in the order of 10-3M indicates 
that the compound is not a particularly good inhibitor, it therefore 
seems unlikely that product inhibition would be responsible for the 
rapid curving off of the rate of oxidation of phthalazine with 
aldehyde oxidase. 
In a similar investigation into the closely related diaza- 
naphthalene, quinazoline, McCormack et al149 found that although this 
compound was rapidly oxidised to 4-hydroxyquinazoline and 2,4-dihydroxy- 
quinazoline by xanthine oxidase, when quinazoline was incubated with 
aldehyde oxidase the rate of reaction rapidly decreased and ceased 
completely within five minutes. The authors discounted the possibility 
that the cessation of reaction was due to product inhibition, as 4- 
hydroxyquinazoline was rapidly oxidised by aldehyde oxidase to 2,4- 
dihydroxyquinazoline and concluded that quinazoline was able to react 
with and inactivate aldehyde oxidase. 
Whilst phthalazine appears to exhibit the same kinetic properties 
as quinazoline, ie. rapid curving off of the rate of oxidation with 
aldehyde oxidase and a linear reaction rate with xanthine oxidase the 
possibility that this compound may be acting in a similar manner to that 
suggested by McCormack et al for quinazoline, is incompatible with 
finding of Stubley6 that 100% conversion to 1-hydroxyphthalazine can 
be achieved upon incubation of phthalazine with aldehyde oxidase. 
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Determination of the Effect of 1,4-Dihydroxyphthalazine upon the Rate 
of Oxidation of Phthalazine by Aldehyde Oxidase and Zanthine Oxidase. 
® 
1,4-Dihydroxyphthalazine was also found to exhibit inhibitory 
properties towards both aldehyde oxidase and xanthine oxidase. 
An examination of the Lineweaver Burk plots shows that unlike 
1-hydroxyphthalazine, which is a competitive inhibitor of both enzymes, 
1,4-dihydroxyphthalazine, exhibits uncompetitive inhibition of aldehyde 
oxidase (Figure 11) and non-competitive inhibition of xanthine oxidase 
(Figure 12). 
Inhibitor constants for both types of inhibition were calculated 
from the Lineweaver Burk plots using the following formula: - 
intercept on ordinate a 1/V (1 + [I]/Ki) 
V= maximum velocity in absence of inhibitor 
[I] = inhibitor concentration 
i) Determination of Ki of 1,4-Dihydroxyphthalazine with Aldehyde 
Oxidase. (Figure 11) 
Enzyme dilution = 1: 27 
coefficient 
Ki of determination 
1x 10-5M 2.91 x 10-5M 0.997 
2x 10-5M 2.94 x 10-5M 0.999 
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ii) Determination of Ki of 1,4-Dihydroxyphthalazine with Xanthine 
Oxidase. (Figure 12) 
Enzyme dilution = 1: 15 
0 
111 Ki 
1x 10-4M 6.21 x 10-5M 
2x 10-4M 8.65 x 10-5M 
coefficient 
of determination 
0.996 
0.999 
The calculated inhibitor constants indicate that 1,4-dihydroxy- 
phthalazine is a much more effective inhibitor of both aldehyde oxidase 
and xanthine oxidase that 1-hydroxyphthalazine. 
Uncompetitive inhibition, as exhibited towards aldehyde oxidase, 
normally implies reaction of the inhibitor with the enzyme-substrate 
complex [ES] to produce a dead end product [ESI], the inhibitor 
preventing the regeneration of the enzyme in a form capable of reacting 
directly with the substrate. 
The simple non-competitive inhibition exhibited by 1,4-dihydroxy- 
phthalazine towards xanthine oxidase generally indicates the combination 
of the inhibitor with various forms of the enzyme at a site other than 
the catalytic centre. 
The difference in the types of inhibition exhibited by 1,4-dihydroxy- 
phthalazine towards aldehyde oxidase and xanthine oxidase highlights the 
differences which exist between the two closely related enzymes. 
Elucidation of the exact nature of the interaction of 1,4-dihydroxy- 
phthalazine with these enzymes would require further detailed invest- 
igations, which are outside the scope of the work reported in this thesis. 
SECTION IV 
METABOLIC FATE OF PHTHALAZINE IN RABBITS. 
INTRODUCTION. 
0 
In vitro studies48 have demonstrated that simple azanaphthalenes 
are among the best substrates so far identified for the liver cytosolic 
enzyme aldehyde oxidase. However, apart from quinoline, very little is 
known about the metabolic fate of these compounds in vivo. The aim of 
this study therefore was to determine whether the molybdenum hydroxy- 
lases also play a significant role in the metabolism of the azanaphtha- 
lenes in vivo. 
Phthalazine is rapidly and quantitatively oxidised by rabbit liver 
aldehyde oxidase to its 1-hydroxylated derivative. However, unlike the 
other diazanaphthalenes quinoxaline and quinazoline and despite the fact 
that phthalazine also contains two available sites for nucleophilic 
attack, no evidence of a dihydroxylated metabolite can be found 
following incubation with aldehyde oxidase. 
6 
In view of these findings, coupled with the observation that in 
vitro studies have indicated that phthalazine is not subject to 
microsomal oxidation, the metabolic profile of this compound might be 
expected to be relatively simple and therefore phthalazine was chosen as 
the candidate for the in vivo study. 
Although the study of the metabolism of a compound in vitro is 
relatively simple depending upon the enzyme system and the conditions 
used, the determination of the route of biotransformation of a compound 
in vivo is generally more difficult and the resultant metabolic products 
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may be numerous and varied. A number of factors, such as the age and 
sex of the subject and the dose and route of administration of the 
compound also interact to influence the metabolic fate of the compound. 
® The major function of metabolism is to render the foreign compound 
water soluble thus facilitating its elimination from the body. As the 
products of simple functionalisation reactions such as oxidation are not 
always more water soluble than the parent compound, Phase II or 
conjugation reactions frequently occur. 
Conjugates are generated by the transfer of a polar endogenous 
molecule, either to the foreign compound if it possesses the necessary 
functional group, or to the product of Phase I'metabolism. Functional 
groups necessary for conjugation reactions include hydroxyl (phenolic, 
alcoholic and carboxyl), amino, heterocyclic nitrogen or thiol groups. 
In some cases, chemically unstable species such as epoxides, arene 
oxides and carbonium ions may also be involved. 
Generally, conjugation reactions tend to detoxify more effectively 
than Phase I reactions and the resulting conjugates are frequently 
highly water soluble, favouring rapid excretion from the body. 
Conjugation Reactions. 
Glucuronidation. 
The most important of the Phase II reactions is the formation of 
glucuronide conjugates. An ability to produce glucuronides is common to 
virtually all mammals150 and a number of different functional groups may 
act as acceptors, the most important being phenols, carboxylic acids, 
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alcohols, amines and thiols. 
The mechanism of formation of a glucuronide involves the enzymic 
transfer of glucuronic acid from the activated conjugating moiety 
0 uridine-5'-diphospho-a-D-glucuronic acid (UDPGA) to the foreign compound 
or metabolite. 
The overall pathway may be represented as follows: - 
glucose- I -phosphate + UTP pyrophosphorylase üridine-5'-diphospho- OX-D- 
glucose (UDPG) + PP 
UDPG + 2NAD ++ H2O UDPG dehydrogenase UDPGA +,, 2NADH + 2H+ 
UDPGA + RXH UDP-glucuronyl transferase R-X-glucuronic acid + UDP 
Whilst glucuronic acid has an OX configuration when bound to the 
precursor, the transfer results in the inversion of the configuration and 
the resulting conjugate is a ß-D-glucuronide. 
,... 
The transfer of glucuronic acid to the compound is mediated by the 
enzyme UDP-glucuronyl transferase, which is located on the membrane of 
the microsomal fraction of liver and other tissues. The enzyme is - 
believed to exist in a number of different forms of varying substrate 
specificity. 
Glucuronide conjugates may be hydrolysed by the enzyme ß -gluc- 
uronidase which is present in the lysosomes of many tissues, ' including 
the liver, kidney and gastro-intestinal tract and also in the bacteria 
present in the gut. 
The exact function of ß-glucuronidase is not-clear, although it is 
not thought to be specifically concerned with the hydrolysis of the 
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0 
glucuronides of drugs and other foreign compounds-151 It has been 
suggested however that ß -glucuronidase may regulate hormonal activity 
by liberating active hormones from inactive conjugates. 
151 
Glucuronides may be of several different types: - 
0-Glucuronides are formed by a linkage of the oxygen on carbon 1 of 
glucuronic acid to an oxygen containing function in the foreign 
compound. 
COOH 
R-OH + UDPGA HO 
O--R + uDP 
HO 
OH 
If the oxygen containing function of the foreign compound is a 
phenolic or alcoholic group, the resulting 0-glucuronide has an ether 
linkage. However, if the function is a carboxyl group, an ester 
glucuronide results. 
This difference is exemplified by salicylic acid which yields both 
an ether and an ester glucuronide. 
152 
COOH 
OH 
UDPGA 
glucuronyl transferase 
COOC6H906 
OH 
COOH 
1,11JOC6H9O6 
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Linkage of glucuronic acid to atoms other than oxygen is also possible 
but appears to be less common. N-Glucuronides are most frequently 
formed from primary or secondary amines and sulphonamides provide an 
® important group for these reactions, undergoing conjugation at N4, N1 or 
at a ring nitrogen if the molecule contains a suitable heterocyclic 
substituent. 
H2N4 
/\ 
SO2-N1-R R- heterocyclic 
substituent -H 
It has recently been discovered that N-glucuronidation of tertiary 
amines to form quaternary ammonium glucuronides may also occur. 
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However, although N-glucuronides have been isolated as metabolites 
of many aromatic and aliphatic amines, the reaction is generally of 
minor quantitative importance in comparison to other metabolic pathways. 
S-glucuronides have been isolated, but they are also uncommon. 
An important structural characteristic of glucuronides is that the 
free carboxylic acid group has a pKa of approximately 3.5 - 4.0 and is 
therefore practically fully ionised at physiological pH. Consequently, 
the carboxylate anion and the hydroxyl group render the glucuronyl 
moiety extremely polar, thus facilitating urinary excretion. 
AM However, because glucuronic acid is'a bulky group, its conjugates 
often have a molecular weight which exceeds the 'threshold value' for 
biliary excretion. This fact, coupled with the polarity of the 
glucuronides means that the bile is also an important excretory route. 
As a consequence of biliary excretion compounds are exposed to gut flora 
and glucuronides may become substrates for the bacterial ß-glucuronidase, 
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causing hydrolysis of the conjugate and subsequent enterohepatic 
circulation of the foreign compound. 
Conjugation with other Sugars. 0 
Mammalian tissues are also capable of conjugating both endogenous 
and exogenous compounds with sugars other than glucuronic acid by 
utilising the corresponding UDP derivatives as donors in similar 
glycosyl tranferase reactions. 
Conjugation with glucose completely replaces glucuronidation in 
insects and other invertebrates and can also occur to some extent in 
mammals. For example, the xanthine oxidase inhibitor, 3-(4-pyridyl)-5- 
(4-pyrimidyl)-1,2,4-triazole is converted to its N-glucoside in some 
species including dog, cat and man. 
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In addition to glucose conjugation, a number of conjugates with 
other sugars have been reported, although these appear to be restricted 
to certain combinations of substrate and species. The best documented 
examples appear to be ribose and xylose conjugates. Thus, 2-hydroxy- 
nicotinic acid, an inhibitor of cholesterol and fatty acid synthesis is 
conjugated through the nitrogen atom with ribose_. in both dogs and 
cats. 155 
COOH 
OH 
COON 1%, COOH 
ýNAO 
H 
'! ý" NO 
CH2OH 
O 
HO OH 
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Although this is a common metabolic route for endogenous substrates 
such as purines and pyrimidines, only foreign compounds possessing a 
close structural similarity to these endogenous substrates appear to be 
0 metabolised in this way. 
155 
Sulphate Conjugation. 
For many compounds conjugation with sulphate represents an 
alternative metabolic pathway to glucuronidation. Phenols, alcohols, 
amines, phosphates and thiols may all undergo this type of conjugation 
reaction. 
Sulphate conjugates are formed by the transfer of an activated 
sulphate group from 3'-phosphoadenosine-5'-phosphosulphate (PAPS) to the 
foreign compound, according to a three step process involving the 
synthesis of the coenzyme (PAPS) from inorganic sulphate and ATP. 
ATP + SO42- ATP-sulphurylase adenosine-5'-phosphosulphate (APS) + 
pyrophosphate 
ATP + APS APS phosphokinase 3'-phosphoadenosine-5'-phosphosulphate 
(PAPS) + ADP + H+ 
PAPS + 8-OH sulphotransferase R-0-SO 3H + 3'-phosphoadenosine- lip 5'-phosphate 
The transfer of the activated sulphate to the acceptor molecule is 
mediated by the enzyme sulphotransferase. The sulphotransferase enzymes 
are located in the cytoplasm and have a wide tissue distribution. In 
common with the glucuronyl transferases, there is evidence for the 
existence of multiple forms of the sulphotransferases, each exhibiting 
different substrate specificities. 156 
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Conjugation with sulphate, a completely ionised and highly 
hydrophilic group markedly alters the physico-chemical properties of the 
foreign compound, generally resulting in a loss of pharmacological 
activity and also facilitating excretion. 
As for the glucuronides, the major excretory route is via the urine, 
although biliary excretion of the sulphate conjugates may also occur. 
Sulphate conjugation is widespread throughout the animal kingdom, 
4 
occurring in most mammals, insects and birds. 157 However, the importance 
of this form of conjugation depends upon the dose of compound 
administered, as the reaction is easily saturated due to the low 
availability of inorganic sulphate and consequently PAPS in the body. 
As glucuronidation normally accompanies sulphate conjugation, the 
relative proportions of the two competing reactions are determined by 
dose'and substrate. Sulphate conjugation tends to predominate at low 
doses and is a feature of the metabolism of small, chemically simple 
molecules. As the dose increases the sulphation reaction is saturated 
and glucuronidation becomes the major route of metabolism. 
Phenols form the main group of exogenous sulphate acceptors and 
sulphate conjugation is a significant route of metabolism for compounds 
already possessing a phenolic group as well as phenolic metabolites 
mlý produced by Phase I biotransformation reactions. For example, the 
sympathomimetic agent terbutaline is excreted only as unchanged drug and 
its sulphate conjugate-158 
HO 
CH3 
CH-CH2 NH-C-CH3 Terbutaline 
HO OH CH3 
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Methylation. 
Compounds subject to methylation reactions include phenols, thiols 
and amines. The source of the methyl group is usually the high energy 
0 nucleotide S-adenosylmethionine and the transfer of the methyl group to 
the substrate is mediated by methyl transferase enzymes located in the 
cytosolic and microsomal cell fractions. Apart from the methylation of 
tertiary amines to give rise to quaternary ammonium derivatives, this 
type of conjugation reaction is unusual in thatýit frequently results in 
a decrease in the polarity and hydrophilicity of the substrate. 
Methylation is often not of quantitative significance in the 
metabolism of xenobiotics, although it is an important route of 
metabolism for endogenous compounds such as catecholamines. 159 
Phenolic compounds undergoing methylation are frequently catechols, 
but compounds containing bulky groups ortho to the hydroxyl group may 
also be subject to 0-methylation eg. codeine results from methylation of 
morphine. 
160 Primary, secondary and tertiary amines may all undergo 
methylation reactions, although aromatic heterocycles form the most 
important group. N-Methylation of these heterocyclic compounds results 
in the formation of a quaternary nitrogen atom which completely alters 
the physico-chemical properties of the compound, turning a weakly 
basic lipophilic compound into a strongly basic quaternary ammonium 
IF/ metabolite, which may also be biologically active. '161 
In addition, N-methylation of pyridine and related fused rings 
leads to a destabilisation of the pyridine moiety, in particular causing 
labilisation of the (X-carbon rendering it susceptible to nucleophilic 
attack. For example, nicotinic acid is metabolised via a two step 
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0 
process to N1-methylnicotinamide which is a substrate for both aldehyde 
oxidase and xanthine oxidase. 
162 
COOH 
N 
Acetylation 
(CONHz 
+ N 
I 
CH3 
A. O. 
2&4 pyridones 
An important metabolic route for compounds'contäining ä primary 
amine group is N-äcetylation. Aromatic amines, sulphonamides, 
hydrazines and hydrazides all undergo this type of conjugation reaction. 
Acetylation of alcohols (eg. choline) and thiols (eg. CoA. SH) is also 
possible, although-this type of reaction appears to be restricted to 
endogenous compounds. 
The conjugation reaction involves the formation of an amide bond 
between the NH2 function of the substrate and acetate derived from the 
high energy intermediate acetyl coenzyme A. The transfer of the acetyl 
group is mediated by the enzyme N-acetyltransferase and the reaction is 
exemplified by the acetylation of the hydrazine containing drug 
isoniazid. 163 
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CONHNH2 CONHNHCOCH3 
Acetyl coenzyme A 
N-acetyltransferase 
nLI, 
NN 
The acetylation of an amine group leads to amide formation, which 
suppresses the potential ionisation of the nitrogen at physiological pH 
values, with the result that the N-acetylated metabolite may be less 
water soluble than the parent compound. 
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Conjugation with Amino Acids. 
Although carboxylic acids may be conjugated with glucuronic acid to 
produce ester glucuronides, conjugation with amino acids is an important 
metabolic route for these compounds. 
Both endogenous acids, eg. bile acids and exogenous carboxylic 
acids undergo this type of conjugation reaction. 
The most important conjugating amino acid is glycine, which 
together with glutamine accounts for the majority of amino acid 
conjugates found in mammals. 
In contrast to the reaction sequences for both glucuronide and 
sulphate conjugation, in which the foreign compound interacts with the 
activated conjugating agent, the mechanism for conjugation with amino 
acids comprises a two step activation of the carboxylic acid by ATP and 
coenzyme A. This is followed by the transfer of the activated acyl 
group to the NH2 group of the amino acid, mediated by acyl transferase 
enzymes. 
93 
One of the most important groups to yield glycine conjugates are 
0 
the aromatic carboxylic acids, for which benzoic acid is a model 
compound. 165 The glycine conjugate hippuric acid is found as a major 
metabolite of benzoic acid in a number of mammals including herbivores. 
COOH CONHCH2COOH 
ATP. Coenzyme A. 
I 
NH2CH2COOH. Acyl Transferase. 
I 
Aryl acetic and aryl alkyl acids are also 'capable of forming 
glycine conjugates, as are heterocyclic aromatic acids such as nicotinic 
and isonicotinic acid. 
Glutathione Conjugation. 
A variety of foreign compounds may be conjugated with the 
nucleophilic tripeptide glutathione (glutamyl-cysteinyl-glycine). 
Compounds which conjugate with glutathione fall into two 
categories: - 
Firstly, those that are directly conjugated with glutathione, the 
jeh r"ri 
mechanism involving nucleophilic substitution at a carbon atom. This 
group includes alkyl halides and aromatic nitro derivatives. 
The second group comprises compounds metabolised to arene oxides, 
epoxides or reactive N-oxidation products. In these cases, the 
glutathione breaks the oxirane ring, or interacts with an electron 
deficient carbon atom. 
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In all cases the foreign compound replaces the proton on the 
sulphur atom of the cysteine residue. 
The conjugation reactions are catalysed by a group of enzymes known 
as the glutathione transferases, which are located in the soluble 
fraction of the liver and other tissues. 
Glutathione conjugates are normally excreted in the bile rather 
than the urine because of their high molecular weight and amphiphilic 
nature. However, they frequently undergo further metabolism of the 
peptide moiety to give rise to S-substituted N-acetylcysteines (mercap- 
turic acids) which may be excreted in the urine. 
F"i 
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1 XPERIKENTAL. 
General Regime for In Vivo Study. 
Young, mature, female New Zealand White rabbits weighing 
approximately 2kg were used throughout the study. 
A simple metabolic cage, designed to separate the urine and faeces 
was used and the rabbit introduced into the cage three to four days 
prior to the commencement of treatment in order to accustom the animal 
to the unfamiliar conditions and to ensure normal urine flow. Urine was 
collected daily during this period for use as a control in the 
preliminary studies. 
The rabbit was fed on solid pellet food and both the food and water 
supply were located externally to the cage in order to minimise 
contamination of the urine and faeces. 
Phthalazine or 1-hydroxyphthalazine was administered orally, being 
supplied as a solution in drinking water at a concentration of 200jig/ml 
which, based upon the observation that rabbits drink approximately 150ml 
of water daily, gives a total dose of approximately 15mg/kg daily for a 
rabbit weighing 2kg. 
The rabbit was treated with the phthalazine solution for a period 
Amps\ 
of ten days and the volume of solution drunk during each twenty-four 
hour period was recorded, along with the volume of urine produced over 
the same period of time. Urine samples were stored at -20°C until 
required for analysis. 
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Treatment of Urine. 
i) Extraction. 
The urine was adjusted to pH 10.0 and extracted three times with 10 
twice the volume of chloroform. The organic extracts were pooled, the 
solvent removed under reduced pressure and the residue redissolved in a 
small volume of chloroform. -- 
ii) Hydrolysis. 
a) Acid Hydrolysis. 
Equal volumes of urine and concentrated hydrochloric acid were 
refluxed in a round bottomed flask for eight hours. After cooling, the 
solution was neutralised with 10x1 sodium hydroxide solution. 
Controls were prepared as follows: - 
1) Equal volumes of urine and water were refluxed for eight hours. 
2) Equal volumes-of urine and concentrated hydrochloric acid were 
immediately neutralised, with cooling, by sodium hydroxide. 
b) Enzymic Hydrolysis. 
1) Conditions for Incubation with ß -Glucuronidase. 
Urine 
Ahý 
qw) O. 1M Potassiun Phosphate Buffer (pH 6.8) 
ß -glucuronidase 
10ml 
25m1 
2,000 'Fishman' Units added 
initially and also after 12 
hours. 
"ý 
aý 
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2) Conditions for Incubation with Arylsulphatase. 
Urine IOml 
0.2M Sodium Acetate Buffer (pH 5.0) 25m1 
Arylsulphatase 50 Units added initially 
and also afer 12 hours. 
(In this case one unit was defined as the amount of enzyme which would 
hydrolyse lpmol of p-Nitrocatechol Sulphate per hour under standard 
incubation conditions. ) 
The mixtures were incubated for twenty-four hours in air at 370C in 
a shaking water bath. 
Control incubations were carried out using the same conditions as 
described above but omitting the enzyme from the incubation mixture. 
At the end of the incubation period the mixtures were cooled and 
used directly for chromatographic purposes, or subjected to extraction 
by organic solvents. 
iii) Reduction of Urinary N-Oxides. 
A 0.2N titanium trichloride solution was prepared as follows: - 
10ml concentrated hydrochloric acid 
20ml 15% titanium trichloride solution 
0 75m1 water 
and the incubation mixture contained: - 
20ml urine 
0.2ml 5N hydrochloric acid solution 
0.2ml 0.2N titanium trichloride solution 
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A control incubation mixture was prepared by replacing the titanium 
trichloride solution by 0.2m1 water and the efficiency of the reducing 
agent tested by adding 3-methylisoquinoline -N-oxide to a sample of urine 
and subjecting this to an identical incubation process. 
The mixtures were incubated for one hour in air at room 
temperature. 
Chromatographic Procedures. 
i) Thin Layer Chromatography. (TLC) 
Thin layer chromatograms were run on glass plates coated with 
silica gel G containing a fluorescent indicator for irradiation at 
254nm. (Silica gel GF254) 
Reference solutions were made up in an appropriate solvent at a 
concentration of 1mg/ml and samples of 1- 25 yl were applied to the 
plate. 
The chromatograms, which were run in a number of different solvent 
systems were developed to 10cm, dried and examined under ultraviolet 
light. Spots were detected by the quenching of the fluorescent 
background at 254nm, or by native fluorescence upon irradiation at 
9) 365nm. 
ii) Preparative Thin Layer Chromatography. 
This was carried out using 20 x 20cm glass plates coated with 
silica gel GF254 (1m m thick). A sample volume of approximately 100pl 
was consistently used and the plates were developed to the full 20cm. 
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Similar detection techniques to those described previously were employed. 
iii) Gas Liquid Chromatography. (GLC) 
0 Gas liquid chromatography was carried out using a Pye Unicam 104 
instrument fitted with dual columns and a flame ionisation detector. 
The columns used were 5% KOH, 3% PEG 20M on Chromosorb W 100/120 
and an operating temperature of 200°C was used. 
iv) High Performance Liquid Chromatography. (HPLC) 
High performance liquid chromatography was carried out using 
a Waters Model 6000 Chromatograph fitted with a Model 600 Solvent 
Programmer and a Cecil 212 variable wavelength spectrophotometer, an 
Altex Model 110A solvent metering pump, connected to the Cecil 
spectrophotometer, or a DuPont Pump Module 870 chromatograph connected 
to a DuPont variable wavelength spectrophotometer. 
The separation of compounds was carried out using"either a 
partition system, employing a column containing a bonded non-polar 
stationary phase together with an aqueous eluting solvent, or an 
absorption system with a silica stationary phase and using various 
mixtures of organic solvents as eluting agents. All work was carried 
0 
out at room temperature. 
Normal reaction grade solvents were used for the majority of the 
work, but where eluate was collected for isolation purposes, HPLC grade 
solvents were used. 
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The following conditions were used for the preliminary analysis of 
urine and the subsequent calibration curves: - 
Column Zorbax silica (5 micron) 25cm x 0.46cm (i. d. ) 
Solvent 2% methanol in chloroform 
Flow rate 1.5ml/min 
Detection wavelength 270nm 
Isolation of Metabolites using HPLC. 
The retention volume of the metabolite was ascertained in a 
suitable solvent system and 20 - 100y 1 aliquots of the reference 
solutions or sample mixtures were injected. The eluate fraction 
corresponding to the peak, normally 2- 3m1, was collected in a 5ml 
reacti-vial and the solvent gently evaporated on a hot plate. 
Organic eluting solvents, (ie. absorption systems) were used in 
preference to aqueous solvents because of their greater volatility. 
However, in cases where aqueous solvents were necessary, the eluate 
corresponding to the peak was collected and a little hydrochloric acid 
added, to convert any free bases present to their hydrochloride salt in 
order to prevent loss of the base by steam distillation during the 
e evaporation step. 
Repeat injections were carried out until sufficient compound had 
been collected to enable identification by microdisc infra-red 
spectroscopy and mass spectral analysis. 
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Infra-Red Spectra. 
Infra-red absorption spectra were obtained using a Perkin Elmer 
Model 297 Infra-Red Spectrophotometer fitted with a beam condenser, 
0 microdisc holder and a beam attenuator. 
3- 4mg of potassium chloride, which had been previously ground in 
a ball mill, was weighed onto a small piece (approximately 1" square) of 
aluminium foil. 
The residue remaining in the reacti-vial after, evaporation of the 
HPLC eluting solvent was redissolved in approximately 25)11 of methanol. 
The foil was placed underneath an infra-red lamp and the methanol 
solution added dropwise to the potassium chloride. When all the 
methanol had evaporated the potassium chloride was transferred to the 
microdisc die. The die was evacuated for 30 seconds sufficient pressure 
being applied to form a transparent disc. The die was then transferred 
to the microdisc holder in the beam condenser and the spectrum run. 
Mass Spectra. 
Mass spectral data were determined on an AEI Model MS 902 Mass 
Spectrometer. 
The material isolated using HPLC could also be subjected to mass 
spectral analysis. The residue in the reacti-vial was dissolved in 10 - 
20) il of methanol and the solution evaporated directly onto the probe 
tip. 
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Method for Preparation of 14C-1-Phthalazine from 14C-1-Hydralazine 
Hydrochloride. 
As the sample of 14C-1-hydralazine hydrochloride had a specific 
0 activity of 19.8mCi/mmol, 1mg of the compound contained, 100)lCi of 
activity. - 
In order to enable accurate handling of the small quantities of 
radioactive material required for each synthesis, 3mg of unlabelled 
hydralazine hydrochloride was intimately mixed with the radioactive 
compound so that 1mg of the mixture contained approximately 25pCi, the 
amount of radioactivity generally used in each synthetic procedure. 
The required quantity of diluted 
14C-1-hydralazine hydrochloride 
was dissolved in 5ml of 2N sodium hydroxide solution, stoppered and left 
to stand for forty-eight hours at room temperature. 
The resulting solution was extracted with three 5m1 portions of a 
chloroform: isopropanol mixture (3: 1) and 10mg of phthalazine was 
subsequently added to the combined organic extracts. The solvent was 
evaporated under reduced pressure and the residue redissolved in 0.5m1 
of the same solvent. 
The entire solution was transferred onto a preparative TLC plate and 
e developed using chloroform: acetonitrile: cyclohexane (2: 1: 1) as the 
mobile phase. After drying the plate, the band of silica corresponding 
to the Rf value of phthalazine was -removed 
from. the. plate and extracted 
with hot methanol. Following double filtration, the methanol was 
removed under reduced pressure and the residue dissolved in water to 
give a suitable concentration and activity. 
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Methods used for Liquid Scintillation Counting. 
A Packard Tri-Carb 460C Liquid Scintillation Counter was used. 
1- 100pl of sample was added to 10ml of scintillant in glass screw- 
"1 capped vials, which were counted for between two and ten minutes depending 
upon the activity. The net cpm values were calculated by subtraction of 
the average value obtained from two background counts, each of ten minutes. 
i) Determination of Counting Efficiency using an Internal 
Standardisation Technique. 
As most scintillation counters are only approximately 90% efficient 
towards 14C, the efficiency of counting was determined in the following 
way: - 
A sample was counted and the net cpm calculated. A known amount of 
activity from a 14C-toluene standard was then added to the same vial, 
the total activity of the standard and the sample counted and the total 
net cpm determined. 
The following formula may be used to calculate the counting 
efficiency: - 
Efficiency 
C2 - Cl 
D 
15 where: C, is the net cpm of the sample without internal 
standardisation. 
C2 is the net cpm of the sample plus the internal 
standard. 
D is the dpm of the internal standard. 
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By knowing the efficiency of counting towards 
14C, it was possible 
to calculate the dpm of any sample by dividing its net cpm value by the 
efficiency value calculated as above and multiplying by 100. 
" 
cpm 
ie. dpm z 100 
efficiency 
The scintillation counter was found to be approximately 93% 
efficient towards 
14C and this value was therefore incorporated into all 
subsequent calculations involving accurate 
14C 
measurement. 
ii) Determination of Quenching. 
As the major loss of counting efficiency is due to either chemical 
or optical quenching caused by the addition of sample material to the 
scintillant it was necessary to determine the degree of quenching caused 
by urine samples and organic solvents. 
As quenching increases, the distribution spectrum of the pulses 
shifts to a lower channel and the sample channel ratio (SCR) gives an 
indication of the degree of quenching. Consequently, a correlation of 
the measuring efficiency in one region related to the ratio of the 
counts in the two regions can be obtained by measuring a series of 
quenched solutions and, if the activity of the standard is known, a graph 
of efficiency in one region against the ratio of the counts in the two 
'', channels can be plotted. 
Quench curves were constructed for urine, chloroform, butanol and 
phthalazine solutions using efficiency and SCR values obtained by adding 
varying amounts of these potential quenching agents to vials containing 
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a known amount of 14C-toluene standard. 
Figure 13. Example of an Efficiency Correlation (Quench) Curve for 
14C. 
01 
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Neither urine, a solution of phthalazine (200)g/ml) nor butanol 
had any effect upon the counting efficiency when volumes of between 5- 
200)11 were added. However, chloroform, in common with all halogenated 
solvents, did have a quenching effect particularly when the larger 
volumes were added. However, as the volume of chloroform likely to be 
added to the scintillant, was only, 10 - 50y l and the quenching effect of 
this volume was negligible, it was not considered necessary to 
``ý incorporate this value into activity calculations. 
Autoradiography of Thin Layer- Chromatography Plates. 
Under appropriate dark room conditions the TLC plate to be examined 
was positioned against the sensitive side of a screenless X-ray 
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photographic plate. The plate and the film were then sealed into the 
light-tight envelope provided with the photographic plate so that dark 
room conditions were no longer necessary. 
0 
The envelope was placed into a strong polythene bag which was then 
sealed thermally. A small hole was made in the bag near to the seal and 
a teflon catheter introduced. The catheter was connected to a vacuum 
pump and the bag evacuated until the photographic film was held firmly 
against the thin layer chromatography plate. Whilst. maintaining the 
vacuum, the bag was then resealed below the point of entry of the 
catheter, thus preventing the re-entry of air. 
After examination to ensure that the seal was airtight, the bag 
was placed in a freezer at -20°C for five days. At the end of this 
period, the seal was broken and under safelight conditions the photo- 
graphic plate was removed from the surface of the thin layer plate. 
Method for Developing an X-Ray Plate. 
The plate was developed by immersing it in a1 in 10 dilution of 
developer for approximately five minutes. It was then transferred to a 
dish containing a1 in 10 dilution of fixing solution and left for five 
minutes. Finally it was thoroughly washed under cold running water and 
allowed to dry. 0 
Conditions for Incubations With Liver Enzyme Fractions. 
Enzyme fractions were prepared as described in the following 
section (page 166). 
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i) 10,000xg Supernatant. 
This was used as a source of both microsomes and aldehyde oxidase. 
The incubation conditions were as follows: - 
Substrate 
Glucose-6-phosphate 
NADP 
Potassium chloride 
Tris-buffer salt 
Enzyme 
0.067M potassium phosphate 
buffer (pH 7.0) 
16pmo 1 
30jnmo 1 
1ymol 
600pmo1 
4mmol 
volume equivalent to 0.8g of liver 
to give a total incubation volume 
of 14. Om1 
When the 10,000xg supernatant was used solely as a source of 
aldehyde oxidase the incubation mixture contained only: - 
Substrate 16xmol 
Enzyme vol. equivalent to 0.8g of liver 
0.067M potassium phosphate to give a total incubation volume 
buffer (pH 7.0) of 14. Oml 
ii) 100,000xg supernatant. 
This fraction can only be used as a source of aldehyde oxidase. 
Incubation conditions were as follows: - 
Substrate 2mg 
10 Enzyme 
, volume equivalent 
to 2g of liver 
0.067M potassium phosphate to give a total incubation volume 
buffer (pH 7.0) of 40m1 
iii) Washed Microsomes. 
When microsomes were used as a source of enzyme, the incubation 
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conditions were identical to those used when the 10,000xg supernatant 
fraction was used as a source of microsomal activity, except that NADP 
was replaced by NADPH (8jmol) and microsomes equivalent to 1. Og of liver 
replaced the 10,000xg supernatant. 
All incubations were carried out in air for one hour at 37°C in a 
shaking water bath. 
Control experiments were carried out in two ways: - 
1) Mixtures containing all components except substrate were incubated 
in a similar manner to the test mixtures. 
2) Enzyme activity was destroyed by heating enzyme fractions at 100°C 
for ten minutes and this denatured enzyme replaced viable enzyme in 
the incubation mixture. 
iv) Extraction Procedure. 
When the incubation period was complete, the mixtures were 
saturated with crystalline sodium sulphate and heated on a boiling water 
bath for thirty minutes in order to precipitate the protein. 
After cooling, the contents of each flask were extracted with 
four 15ml portions of n-butanol. The butanol extracts were combined 
and evaporated to provide a final volume of 1.0ml. This concentrate 
6 could be used directly in chromatographic identification procedures. 
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RESULTS AND DISCUSSION. 
General Scheme for In Vivo Study. 
The in vitro studies reported in this thesis have all been carried 
out using aldehyde oxidase prepared from rabbit liver. Consequently, 
rabbits were also used as the subjects for the in vivo study, to enable 
direct comparisons to be made with the in vitro situation. The use of 
rabbits has the added advantage that they are easy to handle and produce 
relatively large volumes of urine daily. 
Phthalazine, the compound chosen to study, was administered to the 
rabbits as a solution in the drinking water and the urine collected 
daily to be subsequently analysed for products of metabolism. 
In order to facilitate the investigation into the metabolic fate of 
this compound, the majority of the work was carried out using 
14C-labelled 
phthalazine. 
Discussion of the Preparation of 
14C-1-Phthalazine. 
As 14C-1-phthalazine is not commercially available, it was 
necessary to synthesise this compound from14C-1-hydralazine hydro- 
chloride. 
ý, 
I 
\N 
HCI 
\ *, N 
NHNH2 
The preparation, which is based upon the decomposition of 
hydralazine in alkaline solution to give phthalazine, is described in 
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the experimental section (page 102). 
Although the methods described in the literature for the 
preparation of phthalazine from hydralazine are all based upon the 
decomposition of hydralazine by sodium hydroxide, the solvent used to 
extract the resulting phthalazine varies and while Lesser et all 
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used 
toluene, Haegele and coworkers167 employed a chloroform: isopropanol 
mixture. 
In order to establish the best extracting solvent, unlabelled 
hydralazine hydrochloride was added to sodium hydroxide and after forty- 
eight hours the resulting solution was divided and extracted with both 
solvents. ` 
The amount of phthalazine remaining in the aqueous phase after each 
extraction was determined by the use of gas liquid chromatography as 
described in the experimental section (page 99). 
After two 5ml extractions of the alkaline solution with the 
chloroform: isopropanol mixture, the phthalazine was completely 
extracted into the organic phase. However, after five 5m1 extractions 
with toluene approximately 10% of the phthalazine still remained in the 
aqueous phase. Consequently, the chloroform: isopropanol mixture was 
employed as the extracting solvent. 
Upon mixing hydralazine hydrochloride with sodium hydroxide, the 
solution became yellow in colour. The origin of this colour is not 
clear, but it has been suggested that it may be due to reaction between 
phthalazine and hydralazine giving rise to diphthalazinylhydrazine. 
168 
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Diphthalazinylhydrazine 
This yellow compound was also extracted into the organic solvent, 
thus removal of the solvent left a mixture of phthalazine and this 
contaminant. Consequently, a method was required for the purification 
of phthalazine prior to use. 
Lesser et a1166 employed a differential recrystallisation technique 
in order to obtain radiochemically pure phthalazine. However, when this 
technique was tested, only a 20 - 30% yield of phthalazine was achieved 
and the recrystallised product still contained traces of the yellow 
compound. 
Therefore, in order, to achieve separation of-the phthalazine from 
this yellow material and other possible contaminants, which may include 
unchanged hydralazine and 1-hydroxyphthalazine, the use of thin layer 
chromatography was investigated. Two solvent systems were used and the 
retention values for the compounds of interest are reported in Table 5. 
Although both-solvent systems separated, phthalazine from 1-hydroxy- 
0 phthalazine and hydralazinehydrochloride, the yellow contaminant had a 
similar Rf value to phthalazinein solvent A. Therefore, as adequate 
separation of all four compounds was achieved using solvent B, this was 
chosen as the mobile phase. 
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Table 5. Retention Values for Hydralazine and its Decomposition 
Products. 
Rf x 100 
A' B 
Phthalazine 56 27 
1-Hydroxyphthalazine 75 38 
Hydralazine HC1.40 0 
Yellow contaminant 55 80 
Solvent systems: A=n butanol: glacial acetic acid: water. 60: 20: 20 
B= chloroform: acetonitrile: cyclohexane. 2: 1: 1 
Spots were detected by the quenching of the fluorescent background at 
254nm. 
The amount ofý14C activity present in the prepared phthalazine 
solution was determined by scintillation counting and the solution 
adjusted in order to provide a suitable concentration of phthalazine, 
together with an adequate dose of radionuclide. 
However, before the radiolabelled solution was administered to the 
rabbit, it was necessary to confirm its chemical and radiochemical 
purity. This was carried out by testing aliquots of the radiolabelled 
phthalazine, isolated from the preparative TLC plate, in two further 
solvent systems, namely: - n butanol: glacial acetic acid: water 
(60: 20: 20) and methanol: chloroform (5: 95). All the 14C-labelled 
activity was found to be present in a single spot, corresponding to the 
Rf value of phthalazine in each solvent system. Therefore, the solution 
was considered to be both chemically and radiochemically pure and 
ready for administration to the rabbit. 
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Metabolic Profile of 
14C-Labelled Phthalazine. 
The 14C-1-phthalazine solution was prepared so that the amount of 
It activity present was 0.22pCi/ml and the phthalazine concentration was 
approximately 200}zg/ml. 
The solution was administered to a rabbit in place of the drinking 
water over a period of twelve hours, after which time the volume drunk 
was noted. The rabbit was then treated with a 200jig/ml solution of 
unlabelled phthalazine for the following seven days, during which time 
twenty-four hour urine samples were collected and stored at -200C until 
required for analysis. 
Over the twelve hour period, the rabbit drank 43m1 of the radio- 
active solution, which corresponded to a total dose of 9.62pCi. 
The activity of an aliquot of each urine sample was measured by 
liquid scintillation counting and the percentage excreted into each 
days urine was calculated. 
Figure 14. Graph to Show the Cumulative Excretion of the Radiolabelled 
Material. 
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Over a six day period 87.2% of the total dose of 
14C was excreted 
into the urine. The majority of the activity was excreted within 
twenty-four hours of commencement of treatment with the 
14C-labelled 
phthalazine solution, with only small and decreasing amounts being 
excreted on the two subsequent days. After three days, only a neglig- 
ible amount of activity could be detected in the urine. 
Without catheterisation of the rabbit it was impossible to establish 
more accurately how quickly the radioactivity appeared in the urine. 
Nevertheless, the fact that the majority of the dose appeared within the 
first twenty-four hours indicates that phthalazine must be readily 
absorbed from the gastro-intestinal tract in°. order to undergo biotrans- 
formation reactions which yield metabolites sufficiently water soluble 
to be rapidly excreted-into the urine. 
Preliminary Investigation of Metabolic Products using Unlabelled 
Phthalazine. 
As the aim-of the investigation was to determine whether aldehyde 
oxidase played a significant role in the in vivo metabolism of 
phthalazine, it was important to develop a method for the separation of 
unchanged phthalazine and its aldehyde oxidase mediated oxidation 
product, 1-hydroxyphthalazine from urine. 
0 
The use of simple chromatographic techniques was initially 
investigated for this purpose. Thin layer chromatography of phthalazine 
and 1-hydroxyphthalazine may be carried out according to the method 
described in the experimental section (page 98). Table 6 shows the 
retention distances of phthalazine and 1-hydroxyphthalazine in several 
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solvent systems. 
Table 6. TLC Retention Data for Phthalazine and 1-Hydroxyphthalazine. 
Rf x 100 
ABCD 
Phthalazine 56 8 56 90 
1-Hydroxyphthalazine 74 31 76 90 
Solvent systems :-A= methanol: chloroform (5: 95) 
B= isopropanol: cyclohexane (10: 90) 
C=n butanol: glacial acetic acid: water (60: 20: 20) 
D=n propanol: conc. ammonia 0.880. (70: 30) 
Detection: - Both compounds were detected as quenched spots on a 
fluorescent background at 254nm. 
A high performance liquid chromatography system was established for 
the separation of phthalazine and 1-hydroxyphthalazine. An absorption 
system was employed as described in the experimental section. (page 100) 
Upon examination of the absorption spectra of phthalazine and 
1-hydroxyphthalazine, a wavelength of 270nm was deemed most sensitive 
for the spectroscopic identification of these compounds and had the 
added advantage of reducing background absorbance due to chloroform. 
0 
Using this system, the retention volumes of the two compounds 
were: - 
phthalazine 12.3m1 
1-hydroxyphthalazine 6.15m1 
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This HPLC system was used throughout the preliminary invest- 
igations. Calibration curves were constructed for both phthalazine and 
1-hydroxyphthalazine and two concentration ranges, 0- 100 and 50 - 50Ung 
were used for each compound. Duplicate injections were made at each 
concentration and the peak heights measured. Examples of the calibra- 
tion graphs, which were found to be linear, are shown in Figure 17. 
In order to determine whether urine could be directly analysed by 
HPLC for the presence of phthalazine and 1-hydroxyphthalazine, a sample 
of untreated urine was chromatographed using this system. (see Figure 16) 
However, urine contains a vast number of metabolites of compounds 
of both endogenous and exogenous origin, many of which may have similar 
chromatographic characteristics to phthalazine and its derivatives. 
The resulting chromatographic profile was extremely complex, 
exhibiting absorption in areas of the HPLC trace corresponding to the 
position of elution of phthalazine and 1-hydroxyphthalazine. 
For the same reasons, it was not possible to distinguish the 
presence of phthalazine and 1-hydroxyphthalazine in a urine sample by 
TLC with traditional UV detection methods and spray reagents could not 
be used for detection purposes as many of the constituents of urine 
contain functional groups which would also react with the visualising 
agent., 
0 
Consequently, it became apparent at an early stage that a 
preliminary extraction step would be necessary prior to chromatographic 
identification of these compounds. 
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Figure 17. Calibration Curves for Phthalazine and 1-Hydroxyphthalazine. 
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In order to establish a suitable extraction procedure, phthalazine 
and 1-hydroxyphthalazine were added to a sample of untreated rabbit 
urine, such that the final concentration of each compound was 200jig/ml. 
The urine sample was subjected to various methods of extraction, 
including simple solvent extraction, chromatography on the hydrophobic 
resin Amberlite XAD2 and alumina column chromatography. 
The efficiency of each of these extraction techniques was 
established using HPLC. Upon comparison of the amount of phthalazine 
and 1-hydroxyphthalazine extracted by each method and the extent of the 
background interference from urinary constituents, simple solvent 
extraction into chloroform at pH 10.0 (see experimental section, page 
96) appeared to produce the best results. 
The efficiency of the extraction process was determined by spiking 
samples of untreated urine with phthalazine and 1-hydroxyphthalazine 
such that the final concentration of each compound was 2.5,5 or 
10jig/m1. 
The urine was adjusted to pH 10, extracted into chloroform and the 
resultant concentrate injected onto the HPLC. The average extraction 
efficiency at each concentration was calculated with reference to the 
calibration graphs. (see Table 7) 
0 
Although in some cases greater than 100% extraction appears to have 
been achieved this must be attributed to experimental error associated 
with the accurate measurement of small volumes and possibly the 
volatility of the final chloroform concentrate. 
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Table 7. Extraction Efficiency of Phthalazine and 1-Hydroxyphthalazine 
from Urine into Chloroform. 
Efficiency % (Av. of 2 extractions) 
2.5)Zg/ml 5pg/ml t 0pg/ml 
Phthalazine 90 108 99 
1-Hydroxyphthalazine 99 110 110 
However, in each case the average efficiency of extraction was at 
least 90% and consequently over this range of concentrations, which were 
chosen to correspond to the concentrations of these compounds which 
might be expected in the urine of the phthalazine treated rabbit, this 
method of extraction was acceptable. 
Having confirmed the efficiency of the extraction technique it was 
possible to determine whether unchanged phthalazine and 1-hydroxy- 
phthalazine were present in the twenty-four hour urines of the 
phthalazine treated rabbit. 
An aliquot of each urine sample was extracted and the resulting 
chloroform concentrate chromatographed by HPLC. The height of the peaks 
corresponding to phthalazine and 1-hydroxyphthalazine were measured and 
using the calibration graphs it was possible to calculate the absolute 
amount of compound present in each sample. Using this value and taking 
into account the volume of phthalazine solution drunk daily, together 
with the volume. of urine excreted, it was possible to calculate the 
percentage of the total daily dose occurring as either phthalazine or 
1-hydroxyphthalazine. 
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Upon examination of the HPLC traces it became apparent that the 
amount of unchanged phthalazine present in the urine was negligible and 
could not be accurately quantified. 
S 
However, 1-hydroxyphthalazine did appear to be present in the urine 
as a product of the metabolism of phthalazine. The amount was 
calculated and the result expressed as a percentage of the total 
1-hydroxyphthalazine possible assuming 100% conversion. 
Table 8. Percentage of Total Activity Excreted Daily as 
1-Hydroxyphthalazine. 
Day 123 4' 56"789 10 
% 
1-Hydroxy- 0.27 0.31 - 0.57 0.5 0.52 0.39 0.24 1.01 1.1 
phthalazine 
The amount of 1-hydroxyphthalazine excreted'daily in the urine 
varied from 0.24 - 1.1% of the total dose administered, expressed as 
1-hydroxyphthalazine. ' 
In comparison to the in vitro situation where phthalazine is 
rapidly and quantitatively hydroxylated by aldehyde oxidase, only a 
small percentage of the administered dose appeared in the urine as 
1-hydroxyphthalazine. 
Isolation and Identification of 1-Hydroxyphthalazine. 
Absolute proof of the identity of this metabolite was provided by a 
combination of chromatographic and spectroscopic techniques. 
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As only approximately 0.5% of the total dose of phthalazine 
administered appeared to be excreted in the urine as 1-hydroxy- 
phthalazine it was necessary to use large quantities of urine in order 
to extract sufficient material for identification purposes. 
Consequently, two rabbits were treated with 14C-1-phthalazine in an 
identical_manner-to! that previously described. 
Urine from the rabbits was pooled (total volume = 370mis) and 
extracted into chloroform under alkaline conditions. The chloroform 
extract was evaporated under reduced pressure until 5ml remained and 
liquid scintillation counting indicated that 2.3% of the total activity 
present in the urine was extracted into chloroform. 
Upon subjecting the chloroform concentrate to HPLC using a Zorbax 
silica column and 2% methanol: chloroform as the mobile phase (see 
experimental section page 100 for conditions) the resultant profile, 
although adequate for peak height measurement, was too complex to allow 
collection of the eluate corresponding to 1-hydroxyphthalazine without 
contamination by urinary constituents with similar retention volumes. 
The chloroform concentrate was therefore spotted onto preparative TLC 
plates which were then developed in 5% methanol: chloroform. 
The band of silica with a retention distance identical to that 
of 1-hydroxyphthalazine was scraped off the plate and eluted with 
50% methanol: chloroform. 
Following concentration, the eluate was chromatographed by HPLC 
using the system described above. The resultant profile was much 
cleaner than that observed upon chromatography of the chloroform extract 
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(see Figure 18) and consequently this system was used to isolate the 
metabolite corresponding to 1-hydroxyphthalazine. The eluate 
corresponding to 1-hydroxyphthalazine was collected and the identity of 
the metabolite was confirmed by carrying out infra-red and mass spectral 
analysis. 
Figure 18. Comparison of HPLC Profiles of Urine Extracts before and after 
Preparative TLC. 
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The resulting spectra were compared with those obtained upon 
treating an authentic sample of 1-hydroxyphthalazine to the same 
chromatographic and spectroscopic procedures. 
The infra-red spectrum of the isolated metabolite was identical to 
that of 1-hydroxyphthalazine, exhibiting a characteristic C=0 peak at 
1,680cm 1 (Figure 19). 
As the mass spectra of 1-hydroxyphthalazine and the metabolite both 
showed a molecular ion at m/e = 146 and an identical fragmentation 
pattern (Figure 20) it was concluded that the radiolabelled metabolite 
isolated from the urine was 1-hydroxyphthalazine. 
Treatment of Rabbit with 1-Hydroxyphthalazine. 
It has been demonstrated that only a small percentage of 
phthalazine is excreted either as the parent compound or its 1-hydroxy- 
derivative. Therefore, it appears that further metabolism must be 
occurring to. account. for. the large amount of radioactivity detected so 
rapidly in the urine. 
Two possibilities exist for the metabolic fate of phthalazine. It 
may be rapidly converted to 1-hydroxyphthalazine, which is then subject 
to further biotransformation reactions, or alternatively, only a small 
percentage may be oxidised to 1-hydroxyphthalazine, the majority of the 
40 
dose being rapidly metabolised by a different route giving rise to other 
metabolic products. 
In order to determine which of these possibilities was most likely, 
a rabbit was treated with 1-hydroxyphthalazine and the metabolic fate of 
this compound investigated. 
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Figure 19. Infra-Red Spectra of 1-Hydrozyphthalazine and Metabolite 
Isolated from the Urine. 
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Figure 20. Mass Spectra of 1-Hydroxyphthalazine and Metabolite 
Isolated from Urine. 
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The rabbit was treated in an identical manner to the phthalazine 
treated rabbit, except that 1-hydroxyphthalazine (200yg/ml) replaced 
phthalazine in the drinking water. The twenty-four hour urine samples 
were collected over a period of ten days, extracted and the percentage 
of the total dose excreted as unchanged 1-hydroxyphthalazine was 
determined using HPLC. 
The resulting chromatographic profile closely resembled that of a 
chloroform extract of urine from a phthalazine treated rabbit and, over a 
ten day period, only 0.3 - 2.1% of the administered daily dose of 
1-hydroxyphthalazine was excreted unchanged in the urine. 
Consequently, 1-hydroxyphthalazine appears to be subject to 
metabolism in the rabbit. Whilst this does not provide conclusive 
evidence, it suggests that phthalazine may be rapidly metabolised in 
vivo by the cytosolic enzyme aldehyde oxidase, giving rise to 1-hydroxy- 
phthalazine which is then subject to further biotransformation reactions 
prior to excretion. 
The results from these preliminary studies indicated that the 
metabolism of phthalazine is more complex than initially anticipated. 
It has been shown that only a small amount of unchanged phthalazine 
was present in the urine of a phthalazine treated rabbit, indicating 
that the compound was metabolised prior to excretion. However, although 
1-hydroxyphthalazine was also detected in the urine as a metabolite of 
phthalazine, it was only present in very small amounts. 
These observations, along with the fact that 80% of the radioactive 
dose of phthalazine is excreted within twenty-four hours suggests that 
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metabolic routes other than the aldehyde oxidase mediated hydroxylation 
of phthalazine may also be involved. 
The similarity. of the HPLC traces of extracts of urine from 
6) 
phthalazine and 1-hydroxyphthalazine treated rabbits, together with the 
lack of unchanged 1-hydroxyphthalazine in the urine of the 1-hydroxy- 
phthalazine treated rabbit, indicate that phthalazine may be first 
converted to its 1-hydroxylated derivative which is then subject to 
further metabolism. 
Based upon these findings it became apparent that a more detailed 
investigation was, required in order to determine the metabolic fate of 
phthalazine in rabbits. Consequently, the remainder of the in vivo 
studies were carried out using radiolabelled phthalazine (14C-1-phthalazine) 
in order to facilitate the investigation into the fate of this compound. 
Extraction and Thin Layer Chromatography of Urine Samples. 
As the products of phthalazine metabolism could not be readily 
identified using simple chromatographic techniques alone, it was 
necessary to establish, suitable conditions for. the isolation of the. 
metabolites. - 
Simple solvent extraction was again employed as the method of 
choice. Rabbits were treated with 
14C-labelled phthalazine and the 
0- 24 hour urine divided-into two portions, one aliquot was adjusted to 
pH 3 and the remaining portion made alkaline (pH 10) in order to 
facilitate the extraction ofboth acidic and basic metabolites. The 
acidified or basified urine was extracted first with chloroform and then 
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with n. butanol. 
Although less selective than chloroform as an extracting agent, 
butanol is a more polar solvent and as such would be more likely to 
extract water soluble metabolites present in the urine. 
After extraction, the percentage of the total activity present in 
each of the organic concentrates and the extracted urine samples was 
determined by liquid scintillation counting. The results obtained are 
tabulated below: - 
Table 9. Percentage of Total Radioactivity Extracted into Organic 
Solvents from Urine of t4C-1-Phthalazine Treated Rabbit. 
% Total Activity in Urine 
Extract pH 10 pH 3 
'Chloroform 0.6 3.3 
Butanol 17.0 32.6 
Remaining urine 77.0 57.4 
It will be observed that the total activity recovered at each pH 
value does not add up to 100%. This discrepancy may be accounted for by 
the losses incurred during the extraction processes and errors in 
measuring the small volumes added to the scintillant. 
In order to gain some insight into the number of metabolites 
present in the urine and their characteristics, the urine samples and 
the organic extracts were subjected to thin layer chromatography on 
silica gel plates using three different mobile phases. The solvent 
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systems used were: - 
a) methanol: chloroform (5: 95) 
b) n. butanol: glacial acetic acid: water (60: 20: 20) 
0 c) n. propanol: conc. ammonia 0.880 
(70: 30) 
An organic mobile phase (a) was chosen in which lipophilic 
metabolites, but not polar compounds would be likely to run. Two polar 
aqueous mobile phases, one acidic (b) and one basic (c) were also 
employed, in an attempt to differentiate between the polar metabolites 
shown to be present in the urine. 
After developing the thin layer chromatogram in the appropriate 
solvent the silica was divided into small sections between the origin 
and the solvent front and scraped into scintillant. The results 
obtained from the liquid scintillation counting were used to calculate 
the percentage of the activity in each sample present within a 
particular area of the chromatographic plate. 
i) Alkaline Chloroform Extract. (Figure 21) 
Upon chromatography of the chloroform extracts of alkaline urine in 
all three solvent systems, the majority of the activity was soluble in 
the mobile phase. Furthermore, two major bands of activity 
corresponding to the Rf values of phthalazine and 1-hydroxyphthalazine 
were seen in each case. 
Therefore, the amount of activity present in the chloroform extract 
(only 0.6% of the total activity in urine) probably corresponds to 
phthalazine and its 1-hydroxylated metabolite which are totally extracted 
under alkaline conditions (see page 120) and have already been shown to 
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Figure 21. Graphical Representation of Rf Values and Percentage Activity of 
Radiolabelled Metabolites present in Chloroform Extracts of Urine. 
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account for less than 1% of the administered dose of phthalazine. 
ii) Acidic Chloroform Extract. (Figure 21) 
Approximately five times the amount of activity present in the 
alkaline extract was partitioned into chloroform under acidic 
conditions, however, this still only accounted for a small percentage of 
the total dose. 
A large percentage of the activity present remained at the origin 
of the chromatogram when developed in methanol: chloroform (5: 95). This 
band of activity was probably due to the partial extraction of an acidic 
polar compound which was strongly adsorbed onto the silica and was too 
polar to run in this organic mobile phase. 
This was also reflected in the metabolic profile in the acidic 
solvent system (b) when over 80% of the activity ran to the top of the 
plate. Using n propanol: ammonia (c) as the solvent, the majority of the 
radioactivity was present between Rf values 60 - 80 with very little 
activity elsewhere on the chromatographic plate. - 
A second band of activity was detected at the top of the plate in 
the organic system, which indicates that some of the activity in this 
extract is also attributable to a lipophilic metabolite. 
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iii) Butanol Extracts. (Figure 22. ) 
The finding that a much larger proportion of activity extracted 
into the butanol than into chloroform indicates that the products of 
1 55 
Figure 22. Graphical Representation of Rf Values and Percentage Activity of 
Radiolabelled Metabolites present in Butanol Extracts of Urine. 
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phthalazine metabolism present in the urine are relatively polar. The 
results also showed that approximately twice the amount of activity 
extracted under acidic conditions into butanol than under alkaline 
'ý conditions. This suggests that besides being relatively water soluble, 
the metabolites are acidic in nature. 
The chromatographic profile of both butanol extracts in each 
solvent system were remarkably similar, probably indicating that the 
difference in the amount extracted is purely a function of the greater 
overall extraction of the metabolites under acidic conditions, rather 
than selective extraction of one metabolite. 
The majority of the extracted activity remained at the origin in 
the methanol: chloroform system, which is to be expected as compounds 
soluble in the mobile phase would have already been removed during 
chloroform extraction. 
iv) Urine Residue. (Figure 23. ) 
Most of the activity (60 - 77%) remained in the urine after 
sequential extraction with chloroform and butanol at both pH values. 
Not surprisingly, when' chrömatographed in an organic mobile phase the 
majority of this activity remained at the origin. This would be expec- 
ted if the major metabolites of phthalazine are very polar compounds. 
The chromatographic profiles of the urine in solvent systems (b) and (c) 
were diffuse, showing activity from the origin to the solvent front, but 
with a peak of activity around Rf 60 - 80. This is thought to be due to 
salts and naturally occurring urinary constituents which have a distor- 
ting effect upon the chromatography of the metabolites, producing 
1 5j 
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Figure 23. Graphical Representation of Hf Values of Hadiolabelled 
Metabolites present in Urine Samples after Extraction. 
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poor chromatographic definition of the urine sample and consequently 
tailing off of the radioactivity towards the origin. 
Investigation into the Possible Identity of Phthalazine Metabolites. 
Having demonstrated that the majority of the dose of phthalazine 
administered to the rabbit was excreted in the urine and that relatively 
polar metabolites accounted for the majority of the excreted dose, the 
next stage was to attempt to isolate and identify the major metabolic 
products. 
i) 1,4-Dihydroxyphthalazine. 
Although 1,4-dihydroxyphthalazine has never been identified as a 
product of the oxidation of phthalazine or 1-hydroxyphthalazine in 
vitro, the possibility that this compound might arise as a result of 
the in vivo metabolism of phthalazine was investigated. 
The retention distances for 1,4-dihydroxyphthalazine, when 
subjected to thin layer chromatography are reported below: - 
Table 10. Retention Data for 1,4-Dihydrozyphthalazine. 
Solvent System Rf x 100 
Methanol: chloroform 0- 20 (tails) 
( 5: 95 ) 
Butanol: acetic acid: water 90 
( 60: 20: 20 ) 
n propanol: ammonia 60 
( 70: 30 ) 
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The spots were detected by the quenching of the fluorescent 
background at 254nm and a slight purple fluorescence was observed upon 
irradiation at 365nm. 
6 
Upon comparison with the radioactivity profiles obtained when the 
urine was chromatographed using these mobile phases it was observed that 
1,4-dihydroxyphthalazine had the same retention value as a major band of 
radioactivity in each solvent system. 
Similarly, the butanol extracts also showed peaks in activity 
corresponding to the retention distances of 1,4-dihydroxyphthalazine in 
all the solvent systems. As 1,4-dihydroxyphthalazine has a pKa of 5.95 
and reacts as a monobasic acid it might'be expected to extract to some 
extent into butanol, especially under acidic conditions. 
In order to establish whether this compound was one of the products 
of phthalazine metabolism'-in vivo, a butanol extract of acidified urine 
was subject to preparative TLC, followed by HPLC. However, this had 
to be carried out with cold material due to the limited supply of 
radiolabelled phthalazine. 
150m1 of urine from a rabbit treated with unlabelled phthalazine 
was acidified and extracted into butanol. After concentration, the 
butanol extract was spotted onto a preparative TLC plate and 'developed 
0 in butanol: acetic acid: water. This was chosen as the most suitable 
mobile phase as 1,4-dihydroxyphthalazine forms stable salts with ammonia 
and has been found to tail badly using 5% methanol: chloroform as the 
solvent. 
The band of silica corresponding to the Rf value of 1,4-dihydroxy- 
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phthalazine in this solvent system was scraped from the plate and eluted 
with redistilled tetrahydrofuran, which was found to be the most 
effective solvent for the extraction of 1,4-dihydroxyphthalazine. 
The concentrate produced by removal of most of, the tetrahydrofuran 
under reduced pressure was subject to HPLC using a reverse phase system 
with a 25cm Zorbax ODS column and 50% methanol: water as the eluting 
solvent. 
Several peaks were detected at 254nm, none of which had a retention 
volume which exactly corresponded to that of an authentic sample of 
1,4-dihydroxyphthalazine. Unfortunately, there was not sufficient 
material present to permit infra-red or mass spectral identification of 
these compounds. 
These results seemed to indicate that the major band of activity 
detected upon chromatography of the twenty-four hour urine from the 
14C-1-phthalazine treated rabbit was not due either wholly or partly to 
1,4-dihydroxyphthalazine. 
This result is, however, not surprising, as 1,4-dihydroxyphthalazine 
has never been identified as a product of the molybdenum hydroxylase 
mediated oxidation of phthalazine or 1-hydroxyphthalazine in vitro. 
Furthermore, 1-hydroxyphthalazine has been found to be a competitive 
40 inhibitor of both aldehyde oxidase and xanthine oxidase, thus it would 
seem unlikely that 1,4-dihydroxyphthalazine would arise in vivo either 
as a product of the molybdenum hydroxylase mediated oxidation of 1-hydroxy 
phthalazine. 
Moreover, it would be expected that carbon 4 in 1-hydroxyphthalazine 
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would be electron deficient and therefore unlikely to be hydroxylated by 
the microsomal monooxygenase system. 
The possibility that the formation of 1,4-dihydroxyphthalazine in 
vivo may be overlooked because of its appearance in the urine as a 
conjugate may also be discounted. Mclsaac, 
169 upon administering 1g of 
1,4-dihydroxyphthalazine to rabbits via a stomach tube found that 
although approximately 50% of the dose was directly conjugated with 
glucuronic acid prior to excretion, 30% of the dose was excreted 
unchanged in the urine. Therefore, although this compound is subject to 
further metabolism in the rabbit it might be expected that there would 
still be sufficient unconjugated compound present in the urine to detect 
by HPLC. 
r. Ya 
OH C6H906 
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Although the finding that 1,4-dihydroxyphthalazine could not be 
isolated as a product of the metabolism of phthalazine by rabbits may 
not be completely unexpected, the fact that some of the radiolabelled 
material excreted into the urine exhibited similar chromatographic 
characteristics to 1,4-dihydroxyphthalazine suggests that the two 
compounds may be structurally very similar. 
One explanation of this might be that if microsomal oxidation of 
1-hydroxyphthalazine did occur in vivo, hydroxylation of the carbocyclic 
ring would be expected, giving rise to a dihydroxylated metabolite, 
which may have similar chromatographic characteristics to 1,4-dihydroxy- 
phthalazine. 
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ii) Phthalazine N-Oxide. 
O Whilst this work was being carried out, some studies were being 
conducted by Pfizer into the metabolism of a potential cardiovascular 
agent, Carbazeran, a 6,7-dimethoxy-l-substituted phthalazine. 
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Following oral administration of carbazeran to rabbits it was found 
that the major metabolic product, accounting for 30% of the administered 
dose, was an N-oxide, substitution probably occurring at one of the 
phthalazine nitrogens. 
In order to determine whether N-oxidation was one of the metabolic 
pathways for phthalazine itself, a sample of urine containing the 
radiolabelled metabolites was incubated with titanium trichloride, an 
effective reducing agent for N-oxides. 
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The method used was similar to that described by Beckett et a1172 
for the reduction of nicotine-1'-N-oxide to nicotine and is described in 
the experimental section. 
At the end of the incubation period, aliquots of the incubation 
mixtures, together with reference samples of phthalazine and 1-hydroxy- 
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phthalazine were spotted onto TLC plates, developed in methanol: 
chloroform (5: 95) or one of the two aqueous mobile phases and the 
position of the radiolabelled metabolites detected by scintillation 
6 
counting. 
Although 3-methylisoquinoline-N-oxide, which was used as a control, 
was reduced to the parent compound, no change in the amount of activity 
corresponding to the position of phthalazine or 1-hydroxyphthalazine was 
detected on the chromatogram developed in methanol: chloroform following 
incubation with titanium trichloride. Similarly', upon examination of 
the chromatograms developed in the polar mobile phases, no differences 
were observed between the positions of the radiolabelled metabolites in 
the test and control incubation mixtures. 
The results of these incubations suggest that neither phthalazine 
nor 1-hydroxyphthalazine are excreted into the urine in the form of an 
N-oxide, nor do any other products of phthalazine metabolism appear to 
be N-oxides. 
However, without ensuring that an authentic sample of phthalazine- 
N-oxide is reduced to the parent compound under identical conditions, 
these results cannot provide conclusive evidence that N-oxidation is not 
a route of metabolism of phthalazine in rabbits. 
k 
iii) Products of Microsomal Oxidation. 
Although previous in vitro studies6 have indicated that 
phthalazine is not subject to microsomal oxidation, no work has been 
carried out by incubating 1-hydroxyphthalazine with the microsomal 
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pellet. 
Consequently, an in vitro study was carried out in order to 
determine whether small amounts of microsomal oxidation product, 
hitherto undetected, resulted from the incubation of radiolabelled 
phthalazine with the appropriate enzyme fractions or whether 1-hydroxy- 
phthalazine was subject to microsomal oxidation. 
(2.3uCi) 
A limited amount4of 1-hydroxy-(14C-1)-phthalazine was produced by 
treating a sample of 
14C-1-hydralazine hydrochloride with 2N sodium 
hydroxide solution for several weeks. Following extraction of the 
with three x 15m1 chloroform 
alkaline solutionhno rädiöactivity corresponding to the retention 
of the concentrated extract 
distance of phthalazine could be detected on a thin layer chromatogram 
but a single spot with the same retention value as 1-hydroxyphthalazine 
was present. The solvent systems used were those described on page 112 
for the determination of the radiochemical purity of phthalazine. 
The incubations were carried out with 10,000xg supernatant and the 
100,000xg microsomal pellet of rabbit liver, prepared as described in 
the following section (page 166), using appropriate cofactors where 
necessary (see page 106 for experimental details). Suitable controls 
were carried out in each case. At the end of the incubation period, the 
mixtures were cooled in ice and spotted directly onto TLC plates 
together with control incubation mixtures and reference samples of 
phthalazine and 1-hydroxyphthalazine. The plates were developed in 
solvent systems (a) and (b) previously described. (seeTable 11) 
After measurement of the retention distances of the spots visible 
under UV light, the silica was sectioned and scraped into scintillant. 
The results obtained appear to confirm the previous studies. When 
phthalazine was incubated with the 10,000xg supernatant fraction it was 
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rapidly oxidised to 1-hydroxyphthalazine, 100% conversion occurring 
within one hour. However, no evidence of the oxidation of 1-hydroxy- 
phthalazine was detected when the appropriate cofactors for microsomal 
oxidation were added to the incubation mixture. 
Table 11. TLC Data following Incubation of Phthalazine and 
1-Hydroxyphthalazine with Liver Fractions. 
Rf x 100 
Sample (a) (b) 
Reference Sample 
Phthalazine 58 56 
1-Hydroxyphthalazine 73 76 
Quinoline 72 89 
3-Hydroxyquinoline 32 80 
Incubations with 10,000xg Supernatant 
With Phthalazine 72 75 
With 1-Hydroxyphthalazine 71 76 
Incubations with Microsomal Fraction 
With Phthalazine 58 55 
With 1-Hydroxyphthalazine 74 75 
With Quinoline 32 79 
Spots detected by quenching of fluorescent background-at 254nm. 
Similarly, although the viability of the microsomal fraction was 
established by the identification of 3-hydroxyquinoline as a product of 
incubation with quinoline, no products were detected when phthalazine 
or 1-hydroxyphthalazine were incubated with the microsomal pellet. 
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Therefore, it appears that in vitro at least, neither phthalazine 
nor 1-hydroxyphthalazine are subject to microsomal oxidation. 
iv) Conjugates. 
The previous section has demonstrated that neither phthalazine nor 
1-hydroxyphthalazine undergo reaction with the microsomal monooxygenase 
system, at least in vitro. However, either compound may be subject to a 
less common Phase I reaction, resulting in the introduction of 
functional groups which may undergo conjugation reactions. 
Any changes in the metabolic profile brought about by hydrolysis of 
the urine sample from a rabbit treated with radiolabelled phthalazine 
may be detected using a combination of TLC and liquid scintillation 
counting. 
The urine was first subjected to acid hydrolysis, which is 
unselective but efficient in the cleavage of conjugates. This was 
carried out according to the method described in the experimental 
section (page 96). After neutralisation, the hydrolysed urine and a 
control sample of urine were subjected to TLC using the three standard 
mobile phases. The control and hydrolysed urine samples were also 
extracted with chloroform and subsequently butanol at pH 3 and 10. 
Figure 24 shows a graphical representation of these results. When 
the acid hydrolysed sample was chromatographed in methanol: chloroform, 
the majority of the activity remained at the origin of the thin layer 
plate. However, unlike the control, some of the activity present in the 
hydrolysed urine was detected further up the chromatographic plate, 
indicating the presence of a more lipophilic metabolite. This would be 
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expected if a water soluble conjugate of a relatively lipophilic 
metabolite had been cleaved by acid hydrolysis. 
The chloroform and butanol extracts of the hydrolysed urine showed 
essentially the same chromatographic profile as the extracts of control 
urine irrespective of whether the extraction was carried out under 
acidic or alkaline conditions. The only significant difference was in 
the profile of the chloroform extracts where the amount of radioactivity 
corresponding to the retention distances of phthalazine was reduced, 
while that corresponding to 1-hydroxyphthalazine was increased by an 
equivalent amount. This was attributed to the non-enzymic oxidation of 
phthalazine when boiled with hydrochloric acid for several hours. 
Upon examination of the radioactivity profiles obtained when the 
urine samples were run in the two polar mobile phases, significant 
changes were observed in the position of the radioactive bands following 
hydrolysis. 
In butanol: acetic acid: water the majority of the radiolabelled 
material was located near the solvent front following hydrolysis, 
whereas in propanol: ammonia, although some of the activity was detected 
near the front, the majority of the radiolabelled material remained 
close to the origin. 
These results seem to indicate that two metabolites may have been 
cleaved by acid hydrolysis and although these products have similar 
characteristics in butanol: acetic acid: water, a distinct separation of 
the metabolites may be achieved using propanol: ammonia as the mobile 
phase. 
0 
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As before, the radioactivity 'profile of the chloroform and butanol 
extracts of the hydrolysed urine were identical to controls in both 
polar mobile phases. These results, along with the finding that the 
ýl same amount of activity was present in the organic extracts from both 
hydrolysed and control urine, indicate that the products of acid 
hydrolysis are both very polar, as are the parent conjugates. 
As the amount of 'radioactivity at positions corresponding to 
phthalazine and 1-hydroxyphthalazine was not significantly altered by 
hydrolysis, these results confirm that neither phthalazine nor 
1-hydroxyphthalazine undergoes direct conjugation. 
However, this study has demonstrated that some of the products of 
phthalazine metabolism excreted into the urine are susceptible to acid 
hydrolysis, giving rise to other'products with different chromatographic 
characteristics. 
Having demonstrated the existence of these acid-labile moieties in 
the urine, an investigation into the nature of the metabolites was 
undertaken. 
Conjugation with glucuronic acid or sulphate is a common route for 
the Phase II metabolism of foreign compounds. Therefore, in order to 
establish whether the 'acid labile metabolites could be attributed to 
0 
either of these forms of conjugate, urine containing the radiolabelled 
metabolites was incubated with either ß-glucuronidase or arylsulphatase. 
Control and test incubations were carried out as described in the 
experimental section (page 96) the mixtures being incubated over a 
twenty-four hour period and an extra aliquot of the appropriate enzyme 
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being added to the test mixture approximately half way through the 
incubation. The viability of the hydrolytic enzymes was established by 
carrying out incubations with 8-hydroxyquinoline glucuronide and p- 
0) nitrocatechol sulphate. 
At the end of the incubation period, the mixtures were subjected to 
TLC followed by liquid scintillation counting of the silica fractions, 
in order to establish whether incubation with either hydrolytic enzyme 
had any effect upon the chromatographic profile. 
No differences were observed between the chromatographic profiles 
of control and test incubations carried out using arylsulphatase, 
indicating-that conjugation, with sulphate may not be one of the 
metabolic routes of phthalazine in rabbits. The results obtained from 
the incubations carried out using ß-glucuronidase are shown in Figure 25. 
When the urine samples were chromatographed in methanol: chloroform 
(5: 95), the majority of, the radiolabelled material remained at the 
origin, although slightly more activity moved up the chromatographic 
plate from the ß -glucuronidase treated urine. . This indicates that 
cleavage of a glucuronide has released a more lipophilic metabolite. 
Upon chromatography in butanol: acetic acid: water, distinct 
differences were observed between the radioactivity profiles of the 
0 control and test samples. Following incubation with ß -glucuronidase, 
the majority of the radiolabelled material, which was present in the 
control incubation with an Rf value of. 30 - 60, moved to the top of the 
chromatography plate. However, unlike the results obtained when acid 
hydrolysed urine was chromatographed in this mobile phase (see Figure 24) 
the intensity of the band between Rf 60 - 80 was unchanged. 
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Figure 25. Graphical Representation of Retention Values of Radiolabelled 
Metabolites following Incubation with ß -Glucuronida, e in 
Comparison to Control. 
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Therefore, it appears that while acid hydrolysis probably cleaved 
two compounds, the products of which were, subsequently chromatographed 
to the top of the silica plate using butanol: acetic acid: water as the 
mobile phase, only the band of activity with the lowest Rf value may be 
"J 
attributed to a glucuronide conjugate. When the incubation mixtures were 
chromatographed in propanol: ammonia the majority of the activity was 
found to be present towards the top of the chromatography plate. This 
is also in contrast to the profile obtained upon chromatography of the 
acid hydrolysed urine, in which some of the radioactivity also appeared 
to move towards the bottom of the chromatographic plate. 
Consequently, it appears that one of the compounds cleaved by acid 
hydrolysis was a glucuronide conjugate, identified by its susceptibility 
to ß-glucuronidase. The nature of the other acid labile compound has 
not been established, although the results of these incubations indicate 
that it is neither a glucuronide nor a sulphate conjugate. 
Autoradiography of Control and Hydrolysed Urine Samples. 
Although TLC coupled with liquid scintillation counting has proved 
an adequate means of measuring the approximate retention distances of 
radiolabelled metabolites and a method for calculating the percentage of 
the total activity present within each radioactive area, it does not 
allow a determination of the exact number of major metabolites present 
in the urine, or the accurate measurement of their retention distances. 
Consequently, an autoradiographic method was also used to examine 
the radioactivity profiles of the control and ß-glucuronidase treated 
urines, following chromatography in either butanol: acetic acid: water 
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or propanol: ammonia. Although this method is not quantitative, it 
allows easy non-destructive determination of the number of major 
metabolites and their exact retention distances, when samples are 
10) chromatographed in a particular mobile phase. 
This technique, the details of which are described in the 
experimental section (page 105) entails the apposition of a thin layer 
chromatogram to a photographic emulsion for several days, after which 
time the photographic plate is developed, revealing the exact positions 
of the radiolabelled metabolites on the chromatogram. 
A conventional screenless X-ray plate was used and the level of 
radioactivity which could be detected was found to be approximately 
500dpm within three days. 
Three samples were subject to autoradiography: - 
a) 0-24 hour-urine from the 14C-1-phthalazine, treated rabbit.:..,..., 
b) An aliquot of the control incubation mixture. (without 
ß -glucuronidase). 
c) An aliquot of the test incubation mixture. (ß -glucuronidase 
treated). 
The samples were streaked onto the origin of the silica plate in 
approximately 1cm strips so that bands of activity rather than spots 
® would be detected on the photographic film and the chromatograms 
developed in butanol: acetic acid: water or propanol: ammonia. 
The autoradiograms are shown in Figure 26. The percentage of the 
total activity corresponding to each band was determined by liquid 
scintillation counting and was facilitated by knowing the precise 
position of the radiolabelled metabolites on the chromatography plate. 
o 
a 
0 
m 
0 a 
A 
O 
C) to 
b 
cl 0 ti 
U 
r-1 
CS 
ry'l 
a 
4-3 
Ei 4-3 
ti E 
4-4 
0 
U 
N 
V-i 
4-ý 
W 
y 
0 
0 
4.3 
e 
ca ti 
0 
ro 
0 4 
N 
a) ti 
a, 
0 
10 Co 
b 
Z 
0 
.ý b 
Co 
0.1 
Cý 
U 
E 
E 
0 
c 
cu 
a 
0 
CL 
a, 
iv 
U 
fQ 
U 
U 
f9 
O 
fC 
C 
0 
M 
OC 
C 
O 
U 
a) 
C 
a) 
C 
O 
'v 
. ia 
U 
O 
C 
O 
U 
v 
Ö rn °°° 
LO 
Op 2 Co (O VN cc: 
153 
Three major metabolites were apparent when urine was 
chromatographed in butanol: acetic acid: water, two upper bands of 
activity each accounting for approximately 28% and the lower band 40% of 
the total radioactivity. 
Upon treatment with ß -glucuronidase, the lower band moved up the 
chromatographic plate, becoming indistinguishable from the top band of 
activity. Using this method it was also possible to confirm that the 
middle band of activity, attributed to an acid labile metabolite, was 
not susceptible to hydrolysis with ß-glucuronidase. 
Only two major bands of activity were evident on the plate 
chromatographed in propanol: ammonia, the top band probably accounting 
for the two upper bands of activity present following chromatography in 
butanol: acetic acid: water. 
Although the lower band of radioactivity moved up the 
chromatographic plate following incubation with ß-glucuronidase, the 
resultant aglycone had a different retention distance to the 
metabolites which ran to the top of the plate, indicating that the 
aglycone was not identical to either of the other major metabolites. 
Attempted Isolation of Major Metabolites. 
Having demonstrated that there are three major products of 
phthalazine metabolism, an attempt was made to isolate and identify at 
least one of these compounds. 
The pooled urine, which had been previously extracted with 
chloroform for the isolation of 1-hydroxyphthalazine was used. The 
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chromatographic profile of the urine was too complex to allow direct 
analysis, only partial extraction of the radiolabelled metabolites was 
achieved using simple solvent extraction and using preparative TLC 
alone, the areas corresponding to the position of the metabolites were 
still contaminated with other urinary excretion products with similar Rf 
values. Therefore, it was necessary to find a method to concentrate and 
clean up the urine before isolation of the metabolites could be achieved. 
The hydrophobic resin, Amberlite XAD2 is frequently used as an 
initial step in the isolation of metabolic products as a means of 
concentrating and desalting the urine. As a preliminary small scale 
study indicated that 94% recovery of the radiolabelled metabolites could 
be achieved following chromatography of the urine on this resin, this 
technique was considered suitable for preliminary concentration of the 
urine. 
75m1 of urine was adjusted to pH 3.0 and chromatographed on lOg of 
Amberlite XAD2. The eluting solvent was a stepwise gradient of methanol 
in water, followed by 100% methanol. The column eluate was collected in 
250 drop fractions and the radioactivity present in each fraction 
determined by-scintillation counting. The fractions containing the 
radiolabelled material were pooled and the solvent evaporated under 
reduced pressure with a solid CO2 trap connected to the vacuum line to 
0 ensure that radiolabelled material. was not lost by entrainment in the 
vapour. The volume of the final concentrate was 5.0ml. 
Separation of the radiolabelled metabolites present in this 
concentrate was attempted by carrying out silica gel column 
chromatography, using an eluting solvent of butanol: acetic acid: water 
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(60: 20: 20) which was found to be the most effective mobile phase for 
separating the three major metabolites on silica gel TLC plates. 
However, an examination of the column eluate by TLC indicated that 
although the chromatographic profile was much cleaner, the method had 
not been successful in separating the radiolabelled metabolites. 
HPLC was then carried out "to determine whether the metabolites 
could be isolated directly from the pooled eluate of the silica column. 
The positions of the peaks corresponding to the radiolabelled 
metabolites was ascertained by collecting 0.5m1 fractions of the HPLC 
eluate into scintillant and determining the radioactive content of 
each solution. 
Although discrete peaks corresponding to the radiolabelled 
metabolites were produced, the amount of metabolite present in each 
injection was too small and the chromatographic profile too complex to 
enable collection of the column eluate for identification purposes. 
Consequently, the eluate from the silica column was chromatographed 
on preparative TLC plates using propanol: ammonia as the mobile phase. 
The bands of silica corresponding to the position of the radiolabelled 
metabolites were identified by autoradiography and the band of activity 
present at the top of the plate, corresponding to the retention value 
of the acid-labile metabolite and the polar non-labile metabolite in 
this solvent system, was eluted into tetrahydrofuran and the concentrate 
resulting from evaporation of the solvent injected onto the HPLC. 
A reverse phase system, comprising a 25cm Zorbax CN column with a 
mobile phase of 5% isopropanol in 1% aqueous acetic acid was found to be 
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the most suitable for the separation of these metabolites. 
As the tetrahydrofuran concentrate exhibited a relatively clean 
chromatographic profile in this system, it was possible to collect the 
0 
eluate corresponding to one of the radiolabelled metabolites without 
contamination by urinary constituents. 
Sufficient quantities of material were collected to enable mass 
spectral analysis to be carried out. The resultant spectrum of this 
metabolite was found to be extremely complex, " exhibiting a molecular ion 
at m/e 520. 
Even taking into account the possibility that this compound may be 
in a dimeric or trimeric form, or that it may be a conjugate, it is 
difficult to envisage a possible. structure for this metabolite. 
As it became apparent at this stage that the isolation of these 
metabolites was proving an intractable problem, difficult to resolve in 
the time allocated to the study, this was therefore not pursued further. 
0 
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CONCLUSIONS. 
These studies have indicated that the metabolic profile of 
phthalazine in vivo is more complex than may have been initially 
6 anticipated from the results of in vitro investigations. 
Phthalazine appears to be readily absorbed from the gastro- 
intestinal tract of the rabbit, the majority of the radiolabelled 
material being excreted into the urine within twenty-four hours of 
administration. However, only a very small amount of unchanged 
phthalazine was present in the urine and although 1-hydroxyphthalazine, 
the product of the molybdenum hydroxylase mediated oxidation of 
phthalazine in vitro, has been isolated from the urine and identified as 
a product of the metabolism of phthalazine in rabbits, this compound 
only accounted for a very small proportion (2-3%) of the total 
radioactivity excreted in the urine. 
Similarly, upon treating a rabbit with 1-hydroxyphthalazine, only a 
very small proportion of the dose was excreted unchanged in the urine. 
This fact, together with the comparability of the chromatographic 
profiles of the urines from phthalazine treated and 1-hydroxyphthalazine 
treated rabbits suggests that phthalazine may first be rapidly converted 
to 1-hydroxyphthalazine in vivo, which is subsequently subject to 
other biotransformation reactions. 
Further investigation, using mainly thin layer chromatographic 
techniques revealed that three major metabolites were present in the 
urine of the phthalazine treated rabbit, together accounting for 
approximately 96% of the radiolabelled material excreted. 
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The major metabolite, which accounted for 40% of the total activity 
I) 
in the urine was found to be a glucuronide conjugate, identified by its 
susceptiblity to hydrolysis by ß-glucuronidase. 
The second of the three major metabolites, accounting for 
approximately 25% of the activity was found to be susceptible to acid 
hydrolysis, but attempted enzymic hydrolysis indicated that this 
compound was neither a glucuronide nor a sulphate conjugate. 
The third metabolite, which accounted for approximately *30% of the 
activity, was also found to be polar, its chromatographic characteristics 
indicating that it was acidic in nature. 
Figure 27. Summary of the Metabolic Fate of Phthalazine in Rabbits. 
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Although phthalazine might be expected to be oxidised via the 
molybdenum hydroxylases to a dihydroxylated product, only 1-hydroxy- 
phthalazine has been identified as a product in the in vitro situation. 
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The possibility that 1,4-dihydroxyphthalazine may be present in rabbit 
urine as a product of phthalazine metabolism in vivo was investigated 
and the results indicated that the polar acidic metabolite, accounting 
for 30% of the total activity had similar but not identical chromato- 
graphic characteristics to 1,4-dihydroxyphthalazine. 
This similarity suggests that this compound may be a dihydroxy 
metabolite produced by the microsomal oxidation of 1-hydroxyphthalazine. 
Although the electron-density_at carbon 4 of 1-hydroxyphthalazine is not 
known it might be expected that microsomal oxidation would occur in the 
carbocyclic ring, the resulting phenolic metabolite having those 
characteristics (ie, high polarity and acidity) attributed to this 
metabolite. 
OH 
NN 
LJLJiH HO I NH 
O O. 
Although the in vitro studies carried out in the course of this 
work indicated that phthalazine and 1-hydroxyphthalazine were not 
subject to microsomal oxidation, Mclsaac and Kanda168 isolated a 
microsomal oxidation product of phthalazine using an in vitro technique. 
0 
Similarly, Moroi et a1173 reported the presence of 6- or 7-hydroxy- 
phthalazine-1 -one as a polar non-extractable minor metabolite of the 
antihypertensive drug budralazine, although the route of metabolism to 
this compound was not made clear. 
It is therefore possible that phthalazine and 1-hydroxyphthalazine 
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are subject to microsomal oxidation in vivo and that the conditions used, 
or the short period of incubation in vitro were inadequate to produce 
sufficient oxidation product to be detected. 
I) 
When McIsaac169 treated rabbits with-1,4-dihydroxyphthalazine, 
approximately 50% of the dose was excreted as a glucuronide conjugate. 
Consequently, it might be expected that if this metabolite was a 
hydroxylated derivative of phthalazine it would also be subject to 
glucuronidation prior to excretion. 
An examination of the chromatographic characteristics of the 
aglycone produced upon treatment with ß-glucuronidase indicated that it 
had similar retention values to the acidic metabolite in each of the 
solvent systems used. However, the autoradiogram of the plate developed 
in propanol: ammonia indicated that the two compounds were not identical. 
Although this evidence appears to preclude the possibility that 
two of the major products of phthalazine metabolism are due solely to a 
phenolic metabolite and its glucuronide conjugate, the chromatographic 
similarity of the aglycone and the acidic metabolite suggests that they 
may be'closely related structurally. 1 
The fact that one of the major metabolites of phthalazine, whilst 
® not susceptible to enzymic hydrolysis was hydrolysed by acid suggests 
the presence of a conjugate other than a glucuronide or sulphate. 
The possibility that this may be'a conjugate with the nucleophilic 
tripeptide glutathione cannot be overlooked because although glutathione 
conjugation most frequently occurs at positions where there is a 
nucleophilic leaving group, eg. halogen, NO2, or with epoxides, any 
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compound having a sufficiently electron deficient centre is a potential 
substrate for this conjugation reaction. 
Carbon 1 (or 4) in phthalazine is sufficiently electron deficient 
to be subject to nuleophilic attack by"aldehyde oxidase and although the 
electron density at carbon 4 in 1-hydroxyphthalazine is not known, it 
might be expected that this position would also be electron deficient. 
Consequently, it is conceivable that these compounds could undergo 
conjugation with glutathione. As glutathione conjugates are frequently 
further metabolised to yield premercapturic and mercapturic acids prior 
to excretion, other acidic metabolites may also arise from such a 
conjugation reaction with phthalazine. 
-A large number of compounds, many of them drugs, containing 
N-heterocyclic rings eg. pyridazines, pyrimidines, triazines and other 
fused ring systems have been reported to be susceptible to 
N-oxidation, 174 and recent studies175 using pyridine as a model compound 
suggest that N-oxidation may be a quantitatively important route of 
metabolism in vivo. 
Although small amounts of quinoline and isoquinoline are excreted 
as their N-oxides by guinea pigs, there is no evidence for these 
metabolites being produced in rabbits. 176 However, studies carried out 
0 to determine the metabolic fate of the substituted phthalazine, 
carbazeran, in rabbits indicated that the major metabolite, accounting 
for approximately 30% of the administered dose, was due to an N-oxide, 
probably of the phthalazine moiety. 
170 
The possibility that one of the highly polar metabolites of 
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phthalazine itself was attributable to an N-oxide was investigated by 
attempted reduction to the parent compound. As there was no change in 
the chromatographic profile it was tentatively concluded that N-oxidation 
was not a major metabolic route for phthalazine in rabbits. However, as 
aromatic N-oxides have a reasonably stable N-0 bond they are less 
susceptible to reduction than aliphatic N-oxides. 
177 Consequently, 
without ensuring that an authentic sample of phthalazine-N-oxide was 
reduced under identical conditions it was not possible to totally 
eliminate N-oxidation as a route of metabolism of phthalazine in rabbits. 
Until recently, N-methylation of heterocyclic compounds was 
considered a minor biotransformation reaction. However, the advent of 
better isolation techniques, eg. ion-pair extraction and ion-exchange 
chromatography, has facilitated the detection of these compounds and this 
type of conjugation reaction is now believed to be an important 
metabolic route in several species, although the number of compounds for 
which it is known to occur is still relatively few. 
N-methylation results in the conversion of a weakly-basic compound 
into a strongly basic quaternary ammonium metabolite and renders the 
carbon atom susceptible to nucleophilic attack. Recent studies178 have 
shown that quaternisation of a number of mono and -diazanaphthalenes 
increases their susceptibility to aldehyde oxidase mediated oxidation, 
0 
resulting in the formation of non-polar hydroxylated metabolites which 
are readily-extracted into organic solvents. Although this study did 
not encompass phthalazine it might be expected that the N-methylated 
derivative of this compound would also behave similarly. 
On the basis that the major metabolites of phthalazine, which are 
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highly polar and acidic, do not exhibit the properties ascribable to an 
N-methylated derivative, or its'possible aldehyde oxidase mediated 
oxidation product, it was concluded that N-methylation was not an 
6 important metabolic route for phthalazine in rabbits. 
Finally, it is worth considering the possible effect of gastro- 
intestinal micro-organisms upon the metabolic fate of phthalazine. It 
has been reported179 that micro-organisms may cause ring fission in 
chemically diverse heterocycles and although the majority of the reports 
pertain to oxygen containing systems, a number of nitrogen heterocycles, 
eg. tartrazine and penicillins containing a ß-lactam ring also undergo 
this type of reaction. The cleavage of these heterocycles results in 
metabolic products unlike those normally produced by the tissues. For 
example, coumarin is cleaved to give melolitic acid. 
OO OH 
CH2CH2000H 
As phthalazine was adminstered orally to the rabbits, it is 
conceivable that this compound, or a metabolite excreted into the bile 
could undergo this type of reaction. If the product of this fission 
reaction was subsequently reabsorbed into the body, it may then be 
subject to both Phase I and Phase II metabolism prior to excretion and 
consequently it would be extremely difficult to predict the structure of 
the final urinary metabolites.., 
SECTION V 
INTERACTION OF PHTHALAZINE AND 1-HYDROXYPHTHALAZINE 
WITH LIVER OXIDATIVE ENZYMES IN VIVO. 
0 INTRODUCTION. 
One of the ways in which an organism adapts to changes in its 
environment is by regulation of enzyme activity. 
The activities of the enzymes involved can be altered by dietary 
and nutritional factors, hormonal changes in the body and ingestion of 
foreign compounds. It is an accepted fact that a large number of drugs, 
carcinogens, other environmental chemicals and steroids have the ability 
to stimulate their own metabolism and possibly that of other compounds 
by elevation of cytochrome P-450 levels. 
180'181 
Theoretically, this process is only termed 'enzyme induction' when 
it has been shown to involve 'de novo' synthesis of enzyme protein at a 
rate greater than that observed in controls. However, the mechanism by 
which an increased rate of metabolism is obtained is frequently unclear 
and is often not related to enzyme synthesis. An increase in enzyme 
concentration may also be observed following a reduction in the rate of 
enzyme degradation, by enzyme stabilisation or by activation of pre- 
existing apoenzyme. Consequently, the term 'enzyme induction' is 
frequently loosely used to be synonymous with an increase in 
metabolising capacity, irrespective of cause. 
Although the majority of the work carried out on enzyme induction 
relates to the microsomal monooxygenase system, more recent studies have 
indicated that many other enzymes are also present in an inducible form, 
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eg. glucuronyl transferases, 182 glutathione reductaset83 and epoxide 
hydratase. 1.84, The. induction of, cytosolic aldehyde dehydrogenase has 
been thoroughly investigated185'186 and a new form of the enzyme 
identified following exposure to polycyclic hydrocarbons. 
Dietrich, 187 in 1954, reported that treatment of mice with xanthine 
resulted in elevated levels-of xanthine oxidase and it is well 
documented188 that. xanthine dehydrogenase levels in chicks and micro- 
organisms may be elevated by a number of different factors. However, 
there do not appear to be any reports of the induction of aldehyde 
oxidase activity. 
Consequently, an investigation was undertaken to determine the 
influence of phthalazine treatment upon the levels of oxidative enzymes 
present in rabbit liver. 
6 
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EXPERIMENTAL. 
Preparation of Purified Enzyme Fractions. 
Female New Zealand White rabbits were used throughout the study. 
6 
Homogenisation was carried out using a Tri-R-Stir-R Model S63C variable 
speed stirrer fitted with a Teflon pestle. 
An MSE High Speed 18 centrifuge fitted with an angled rotor was used for 
low speed centrifugation (10,000xg and 15,000xg). 
High speed centrifugation was carried out using a Beckmann L8 70 
ultracentrifuge fitted with an SW 28 swinging bucket rotor. 
Ultrafiltration was carried out using Millipore CX-10 ultrafilters. 
All apparatus and solutions were cooled to 4°C prior to use. 
Method 
The rabbit was killed by cervical dislocation and the liver 
immediately excised. After removal of the gall bladder, the liver was 
washed with isotonic potassium chloride solution (1.15% w/v) containing 
10-4M EDTA, blotted dry and weighed. 
The liver was then transferred to a dish containing four times by 
volume of potassium chloride solution and finely chopped using scissors. 
Approximately 8ml of this mixture was transferred to a glass 
homogenising tube and, keeping the tube surrounded by ice throughout, at 
least six to eight excursions of the pestle were'made taking 
approximately 10 seconds for each excursion. 
The homogenates were combined and transferred to 250m1 poly- 
carbonate centrifuge tubes. The weights of the tubes and stoppers were 
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equalised and the contents centrifuged at 10,000xg for thirty minutes at 
4°C. The resulting supernatant was divided and used to prepare purified 
aldehyde oxidase fractions and the microsomal pellet. 
® 
i) Isolation of the Microsomes. 
The microsomal pellet was isolated from the 10,000xg supernatant by 
high speed centrifugation. Approximately 70m1 of the supernatant was 
divided between two polycarbonate tubes which were then balanced. 
These'tubes were inserted into the stainless steel buckets of the rotor 
and centrifuged at 100,000xg for one hour at 4°C. 
The resulting microsomal sediment was resuspended in 1.15% potassium 
chloride solution by gentle homogenisation using a small Teflon pestle 
and then recentrifuged at 100,000xg for one hour at 4°C. 
The supernatant was discarded and the microsomes were resuspended 
in a mixture of equal quantities of 1.15% potassium chloride solution 
and 0.067M potassium phosphate buffer (pH 7.0) and used as rapidly as 
possible thereafter. 
ii) Preparation of Purified Aldehyde Oxidase Fractions. 
The remaining 10,000xg supernatant was transferred to two 500m1 
conical flasks and heated on a water bath at 55-600C for ten minutes. 
The flasks were then rapidly cooled to approximately 10°C in an ice bath 
with stirring. The cooled supernatant was transferred to 250m1 centri- 
fuge tubes and centrifuged at 15,000xg for forty five minutes at 4°C. 
The supernatant was filtered through glass wool and the volume of the 
resulting clear red solution was noted. Maintaining the solution at 4°C 
in an ice bath, solid ammonium sulphate was added to 50% saturation in 
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order to precipitate the enzyme. 
The partially purified enzyme was collected by centrifugation at 
6,000xg for thirty minutes and dissolved in 10-15ml of 10-4M EDTA 
solution. This enzyme fraction could be used directly or further 
purified by column chromatography, carried out at 4°C. 
Approximately 10ml of the partially purified enzyme solution was 
chromatographed on a Sephadex G75 gel filtration column (60cm x 2.2cm) 
and eluted with 10-4M EDTA solution. The fractions of the eluate 
containing aldehyde oxidase activity were pooled and concentrated by 
ultrafiltration. 
The resulting concentrate, approximately 5m1, was then 
chromatographed on a DEAE-cellulose ion exchange column (60cm x 1.6cm), 
eluted first with 200ml of 0.1M potassium phosphate buffer (pH 7.8) and 
subsequently with 200m1 of 0.2M potassium phosphate buffer (pH 7.8). 
The active fractions were identified, pooled and concentrated by 
ultrafiltration giving rise to approximately 2m1 of purified aldehyde 
oxidase solution. 
Figure 28 summarises this preparative procedure. 
0 
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Figure, 28. Preparation of Purified Liver Enzyme Fractions. 
Rabbit Liver 
Placed in 4-9 volumes 
isotonic KC1 solution, 
chopped and homogenised 
Homogenate 
Centrifuged - lU, 000xg -30mins 
Residue discarded 
Supernatant* 
Heated at 55-60°C 10min Centrifuged at 100,000xg -1 hour, 
cooled, centrifuged at 15,000xg - 45min supernatent discarded 
Supernatant Residue 
(NH q) 504 added Resuspended in isotonic 
to 501 saturation KC1 solution, 
centrifuged at 6,000xg - 30min recentrifuged at-100,000xg 
Residue dissolved in for I hour 
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Partially Purified*' Microsomes 
Aldehyde Oxidase 
Resuspended in mixture of 
Sorenson's phosphate buffer pH 7"U 
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Chromatographed on 
Sephadex G75 
Eluted with 10-4M 
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"- Enzyme activity tested 
Sephadex G75 Concentrate 
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Eluted with 
(1) 0. IM potassium phosphate buffer 
pH 7.8 
(2) 0.2M potassium phosphate buffer 
pH 7.8 
Active fractions pooled and concentrated. 
DEAF-Cellulose Concentrate 
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Estimation of the Protein Content of Enzyme Fractions. 
The Dye Concentrate was purchased from Bio-Rad Laboratories. 
Measurements were carried out using a Pye Unicam SPS-250 UV/Visible 
f Spectrophotometer. 
Method. 
A series of standard solutions were prepared by diluting a freshly 
prepared stock solution containing bovine serum albumin 2mg/ml, so that 
the standards contained 200,400,600,800,1,000, and 1,200 pg bovine 
serum albumin/ml. 
The dye reagent was prepared by diluting the 'Bio-Rad' 
concentrate one to five with water; mixing thoroughly and filtering 
Five ml of the dye reagent was added to 100)11 of each standard solution 
in a test tube, thoroughly mixed and left to stand for fifteen minutes. 
After this time the absorbance of each solution was determined at 595nm 
against a blank prepared by adding 5m1 of dye reagent to 100ji l of 
water. 
A calibration curve was prepared by plotting A595 against the 
amount of bovine serum albumin present in each 100ul of standard 
solution. 
The protein content of an enzyme fraction was determined by mixing 
100N1 of the suitably diluted enzyme solution with 5m1 of the dye 
reagent and measuring the A595 after fifteen minutes. The protein 
content of the sample was then determined by reference to the 
calibration graph. A typical calibration graph is shown in figure 29. 
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Figure 29. A Typical Calibration Curve for Determination of Protein 
Content. 
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Estimation of Microsomal Activity by Measurement of the 0-Demethylation 
of p-Nitroanisole. 
The 0-demethylation, of p-nitroanisole to produce p-nitrophenol may 
0 be used to estimate the microsomal activity of the 10,000xg supernatant. 
The formation of p-nitrophenol, which is yellow in alkaline 
solution, -can be measured at 420nm. 
Method. 
Test, control and standard incubation mixtures were made up in 10ml 
conical flasks according to the following conditions: - 
Test Control Standard 
Magnesium Chloride 15pmol 15)lmol 15)1mo1 
Glucose-6-phosphate - 15pmol 15}zmol 15pmol 
NADP+ 0.3jimol 0.3, umol 0.3)Zmol 
p-Nitroanisole 2)Zmol 2; Zmol* - 
p-Nitrophenol - - 0.4Jlmol* 
Enzyme (10,000xg supernatant) - equivalent to 130mg of liver 
* Added after completion of the incubation. 
Solutions were made up in 0.067M potassium phosphate buffer pH 7.8 
and an incubation volume of 2.5ml was used. 
The reaction was started by the addition of the enzyme preparation 
to the incubation mixture and the incubation was carried out in air, in 
a shaking water bath at 37°C for thirty minutes. 
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At the end of this period the flasks were rapidly cooled in ice and 
1.0ml of 2N hydrochloric. acid was added to each flask to precipitate the 
protein. At this stage the post incubation additions were made. The 
mixtures were then centrifuged at 3,000 rpm for fifteen minutes. 
Two ml of each supernatant solution was pipetted into clean 
centrifuge tubes and to each tube was added 2. Oml of 2N sodium 
hydroxide. After mixing, the solutions were allowed to stand for five 
minutes and then centrifuged at 3,000 rpm for five minutes. 
The absorbances of the test and standard solutions were measured at 
420nm using the control solution as a reference and the percentage 
conversion of p-nitroanisole to p-nitrophenol calculated. 
Binding Spectra. 
Spectra were obtained using a Pye Unicam SP8-250 UV/Visible 
Spectrophotometer. 
The microsomes were obtained from liver as previously described 
(page 167), suspended in a mixture of 1.15% potassium chloride solution 
and 0.067M potassium phosphate buffer (pH 7.0). 
An aliquot of this microsomal preparation was diluted with 0.067M 
potassium phosphate buffer, (pH 7.0) so that the final protein 
concentration was approximately 2mg/ml, determined using the method 
described on page 170. 
The resulting suspension was divided equally between two cuvettes 
and the baseline of equal absorbance recorded. 
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The substrate, normally lpl of liquid or 1mg of solid was added to 
the sample cuvette and the spectrum was recorded from 340 - 480nm. 
® 0.025m1 of a 20mM solution of NADPH was added to each cuvette and 
the spectrum again recorded. 
Analytical Iso-Electric Focusing of Enzyme Samples. 
Electrofocusing was carried out using an LKB Multiphor 2117 Chamber 
connected to an LKB 2197 Power Supply and a circulating cooling water 
bath maintained at 100C. 0.5mm Agarose gel plates containing carrier 
ampholines, pH range 4.0 - 6.5 were prepared according to the LKB 
Instruction Leaflet 1818-A. A brief outline of this method is included 
below. 
i) Method for Preparation of Agarose Gel Plates. 
The agarose ge1"was prepared by adding 0.18g of agarose to 16.6ml 
of distilled water and heating in a water bath with stirring until all 
the agarose had dissolved. The solution was cooled to 750C and 1.4m1 of 
carrier ampholines, pH range 4.0 - 6.5, was added and mixed thoroughly. 
A'mould was prepared by rolling a backing sheet, hydrophilic side 
upwards onto the'(12 x 26cm) flat'glass plate provided and clamping a 
second plate, with spacers on Weither edge, on top of the first plate. 
The mould was then placed in an oven at 70°C for fifteen minutes. 
The mould was removed and the plate prepared by 'tilting the mould 
to an angle of 30° to'the horizontal and slowly injecting the agarose 
solution into the mould using a 20m1 syringe with a piece of flexible 
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tubing attached to the nozzle. 
When the mould was full it was immediately lowered and left in a 
horizontal position for fifteen minutes to allow the agarose to cool and 
0 set. 
After removing the excess gel at the ends of the plate, the top 
plate was carefully removed and the agarose plate was placed in a 
humidity chamber at 4°C for at least one hour prior to use. 
ii) Focusing of Enzyme Fractions on the Agarose Plates. 
The agarose plate was removed from the humidity chamber, the 
surface of the gel dried with Whatmans 1 MM filter paper for thirty 
seconds and then placed on the Multiphor cooling plate, having applied 
kerosene between the surfaces. 
The electrode strips were soaked in 0.5M acetic acid for the anode 
and 0.5 sodium hydroxide for the cathode. Any excess electrode solution 
was removed using a tissue and the strips were applied to the edges of 
the gel, cutting off any excess which protruded at either end of the 
gel plate. 
Sample application pieces, consisting of small squares of filter 
paper, (approximately 5x 5mm) were applied to the surface of the 
agarose plate at regular intervals, normally positioned approximately 
4cm from the cathode end. 
The enzyme samples to be examined were diluted to give a protein 
concentration of 1mg/ml and 101.11 volumes applied to the pieces of 
filter paper. 
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The plate was focused at constant power, set to give an initial 
voltage of 500V, for one hour, after which time the power was increased 
by 50% and the plate focused for a further ten minutes. 
0 
The sample application pieces were removed approximately half way 
through the running period. 
iii) Staining Techniques. 
Groups of enzyme samples to be examined were normally applied to 
the agarose plate in duplicate so that both a protein stain and a 
specific stain for aldehyde oxidase activity could, be carried out on 
each sample. 
a) Protein Stain. 
The following solutions were used: - 
i) Fixing solution - containing 10% trichloroacetic acid 
and 1% sulphosalicylic acid in 
distilled water. 
ii) Washing solution - 95% alcohol. 
iii) Staining solution - 0.5% Page Blue 83 in destaining 
solution. 
iv). Destaining solution - consisting of 350m1 of 95% ethanol and 
100ml of glacial acetic acid made up 
to 1-litre with distilled water. 
When the focusing period was complete, the section of the agarose 
gel to be stained for protein was placed in fixing solution for ten 
minutes. This solution was then discarded, replaced by 95% alcohol and 
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left for a further ten minutes, after which time the gel was removed and 
dried using a stream of hot air. 
The gel was then placed in staining solution for five minutes, then 
immediately transferred to destaining solution until the excess dye had 
been removed. This normally took approximately fifteen minutes, using 
one change of destaining' solution. Finally the gel was redried. 
b) Stain for Aldehyde Oxidase Activity. 
At"the end of the focusing period; the section of the gel to be 
stained for aldehyde oxidase activity was placed in a dish containing: - 
20m1 pH 7.8 potassium phosphate buffer (1. OM) 
3ml Nitro blue tetrazolium solution (10-3M) 
3m1 Phenazine methosulphate solution (10-4M) 
5m1 Substrate solution (made up at 6x concentration giving maximal 
rate of oxidation) 
All solutions were made up in distilled water. Phenazine 
methosulphate and nitro blue tetrazolium solutions were prepared 
immediately prior to use. 
The dish was placed in a water bath maintained-at approximately 
37°C in the dark. When bands of enzyme activity became apparent, after 
0 
approximately five minutes, the staining solution was replaced by 
distilled water. The gel was left to stand for thirty minutes, also in 
the dark and the water changed several times during this period. The 
gel was finally dried using a stream of hot air. 
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Method for the Determination of the Molybdenum Content of Enzyme Samples. 
The molydenum content of samples of aldehyde oxidase purified by 
DEAE-cellulose column chromatography was determined by electrothermal 
0 
atomic absorption spectroscopy using a method of standard additions. 
A Pye Unicam SP9-01 Digital Flameless Atomiser fitted with a 
pyrolytically coated carbon'graphite tube was used in conjunction with a 
Pye Unicam SP 1950 Atomic Absorption Spectrophotometer connected to a 
Deuterium Lamp Background Corrector and a Rapid Response Electronic Kit 
and linked to a Rikadenki B16 pen recorder and a Hewlett Packard 3388A 
Integrator. 
Grade A volumetric flasks and pipettes were used thoughout and all 
apparatus was soaked overnight in a solution of 2% nitric acid 
immediately prior to use. 
Solutions were made up in freshly prepared double distilled water 
and all standards, apart from the stock solution, were prepared daily. 
i) Method. 
A stock solution of molybdenum was prepared by dissolving 
approximately 100mg of molybdenum wire, accurately weighed, in a mixture 
of 150m1 of concentrated nitric acid and 50m1 of concentrated 
0 hydrochloric acid and diluting to 500ml with double distilled water. 
This stock solution was serially diluted to give standard solutions 
containing 50,100,150,200, and 250ng Mo/ml. 
The enzyme fraction to be tested was diluted to give a protein 
concentration of 0.1mg/ml and a series of solutions, were prepared by 
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mixing 0.5m1 of the enzyme solution with 0.5m1 of water, or 0.5m1 of the 
standard solutions. 
IOul samples were injected into the graphite tube using an 
accurately calibrated SGE syringe and the graphite tube flushed with 
argon by blocking the glass injection port. 
The instrumental parameters and conditions for atomisation were as 
follows: - 
Instrumental Parameters. 
Lamp current 14mA 
Optimum X 313.3nm 
Slit width 0.1mm 
Sensitivity approx 440 
Argon flow rate 2.0 l. miri 
1 
Water coolant flow rate 200m1. min-' 
Atomisation conditions. 
Stage Time (s) Temp. setting 
Dry 30 20 (150°C) 
Ash 15 40 (800°C) 
Delay 15 - 
Ash 25 60 (1,900°C) 
Delay 10 - 
Atomise 8 88 (2,900°C) 
Delay 10 - 
Clean 5 98 (3,100°C) 
Delay 10 - 
Blank 6 88 (2,900°C) 
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Repeat injections of each solution were made and the peak areas 
determined using the integrator. 
A standard additions curve was prepared by plotting peak area 
0 (arbitary units) against the amount of molybdenum derived from the 
standard present each 10Yu1 injection volume. 
The intercept on the X axis was equivalent to the amount of 
molybdenum present in a 10 )1 injection volume of the enzyme sample. 
A typical example of a standard additions plot is shown in Figure 30. 
Discussion of Electrothermal Atomic Absorption Spectroscopy as a Method 
for Determining the Molybdenum Content of Liver Samples. 
The determination of the molybdenum content of aldehyde oxidase and 
xanthine oxidase is most frequently carried out using either the 
'dithiol' method, 
189 involving the formation of a spectrophotometrically 
detectable complex between molybdenum and dithiol, or atomic absorption 
spectroscopy. 
Until recently, the most widely used method of atomisation was that 
of the flame. However,, although precision is usually high, as a result 
of integration of a constant signal, this method suffers from the dis- 
advantage that it requires at least 0.5m1 of sample to obtain one 
integrated reading and although detection limits are usually higher than 
those achieved using other assay methods it still has a relatively poor 
analytical sensitivity. 
However, the development of efficient flameless atomisation 
techniques has led to greater sensitivity and this method is now 
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frequently used for-the determination of the molybdenum content of 
biological samples. 
® Electrothermal atomic absorption spectroscopy is achieved by the 
ohmic heating of a carbon graphite tube and is between 104-105 times 
more sensitive than flame atomic absorption spectroscopy, with the added 
advantage that only very small quantities of sample are required. 
Molybdenum is a difficult element to atomise and requires 
temperatures up to 3,000°C. Upon atomisation it exhibits a complex 
spectrum, the line at 313.3nm being the most sensitive and therefore the 
optimum wavelength. 
The use of a carbon furnace enables the steps which occur in the 
flame atomisation process to be carried out sequentially. There are 
five basic steps to the atomisation sequence, dry, ash, atomise, tube 
clean and tube blank and it was necessary to optimise each stage before 
analysis of the molybdenum'content of enzyme fractions could be carried 
out. 
i) Drying. 
During this phase the solvent is removed from the sample injected 
into the graphite tube in a controlled manner, slow even evaporation 
leaving a discrete sample of dried material. Too rapid removal of water 
results in the loss of sample due to spitting and frothing, while 
inefficient drying leads to the loss of material in a similar way at the 
beginning of the ash sequence. 
The time and temperature settings were optimised by gradually 
increasing both, until no absorption peak, representative of the 
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presence of water, was detected at the beginning of the ash sequence. A 
drying time of thirty seconds at a setting of 20 (150°C) was found to 
give the most satisfactory results. 
ii) Ashes 
The ashing stage removes as much of the matrix as possible without 
loss of the analyte. However, as molybdenum is a relatively involatile 
element, high ashing temperatures can be used without incurring such 
losses. 
Having established an atomisation temperature using a standard 
solution of molybdenum, a suitable ashing temperature was determined by 
preparing a plot of peak area of the analyte signal against ashing 
temperature. Keeping the dry, atomise and tube clean conditions 
constant, the ashing temperature was gradually increased until a 
reduction in the size of the analyte peak was observed and the setting 
approximately 100°C below this point was selected.. The most suitable 
temperature was found to be 60 (1,900°C) and the sequence was carried 
out in two stages to prevent spitting, with the resultant loss of the 
molybdenum, upon rapid heating to this temperature. 
iii) Atomisation. 
0 When peak area is plotted against temperature setting, a maximum is 
normally achieved at a particular temperature, which is designated the 
atomisation temperature. 
However, in the case of molybdenum, increasing the temperature 
continually increased the peak area. This phenomenon occurred because 
4 
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the high temperature required to atomise molybdenum facilitated the 
black body radiation emitted from the graphite tube to 'break through' 
the detection system, resulting in spurious peaks. 
Therefore, in order to establish a suitable atomisation 
temperature, a blank tube was heated to increasingly high temperatures 
until false peaks, ie. break through, was detected. A setting slightly 
below the point at which this occurred was chosen as the atomisation 
temperature. 
The atomisation time was determined by measuring the time taken for 
commencement of the peak to its return to baseline using a fast response 
pen recorder. 
iv) Tube Clean. 
Tube clean conditions were set so that the subsequent blank firing 
gave no peak. As molybdenum forms refractile carbides and because it 
condenses on the cooler parts of the graphite tube, repeated high 
temperature tube clean firings were sometimes necessary to bring the 
blank back to an acceptable level and remove memory effects. 
v) Tube Blank. 
Tube blank time and temperature settings were identical to the 
0 
atomise settings. 
The molybdenum content of the enzyme solutions was determined using 
a technique of standard additions, rather than a simple calibration 
graph, because although the straightforward calibration method works 
well for simple solutions and samples where complete removal of the 
%ýEý 
185 
matrix is possible, it is inadequate when interference may occur, eg. 
due to the incomplete removal of the matrix in high solid samples. 
Tha amount of molybdenum was related to the transient signal 
produced upon atomisation by integration of the peak area. Using this 
method of measurement all atoms which pass through the measuring beam of 
the instrument contribute to the final signal, yielding a value less 
dependent upon the electronic time constant of the machine and offers a 
wider linear calibration range, with better precision and reproduc- 
ibility than using peak height measurement. 
41P 
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RESULTS AND DISCUSSION. 
The activities of both the microsomal monooxygenase system and the 
molybdenum hydroxylases were examined in enzyme fractions prepared from 
0 
the livers of rabbits pretreated with phthalazine and compared with 
control values obtained using enzyme fractions prepared from untreated 
rabbits. 
The androgen, testosterone, has been found to increase the activity 
of the liver microsomal enzymes when administered to female räts. 
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Similarly, testosterone has also been found to have an inductive effect 
upon the aldehyde oxidase activity in female mice which is greater than 
the general anabolic effect of the hormone. 190 
Although testosterone is not believed to have any inductive effect 
upon the liver microsomal activity, in species other than rats, it` is not 
clear whether its effect upon aldehyde oxidase activity is similarly' 
restricted to one species. Therefore, in order to eliminate the 
possibility of any variations in enzyme activity being due to changes in 
testosterone levels, mature female rabbits were used throughout the 
study. 
The-rabbits were treated for seven days with a solution of 
phthalazine (1mg/ml) in place 'of the` drinking water, such that an 
0- approximate daily dose of 50mg/kg was achieved. After the seven day 
period, the phthalazine solution was replaced by drinking water and 
twenty-four hours later the rabbit was sacrificed. The liver enzyme 
fractions were prepared as described in the experimental section (page 
166). 
'ý- 
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Determination'of-the Effect of-Phthalazine Treatment upon Microsomal 
Activity. 
i) Microsomal Activity of the 10,000xg Supernatant. 
The microsomal activity of the 10,000xg supernatant was determined 
by measuring the 0-demethylation of p-nitroanisole using the method 
described in the experimental section (page 172). 
I- 
OCH3 OH 
liver microsomal 0-demethylase I 
NADPH, 02, pH 7.8 
I 
NO2 NO2 
p-Nitroanisole is a convenient substrate for assay as it only 
absorbs slightly at"420nm; whereas theýdemethylated product, p-nitrophenol 
absorbs strongly at that wavelength under alkaline conditions and 
consequently the product can be assayed in the presence of substrate. 
Typical values for the conversion of p-nitroanisoleýto p-nitrophenol, 
under the conditions of the experiment, have been quoted as 3% conversion 
in thirty minutes for a non-treated rabbit and between 10-15% conversion 
using a liver from a rabbit pretreated with sodium phenobarbitone. 
5 
01 
Table 12 shows the percentage conversion obtained over thirty 
minutes using 10,000xg supernatent prepared from the livers of 
phthalazine treated rabbits in comparison to the values obtained using 
untreated rabbit liver. 
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Table 12. Comparison of the Percentage Conversion of p-Nitroanisole 
using 10,000xg Supernatant from Liver of Control and Phthalazine 
Treated Rabbits. 
Sample % Conversion (30 mins) 
Untreated (n = 4) 9.38 + 4.1 
Phthalazine treated (n = 4) 10.105 + 1.386 
The results show that although the percentage conversion of 
p-nitroanisole to p-nitrophenol by the 10,000xg supernatant from control 
liver was considerably higher than the values previously quoted, there 
was no significant alteration in the percentage conversion following 
pretreatment of the rabbit with phthalazine. 
Therefore, on the basis of this test, it appears that treatment of 
the rabbits with phthalazine does not induce the microsomal activity 
present in the 10,000xg supernatant. 
However, although this test has frequently been used to determine 
overall liver microsomal activity, it suffers from the restriction that 
it only measures 0-demethylase activity and therefore the effect of 
phthalazine treatment upon other forms of the enzyme which do not have 
this activity, eg. cytochrome P-448, is not monitored. 
ii) Determination of the Activity of the"Microsomal Fraction. - 
The effect of phthalazine treatment upon the activity of the 
microsomal fraction was determined by examination of binding spectra, 
produced as described in the experimental section (page 173) and 
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comparison with spectra obtained using microsomes isolated from 
untreated rabbits. 
Representative traces of the binding spectra exhibited by 
phthalazine (Type II) and 1-hydroxyphthalazine are shown in Figure 31 
Type II binding spectra are believed to occur via ligand binding of 
a nitrogen atom to the ferrihaemoprotein in cytochrome P-450 and 
consequently phthalazine would be expected to produce a Type II spectral 
change. Indeed, in a qualitative study of the relationship between 
binding spectra and susceptibility to microsomal oxidation, Stubley6 
found that almost all the simple mono and diazanaphthalenes exhibited 
0 
Type II binding spectra. The exceptions were quinoline and quinoxaline 
in which the non-bound electrons are believed to be sterically 
inaccessible, resulting in an inability to effect ligand binding. 
As it is believed that microsomal hydroxylation is probably mediated 
via Type I binding of the substrate137 it is therefore not surprising 
that'phthalazine, exhibiting a Type II spectral change, does not appear 
to be a substrate for the microsomal monooxygenases. 
The difference spectrum exhibited by 1-hydroxyphthalazine was 
indistinct, but upon addition of NADPH to the cuvette, a clear spectrum, 
with a maximum at 405nm and a minimum at 423nm was obtained. The 
production of this spectrum, which resembled a Type I spectral change, 
but had an absorbance maximum at a higher wavelength than that normally 
associated with Type I spectra, indicates that 1-hydroxyphthalazine 
also interacts in some way with the microsomal fraction. 
4 
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Figure 31. Representative Binding Spectra obtained with Phthalazine and 
1-Hpdroxyphthalazine. 
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Studies191. ' 192 have shown that pretreatment of animals with 
phenobarbitone causes an increase in the magnitude of both Type I and 
Type II binding spectra and a study of the relative inductive potency of 
a series of polycyclic hydrocarbons showed that this parameter was 
directly related to an increase in the Type II binding. Consequently, 
as both major groups of inducing agents cause an increase in Type II 
binding, the effect of phthalazine pretreatment upon the Type II binding 
spectra produced by aniline and phthalazine was determined. This was 
carried out by-measuring-the maximal difference between the absorbance -- -- 
maximum and minimum in the difference spectra produced by these 
compounds and dividing by the protein concentration. The results were 
compared with the values obtained using microsomes prepared from the 
livers of untreated rabbits. 
Table 13. Comparison of the Activity of Microsomes Prepared from Livers 
of Phthalazine Treated and Untreated Rabbits by Examination of 
Type II Binding Spectra. 
Source of Enzyme Maximum Absorption 
Difference/mg protein 
Aniline Phthalazine 
Untreated (n=3) 0.086 + 0.012 0.064 + 0.013 
Phthalazine treated (n=4) 0.097 + 0.0093 0.0625 + 0.0072 
The results show that pretreatment of the rabbit with phthalazine 
has no effect upon the magnitude of the Type II spectral change produced 
by aniline and phthalazine. 
lle 
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Similarly, although the Type I binding spectrum exhibited by 
hexobarbitone was variable and more difficult to produce than the Type 
II spectral changes, a qualitative assessment indicated that phthalazine 
Of 
treatment also had no effect upon the magnitude of the Type I spectral 
change. 
These results therefore appear to confirm the findings of the study 
carried out using the 10,000xg supernatent which indicated that 
pretreatment of rabbits with phthalazine does not have an inductive 
effect upon liver microsomal activity. 
Effect of Phthalazine Treatment upon Liver Weight. 
Both major groups of microsomal inducing agents cause an increase 
in liver weight, phenobarbitone type inducers by increasing the 
microsomal protein/g of liver by 20-40% and 3-methylcholanthrene type 
compounds by increasing overall liver weight without affecting the 
specific content of microsomal protein. 
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However, when the weights of livers from phthalazine treated and 
control rabbits were compared, there was no significant difference 
between the two groups. 
Consequently, these results-also appear to confirm the earlier 
findings that phthalazine does not have an inductive effect upon the 
microsomal monooxygenase system. 
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Determination of the Effect of Phthalazine Treatment upon the Molybdenum 
Hydroxylases. 
i) Determination of Specific Activities. 
The specific activities of aldehyde oxidase and xanthine oxidase 
were determined by measuring the rate of oxidation of several substrates 
at concentrations resulting in Vmax using enzyme prepared from 
phthalazine treated rabbits and comparing with the values obtained using 
untreated rabbit liver enzymes. 
Although the partially purified enzyme present in the ammonium 
sulphate fraction is adequate for the majority of the work carried out 
using aldehyde oxidase, accurate determination of enzyme activity 
requires more highly purified enzyme samples. Consequently, the ammonium 
sulphate fraction was further purified by column chromatography using a 
modification of the method described by Johns128 for the isolation of 
human liver aldehyde oxidase. 
Chromatography of the ammonium sulphate concentrate on a Sephadex 
G75 gel filtration column results in the removal of salts and low 
molecular weight proteins. Although the protein concentration of the 
resulting enzyme solution is approximately half that of the ammonium 
sulphate fraction, both aldehyde oxidase and xanthine oxidase activity 
O 
is retained. Further purification and separation of aldehyde oxidase 
and xanthine oxidase is effected by chromatography on the DEAE-cellulose 
ion-exchange column. Elution with 0.1M potassium phosphate buffer 
normally results in the removal of xanthine oxidase and aldehyde oxidase 
is subsequently eluted with 0.2M potassium phosphate buffer. 
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The ammonium sulphate fraction, the concentrated eluate from the 
Sephadex G75 column and the 0.2M potassium phosphate buffer eluate from 
the ion-exchange column were all tested for both aldehyde oxidase and 
xanthine oxidase activity (the latter fraction being tested for xanthine 
oxidase activity to ensure that separation of the two enzymes had 
occurred). 
a) Aldehyde Oxidase Activity. 
Three different substrates were used to determine aldehyde oxidase 
activity. 
1) Phenanthridine. 
Phenanthridine is an extremely good substrate for aldehyde oxidase 
with a Km of less than 10-6M, but is refractory to oxidation by xanthine 
oxidase. The rate of oxidation of a5x 10-5M solution of this compound 
was monitored using oxygen as electron acceptor and measuring the 
increase in absorbance at 322nm. 
2) 3-Methylisoquinoline. 
17Zý CH3 
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3-Methylisoquinoline is a substrate for aldehyde oxidase and has a 
Km of 2.4 x 10-5M, 
6 but is not a substrate for xanthine oxidase. As the 
rate of oxidation of this compound cannot be measured by'following a 
change in absorbance of the substrate at a particular wavelength, a ýJ) 
5x 10-4M solution was monitored by measuring a decrease in absorbance 
at 420nm using potassium ferricyanide as electron acceptor. 
3)'Phthalazine. 
This compound was employed to determine whether pretreatment of the 
rabbit with phthalazine altered its own rate of oxidation by aldehyde 
oxidase in a different manner to that of other substrates. 
Although phthalazine is a substrate for both`aldehyde oxidase and 
xanthine oxidase, the fact that the Km with xanthine oxidase is thirty 
times higher than with aldehyde oxidase and'thät there is only a small 
amount of xanthine oxidase present in rabbit liver means that the 
contribution from xanthine oxidase to the oxidation rate of the compound 
is likely to be negligible. 
The rate'of oxidation Of a 10-3M solution was measured by 
monitoring the decrease in absorbance at 420nm using potassium I 
ferricyanide as electron acceptor. 
b) Xanthine Oxidase Activity. 
Xanthine oxidase activity was determined by measuring the rate of 
oxidation of xanthine, 5x 10-5M, using oxygen as electron acceptor and 
following the increase in absorbance at 295nm due to the formation of 
uric acid. 
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S 
NR=H Xanthine I ý- R 
NR OH Uric acid HO H 
OH 
HO N 
The rate of oxidation of each of the above compounds was determined 
using a suitably diluted solution of enzyme. By using the formula 
AsE cl, the amount of substrate converted per unit time was calculated 
(pmol/min) and the specific activity ()Ilmol/min/mg protein) obtained by 
dividing this value by the appropriate protein concentration. 
Table 14 shows the specific activities obtained using aldehyde 
oxidase from phthalazine treated rabbits in comparison to control 
values obtained using enzyme samples prepared from untreated rabbit 
livers. 
. Treatment of the rabbits with phthalazine resulted in a2-3 fold 
ý' 
increase in the aldehyde oxidase activity of, each of the enzyme 
fractions tested. As the increase in aldehyde oxidase activity 
remained relatively constant throughout the purification procedure, the 
apparent 'inductive effect' of phthalazine upon aldehyde oxidase does 
not appear to be due to a modifier which could be removed during 
purification. 
Although the differences between the values obtained using each of 
the substrates were not statistically significant, the increase in 
specific activity determined using phenanthridine was slightly greater 
than that exhibited using either of the other substrates. 
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Table 14. Effect of Phthalazine Administration Upon Rabbit Liver 
Aldehyde Oxidase Activity. 
Fraction Specific Activity (pmol/min/mg protein) % 
Control ", 
Substrate Control (n=7) Treated (n=7) 
(NH4)2SO4 Fraction 
Phenanthridine 0.229 + 0.088 0.637 + 0.48 278 
Phthalazine 0.595 + 0.25 1.464 + 0.80 246 
3-Methylisoquinoline 0.082 + 0.025 0.19 + 0.12 235 
G75 Fraction 
Phenanthridine 0.249 + 0.061 0.727 + 0.306 291 
Phthalazine 0.655 + 0.23 1.522 + 0.604 232 
3-Methylisoquinoline 0.098 + 0.034 0.211 + 0.107 216 
DEAE Fraction 
Phenanthridine 0.699 + 0.289 1.776 + 1.12 254 
-Phthalazine 2.416 + 0.832 5.337 + 2.73 221 
3-Methylisoquinoline 0.533 + 0.27 1.132 + 0.606 212 
The values are given as means + S. D. for the number of animals examined 
(n). The activity follo wing treatment with, phthalazine was 
significantly different from its corre sponding control to at least 
p <0.05 using atwo-tai led Stud ents t test. 
. _. , 
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The effect of phthalazine treatment upon xanthine oxidase activity 
is shown below. 
Table 15. Effect of Phthalazine Administration Upon Rabbit Liver 
lanthine Oxidase Activity. 
Fraction Specific Activity ( mol/min/m g prot) % 
Control 
Control (n=7) Treated (n: 7) 
(NH Fraction 4)2SO4 0.0072 ± 0.0028 0.0163 + 0.0029 L 226 
G75 Fraction 0.0093 + 0.0036 0.0162 + 0.011 173 
The'activity of the ammonium sulphate fraction following phthalazine 
treatment was significantly different to control (p <0.05). The values 
for the G75 fraction were not significantly different. 
The xanthine oxidase activity of the ammonium sulphate fraction was 
also increased to over twice that of the control level, measured using 
xanthine as substrate. 
Although the increase in activity over control was markedly less in 
the G75 fraction and was not found to be statistically significant, the 
low level of xanthine oxidase in this tissue, coupled with the 
variability in activity following chromatography on Sephadex G75 means 
0 that this result must be interpreted with caution. 
Determination of the Effect of Treatment with 1-Hydroxyphthalazine upon 
the Specific Activities of Aldehyde Ozidase and Xanthine Oxidase. 
As the in vivo studies demonstrated that phthalazine is extensively 
metabolised by the rabbit prior to excretion, it is possible that one of 
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the metabolic products, rather than phthalazine itself, is the true 
inducer. Although the extent of the conversion could not be 
ascertained, the studies indicated that some of the phthalazine 
administered to the rabbits was metabolised to its aldehyde oxidase 
mediated oxidation product, 1-hydroxyphthalazine. 
Consequently, rabbits were treated with 1-hydroxyphthalazine to 
determine whether this compound, whilst not a substrate for the 
molybdenum hydroxylases had any inductive capacity. 
A solution of 1-hydroxyphthalazine (200pg/ml) was administered to 
the rabbits in place of the drinking water, such that the approximate 
daily dose was 10mg/kg. This concentration was less than that used for 
phthalazine because of its lower solubility. Table 16 shows the results 
obtained in comparison to the control values from untreated rabbits. 
Although pretreatment with 1-hydroxyphthalazine also caused 
significant increases in the specific activities when compared to values 
obtained using enzyme from untreated rabbits, the variability in the 
specific activities with the different substrates was more pronounced 
than following treatment with phthalazine, the increase in the enzyme 
activity measured using phthalazine as substrate being less than that 
exhibited using either of the other substrates. 
/ý 
The percentage increases in activity were very similar in both the 
ammonium sulphate and DEAE fractions, but the values for the G75 
fraction were significantly higher. This result, although possibly 
only reflecting the wide variability of a small number of samples could 
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Table 16. Effect of Administration of 1-Uydroxyphthalazine Upon Rabbit 
Liver Aldehyde Oxidase Activity. 
Fraction Specific Activity ( )imol/min/m g protein) % 
Control 
Substrate Control (n : 7) Treated (n - 4) 
(NH4)2SO4, Fraction 
Phenanthridine 0.229 + 0.088 0.556 + 0.29 242 
Phthalazine 0.595 + 0.25 1.089 + 0.46 183 
3-Methylisoquinoline 0.082 + 0.025 0.199 + 0.06 243 
G75 Fraction 
Phenanthridine 0.249 + 0.061 1.043 +'0.86 419 
Phthalazine 0.655 + 0.228 1.855 + 1.55 283 
3-Methylisoquinoline 0.098 + 0.034 0.449 + 0.316 460 
DEAE Fraction 
Phenanthridine 0.699 + 0.289 1.736 + 0.804 248 
Phthalazine 2.416 + 0.832 4.097 + 1.10 170 
3-Methylisoquinoline 0.533 + 0.27 1.033 + 0.34 194 
The difference between the groups was significant to p <0.05 for the 
DEAE enzyme samples but only significant to p <0.1 for ammonium sulphate 
and G75 fractions. 
r9 
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also be attributed to the instability of, the G75 fraction, which unlike 
the ammonium sulphate fraction is not stabilised by the salt. Although 
oxidation rates were measured immediately, the enzyme samples prepared 
from one rabbit liver were retained until the DEAE sample was available 
before carrying out the protein determination. Consequently some of the 
protein in the G75 fraction may have precipitated, resulting in an 
inaccurately low protein content and a correspondingly high specific 
activity value. 
The effect of 1-hydroxyphthalazine treatment upon xanthine oxidase 
activity is shown below. 
Table 17. Effect of Administration of 1-Hydroxyphthalazine upon Rabbit 
Liver Xanthine Oxidase Activity. 
Fraction Specific Activity (pmol/min/mg protein) %, 
Control 
Control (n=7) Treated (n=4) 
(NH4)2SO4 fraction 0.0072 + 0.0028 0.0173 + 0.0035 240 
G75 fraction 0.0093 + 0.0036 0.0308 + 0.019 330 
The specific activity ofýthe (NH4)2504 fraction] was significantly 
different to control to at least p<0.01 and the activity of the G75 
fraction significantly different to at least p<0.1. 
ýG 
The results show that xanthine activity was also increased 
following treatment with 1-hydroxyphthalazine to at least the same extent as 
the aldehyde oxidase activity. 
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Although the amount of-1-hydroxyphthalazine administered to the 
rabbit was only one fifth of the dose of, phthalazine, similar increases 
in both aldehyde oxidase and xanthine oxidase activities resulted from 
Cý treatment with either compound. 
As dose-activity curves were not constructed it is difficult to 
determine whether 1-hydroxyphthalazine was more effective than 
phthalazine in increasing the levels of the molybdenum hydroxylases. 
However, when rabbits were treated with a solution of phthalazine 
100}zg/ml (ie. approximately 5mg/kg daily) for 21 days, the increase in 
aldehyde oxidase activity was slight and not significantly different 
from the control values, suggesting that 1-hydroxyphthalazine may be the 
more effective inducing agent. 
Consequently, the true inducing agent may be 1-hydroxyphthalazine 
itself, arising from the molybdenum hydroxylase mediated oxidation of 
phthalazine in the phthalazine treated rabbit, it may be a further 
metabolite of 1-hydroxyphthalazine, or phthalazine, 1-hydroxyphthalazine 
and further metabolites may all have some inductive effect. 
Determination of-the Molybdenum Content of Aldehyde Oxidase Fractions. 
The complex nature of the molybdenum hydroxylases means that an 
increase in enzyme activity may be achieved via a variety of mechanisms. 
Whilst these may include an increase in the rate, of 'de novo' protein 
synthesis or a reduction in the rate of degradation of the enzyme, 
changes in the molecular activity of the enzymes by. selective-alteration 
of active site components such as molybdenum and cyanolysable sulphur 
are also important factors. 
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In order to determine whether an increase in specific activity was 
accompanied by an increase in the molybdenum content of the enzyme 
fraction, electrothermal atomic absorption spectroscopy was carried out 
0 according to the method described in the experimental section (page 178). 
As high protein contents and the presence of salts may lead to 
gross inaccuracies in the measurement of molybdenum by electrothermal 
atomic absorption spectroscopy, only DEAE enzyme fractions were 
examined. Therefore, although it was possible to determine the effect of 
treatment of rabbits with phthalazine and 1-hydroxyphthalazine upon the 
molybdenum levels in aldehyde oxidase, the lack of xanthine oxidase in 
the DEAE fraction, together with the small amount of this enzyme present 
in rabbit liver, precludes the determination of the molybdenum content 
of xanthine oxidase. 
As a molybdenum determination requires a relatively large volume of 
enzyme solution to make up the necessary standard addition solutions, it 
was only possible to carry out a few determinations for each form of 
treatment. 
A comparison of the molybdenum content (expressed as )xg/mg 
protein) and the activity/Mo ratios of the enzyme samples from control 
and treated rabbits is shown in Table 18. 
A doubling in the molybdenum content of the enzyme fractions was 
observed following treatment with phthalazine and a lesser but still 
significant increase occurred following treatment with 1-hydroxy- 
phthalazine. 
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The specific activities quoted were determined using phthalazine 
as substrate, although similar results were obtained using either phen- 
anthridine or 3-methylisoquinoline. 
(r 
Although a slight increase in the activity/Mo ratio was apparent 
following treatment with phthalazine or 1-hydroxyphthalazine, 
statistically the values were not significantly different from control 
values, indicating that the observed increase in the molybdenum content 
is of'the-same order as-the increase in specific activity. .- 
While this result may be indicative of the occurrence of true 
'induction', ie. an increased rate of synthesis of new enzyme, it may 
also be explained by a reduction in the rate of degredation of the 
enzyme, or by the incorporation of molybdenum into the existing apo- 
enzyme. 
Consequently, further studies would be required to elucidate the 
actual nature of the effect of phthalazine upon aldehyde oxidase 
activity. 
Kinetic Determinations using Aldehyde Oxidase from Phthalazine Treated 
Rabbits. 
In order to determine whether the alteration in specific activity 
following pretreatment with phthalazine was due solely to an increase in 
the number of enzyme molecules, the Michaelis Menten Constants for 
phthalazine and the structurally related monoazanaphthalene, iso- 
quinoline, were determined using the DEAE enzyme fractions from control 
and treated rabbits. (see Table 19). 
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Table 19. Comparison of Michaelis Menten Constants using Aldehyde 
Oxidase from Control and Phthalazine Treated Rabbits. 
re 
Km(M) 
Treatment Phthalazine Isoquinoline 
None (control) 1.1 x 10-4 1.96 x 10-4* 
Phthalazine treated 
(50mg/kg daily) 
<10-5 2.40 x 10-4 
All determinations were carried out using potassium ferricyanide as 
electron acceptor and by monitoring the reduction in absorbance at 
420nm. 
* As only a limited amount of enzyme was available, it was not possible 
to carry out"a kinetic determination of isoquinoline using the DEAE 
fraction from untreated rabbit liver and therefore the Km quoted was 
determined using aldehyde oxidase purified to the ammonium sulphate 
stage. 
The finding that the Km of phthalazine, determined using aldehyde 
oxidase prepared from the liver of a rabbit pretreated with phthalazine 
was significantly lower than that obtained using control enzyme suggests 
that a new form of the enzyme, with an enhanced specificity for 
phthalazine may have been induced. 
Whilst a change in the Michaelis Menten Constant could possibly 
also be attributed to competition by phthalazine with a tight binding 
endogenous substrate/inhibitor in vivo, the finding that the molybdenum 
content of the enzyme fractions increased in proportion to the increase 
in specific activity seems to preclude this possibility. 
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The observation that the Km of isoquinoline was unchanged following 
pretreatment of the rabbit with phthalazine suggests that the induced 
form of the enzyme may be highly specific for phthalazine. 
0 
Comparison of Enzyme Samples using Iso-Electric Focusing. 
A qualitative examination of the enzyme following treatment with 
phthalazine and 1-hydroxyphthalazine was carried out using iso-electric 
focusing according to the method described in the experimental section. 
4 
DEAE enzyme fractions from the livers of both control and treated 
rabbits were focused alongside each other to allow direct comparisons to 
be made. Each group of samples was run in duplicate and at the end of 
the focusing period the plate was divided and stained for both protein 
and aldehyde oxidase activity. 
The enzyme stain is a modification of the technique used by 
" Holmes193 and is based upon the reduction of nitro blue tetrazolium to 
give a blue/purple colour corresponding to the position of the active 
enzyme. This reduction is brought about by the enzymic oxidation of 
substrate and transfer of electrons from the enzyme via phenazine 
methosulphate, the intermediary electron carrier, to the dye. 
Phenanthridine, 3-methylisoquinoline and phthalazine were all used 
0 as substrates. However, as there was no discernable difference between 
the bands of enzyme activity produced using each of the substrates, only 
one example of the enzyme stain is shown in each case. 
Figure 32 shows the protein and enzyme stains for samples from 
both control and phthalazine treated rabbits (50mg/kg daily for 7 days) 
Figure 52" Comparison of Aldehyde Oxidase from Phthalazine Treated 
Rabbits with Enzyme from Untreated Rabbits using lso- 
Electric Focusing. 
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Figure 33. Comparison of Aldehyde Oxidase from 1-Hydroxyphthalazine 
Treated Rabbits with Enzyme from Untreated Rabbits using 
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Iso-Electric Focusing. 
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and Figure 33 shows samples from both control and 1-hydroxyphthalazine 
treated rabbits (10mg/kg daily for 7 days). 
An examination of the protein stains following iso-electric focusing 
of samples from both control and treated rabbits shows that although 
major bands are present at the position corresponding to enzyme 
activity, a number of other bands of protein are also present in the 
DEAE fraction. 
When thep1ates. were. stained for the presence of,. _aldehyde.. oxidase, 
2 to 3 bands of activity became apparent in the samples from control 
animals and a further closely related band of activity was also found to 
be present in the samples obtained from both phthalazine and 1-hydroxy- 
phthalazine treated rabbits. This pattern was reproduced whichever 
substrate was used. The IpH of these bands was found to be approx- 
imately 5" 
Although Holmes193 discovered the presence of two isoenzymes of 
aldehyde oxidase in the livers of mice and Rothe20 demonstrated the 
presence of two forms of the enzyme in potato tubers using electro- 
phoretic techniques, no evidence has been put forward for the existence 
of multiple forms of aldehyde oxidase in rabbits. Furthermore, there do 
not appear to be any reports of iso-electric focusing of aldehyde 
oxidase. 
e 
However, in an attempt to purify xanthine oxidase, Mather et a1194 
used both electrophoretic and electrofocusing techniques. Whilst only 
one major component was identified using electrophoresis, between 5 and 
7 variants of the enzyme, with iso-electric points varying between 
pH 6.9 - 7.6 were isolated using iso-electric focusing. 
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Although iso-electric focusing is more efficient than electro- 
phoresis at separating closely related proteins, artifacts have been 
found to occur-195,196 These artifacts are normally due to strong 
protein : protein interactions and to complexation of the proteins with 
the carrier ampholines. 
Consequently, although the results of iso-electric focusing suggest 
that several isoenzymes of aldehyde oxidase may be present in rabbit 
liver, the use of' this technique cannot provide conclusive evidence. 
However, "it is apparent that a further band of activity has been 
produced' following treatment of the rabbit with phthalazine and 
1-hydroxyphthalazine and this may possibly be attributed to the 
induction of a new form of the enzyme by these compounds. This 
observation correlates well with the results of the Km determinations 
which indicate that a form of the enzyme with a high affinity for 
phthalazine may have been induced. 
0 
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CONCLUSIONS. 
The investigation undertaken has shown that pretreatment of rabbits 
with phthalazine does not appear to have any effect upon the levels of 
cytochrome P450, but causes a significant increase in the activity of 
both aldehyde oxidase and xanthine oxidase. 
Whilst a large number of compounds with extremely diverse effects 
and no apparent structural relationship have been-found to induce the 
microsomal monooxygenases, a common characteristic of these inducing 
agents tends to be a high lipid solubility at physiological pH, 
resulting in a prolonged biological half-life. The earlier metabolic 
studies using 
14C-labelled 
phthalazine indicated that the half-life of 
this compound was relatively short and consequently it is possible-that 
phthalazine does not remain in the body long enough to have any 
inductive effect upon the microsomal enzymes. 
When the specific activities of aldehyde oxidase and xanthine 
oxidase were examined, a2 to 3 fold increase was observed following 
treatment with phthalazine. Similarly, pretreatment of rabbits with 
1-hydroxyphthalazine caused at least a comparable increase in the enzyme 
activities. 
Work reported earlier in this thesis has shown that 1-hydroxy- 
phthalazine, while not a substrate for aldehyde oxidase and xanthine 
oxidase, is a competitive inhibitor of both enzymes, indicating that 
this compound does interact with the molybdenum hydroxylases. On the 
basis that 1-hydroxyphthalazine has been found to be present in the urine 
of rabbits treated with phthalazine it is interesting to speculate that 
this compound and not phthalazine may be the true inducer. 
213 
However, as both phthalazine and 1-hydroxyphthalazine appear to be 
extensively metabolised prior to excretion, resulting in products which 
might also have inductive properties, it is not possible, on the limited 
0 basis of these studies, to ascertain the exact nature of the inducing 
agent. 
A comparison of the molybdenum content of liver enzyme samples from 
untreated and treated rabbits indicates that the amount of molybdenum in 
the enzyme fractions increased in proportion to the increase in specific 
activity observed following pretreatment with phthalazine and 1-hydroxy- 
phthalazine. Whilst this effect may be indicative of 'de novo' protein 
synthesis, it could also be attributed to a decreased rate of 
degradation of the enzyme, or due to the incorporation of molybdenum 
into pre-existing apoenzyme. This finding does, however, eliminate the 
possibility of the apparent 'inductive' effect being due solely to a 
conversion from 'desulpho' to active enzyme, another way in which the 
activity of the molybdenum hydroxylases may be regulated-197 
Further studies would be required to elucidate the exact nature of 
the apparent inductive effect of phthalazine. This could be achieved by 
the concomitant administration of phthalazine and an inhibitor of new 
protein synthesis, eg. Puromycin or Actinomycin D, whereby a lack of 
increased enzyme activity would indicate that true induction, ie. an 
increased rate of protein synthesis was occurring. Alternatively, by 
the administration of a 
14C-labelled 
amino acid eg. leucine, in the 
diet, it would be possible to determine whether a greater proportion of 
radiolabel had been incorporated into enzyme samples prepared from treated 
rabbits, in comparison to controls, which would also be indicative of 
214 
increased 'de novo' protein synthesis. 
Although isoenzymes of aldehyde oxidase have been detected in mouse 
tissues, 193 there appear to be no reports of the existence of multiple 
forms of the enzyme in other animal species. The work reported here 
suggests that rabbit liver aldehyde oxidase may be composed of 2 to 3 
active variants of the enzyme. 
It is also apparent that there is an extra band of enzyme activity, 
detectable on the electrofocusing plate, in aldehyde oxidase samples 
prepared from the livers of rabbits treated with either phthalazine or 
1-hydroxyphthalazine. 
In view of the fact that the Michaelis Menten Constant for 
phthalazine with aldehyde oxidase prepared from the liver of a rabbit 
pretreated with the same compound, is markedly lower than the value 
obtained using untreated rabbit liver enzyme, it appears that 
pretreatment with phthalazine may have induced a form of the enzyme with 
a high affinity for phthalazine itself. 
This occurrence is not unusual and it is believed that many 
compounds stimulate their own cytochrome P-450 mediated metabolism, 
presumably by induction of a specific form of the enzyme. 181 Similarly, 
recent work186 has identified a new form of cytosolic aldehyde 
dehydrogenase, with different kinetic properties, which arises following 
treatment of rats with the carcinogen, 2-acetylaminofluorene. 
SECTION VI 
INTERACTION OF HYDRALAZINE AND RELATED COMPOUNDS 
WITH ALDEHYDE OXIDASE IN VIVO AND IN VITRO. 
0 INTRODUCTION. 
Hydralazine, a potent peripheral acting vasodilator used in the 
management of essential hypertension, is a 1-substituted phthalazine. 
ýN 
Ii 
,N 
NHNH2 
Hydralazine ( 1-hydrazinophthalazine ) 
This compound has been found to be extensively metabolised in a 
number of species, including man198 and rabbit168 and although the 
relative proportions of the metabolites vary between species, the major 
metabolic products appear to be a glucuronide conjugate of a hydroxy 
metabolite of hydralazine together with a cyclic N-acetyl compound and 
its derivatives-144 (See Figure 34) 
Several workers199'166 have also reported the presence of 
phthalazine and 1-hydroxyphthalazine in the urine of subjects treated 
with hydralazine. 
Phthalazine is believed to arise non-enzymically as a decomposition 
product of hydralazine, which is unstable at physiological pH. 
167 
Whilst 1-hydroxyphthalazine may also be produced non-enzymically from 
hydralazine under alkaline conditions200 it has been reported that this 
compound may result from the enzymic oxidation of hydralazine199 and 
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and that"it is present in larger quantities in the urine of slow acetylators 
than the fast acetylator phenotype. 
201 
Stubley6 postulated that aldehyde oxidase may be responsible for 
this oxidation reaction, based upon the observation that hydralazine 
exhibited weak substrate activity with the enzyme in vitro. 
However, in common with hydrazine and other hydrazine containing 
compounds, hydralazine is a potent inhibitor of a number of enzymes, 
including the flavoprotein monoamine oxidase, 
202 dopa decarboxylase203 
and enzymes involved in collagen synthesis. 
204' 205 Inhibition of the 
latter enzymes may be partly responsible for the connective tissue 
disorders frequently associated with hydralazine treatment. 
205 
Although there are no reports of the inhibition of the molybdenum 
hydroxylases by hydralazine, the structurally related compound 1-amino- 
isoquinoline has been found to be an inhibitor of aldehyde oxidase in 
vitro. 
206 
In view of these facts and the structural similarity of this 
compound to phthalazine, parallel investigations were undertaken to 
determine the effect of hydralazine treatment upon aldehyde oxidase and 
xanthine oxidase levels in vivo and to examine the interaction of this 
compound, with both enzymes in vitro. 
. 
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RESULTS AND DISCUSSION. 
All the methods used in this study have been described in the 
earlier sections. 
Effect of Hydralazine upon the Molybdenum Hydrozylases In Vivo. 
In order to determine the effect of. hydralazine upon the molybdenum 
hydroxylases in vivo, rabbits were treated with a solution of 
hydralazine hydrochloride in place of their drinking water. 
f 
Hydralazine is, however, extremely unstable in alkaline solution207 
and it has been reported that 30 to 50% decomposition may occur within 
thirty minutes at pH 7.4.166 The product of*the decomposition reaction 
is phthalazine, together with a minor yellow contaminant believed to be 
diphthalazinylhydrazine. (see Section IV) 
The stability of a solution of hydralazine hydrochloride in tap 
water, as it would be prepared for administration to the rabbits, was 
investigated. A visual examination of the solution, which rapidly 
became yellow upon decomposition, indicated, that the hydralazine was 
only stable for two to three hours at room temperature. 
Consequently, it was necessary to administer the hydralazine under 
acidic conditions to eliminate the possibility of decomposition to 
0 phthalazine occurring. 
A solution of hydralazine in pH 6.0 potassium phosphate buffer 
(0.005M) was found to be stable for over twenty-four hours at room 
temperature and also palatable to the rabbit. Therefore, this buffer 
was considered to be a suitable medium for delivery of this compound to 
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the rabbit. 
The rabbits were treated with a solution of hydralazine 
hydrochloride 200, ug/ml in pH 6.0 phosphate buffer, in place of the 
drinking water, such that the approximate daily dose of hydralazine 
hydrochloride was 10mg/kg (approximately 8mg/kg hydralazine). After 
seven days, the hydralazine solution was replaced by drinking water 
and the rabbit. sacrificed twenty-four hours later. Liver enzyme 
fractions were prepared As described in the previous section (page 166). 
The specific activities of aldehyde oxidase in the ammonium 
sulphate fraction, the Sephadex G75 column eluate and the 0.2M phosphate 
buffer eluate from the DEAE-cellulose column were measured using the 
three substrates described previously ie. phenanthridine, 3-methyl- 
isoquinoline and phthalazine. Xanthine oxidase activity was determined 
using xanthine as substrate. 
In order to ensure that treatment with phosphate buffer itself had 
no effect upon the levels of. the molybdenum hydroxylases, a control 
experiment was carried out by treating a rabbit with pH 6.0 potassium 
phosphate buffer for seven days. After sacrificing the rabbit, liver 
enzyme fractions were prepared and the specific activities determined. 
Upon comparison with the specific activities obtained using enzyme 
0 fractions prepared from the livers of untreated rabbits, there were no 
significant differences, indicating that phosphate buffer alone had no 
effect upon the activity of the molybdenum hydroxylases in vivo. 
Consequently, it was possible to use control values previously 
obtained from untreated rabbit liver enzyme fractions for comparison 
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purposes. 
Table 20 shows a comparison of the specific activities obtained using 
aldehyde oxidase prepared from the livers of hydralazine treated rabbits 
in comparison to control values obtained using liver fractions from un- 
treated rabbits. 
Table 20. Effect of Hydralazine Administration upon Rabbit Liver 
Aldehyde Oxidäse Activity. 
Fraction Specific Activity pmol min mg protein) 
Control 
Substrate Control Hydralazine Treated 
(n=7) (n-5) 
NH4)2SO4 Fraction 
Phenanthridine 
Phthalazine 
3-Methylisoquinoline 
0.229 
0.595 
0.082 
+ 
+ 
+ 
0.088 
0.250 
0.025 
0.113 
0.173 
0.035 
+ 
+ 
+ 
0.028 
0.051 
0.017 
32 
29 
43 
G75 Fraction 
Phenanthridine 0.249' + 0.061 0.142 + 0.092 57 
Phthalazine 0.655 + 0.228 0.271 + 0.168 41 
3-Methylisoquinoline 0.098 + 0.034 0.034 + 0.020 35 
DEAE Fraction 
Phenanthridine 0.699 + 0.289 0.200 + 0.074 29 
Phthalazine 2.416 + 0.832 0.499 + 0.157 21 
3-Methylisoquinoline 0.533 + 0.270 0.140 + 0.057 26 
e The values are given as means + S. D. for the number of animals examined 
(n). The activity following treatment with hydralazine was 
significantly different from its corresponding control to at least 
p<0.01 for values for (NH4)2SO4 and DEAE fractions and p<0.02 for the 
G75 fraction, using a two tailed Students t-test. 
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Treatment of the rabbits with hydralazine resulted in a 
0 
significant reduction in specific activity in comparison to control 
values, indicating that this compound, or one of its metabolites has a 
marked inhibitory effect upon rabbit liver aldehyde oxidase in vivo. 
As this reduction in activity was exhibited at each stage in the 
purification process and was in fact most marked, in the DEAE enzyme 
fraction it appears either that the inhibitor is tightly bound to the 
enzyme, or alternatively the enzyme has been inactivated in some way not 
01 
involving permanent binding of the inhibiting species. 
Although the differences between the percentage reductions 
obtained using each of the three substrates were not statistically 
significant, the decrease in activity in the ammonium sulphate and DEAE 
enzyme fractions appeared to be slightly, greater using phthalazine than 
either of the other substrates. 
The effect of hydralazine treatment upon xanthine oxidase. activity 
is shown below. 
Table 21. Effect of Hydralazine Administration upon Rabbit Liver Xanthine 
Oxidase Activity. 
Fraction Specific Activity ('mol/min/mg protein) % 
Control Hydralazine Treated Control 
10 
(n=7), (n=5) 
(NH4)2SO4 Fraction 0.0072 + 0.0028 0.0122 + 0.0057- 168 
G75 Fraction 0.0093 + 0.0036 0.0085 + 0.0036 91 
The activity following treatment with hydralazine was not significantly 
different to control values using a two tailed Students t-test. 
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The specific activity of the xanthine oxidase, present only in the 
ammonium sulphate and G75 enzyme fractions was not significantly 
different to control values following treatment with hydralazine, 
0 
although a slight increase in enzyme activity was observed in the 
ammonium sulphate fraction. The wide variabilities in the specific 
activities may be attributed to the low quantities of xanthine oxidase 
present in rabbit liver making-accurate determination difficult. 
However, it is clear that whilst hydralazine treatment, causes a 
significant reduction in liver aldehyde oxidase activity, it does not 
have a similar effect upon xanthine oxidase. 
Determination of the Molybdenum Content of the DF. AE Enzyme Fractions 
Prepared from Hydralazine Treated Rabbits. 
The work reported in the previous section demonstrated that the 
increase in the specific activity of rabbit liver aldehyde oxidase, 
occurring upon phthalazine treatment in vivo, was accompanied by a 
proportional increase in the molybdenum content of the enzyme. 
Similarly, a decrease in the amount of molybdenum present in the 
liver enzyme fractions prepared from hydralazine treated rabbits would 
be indicative that the compound was exerting its inhibitory effect by 
0 reducing the amount of aldehyde oxidase presentýin the tissue.. 
I 
Alternatively, it has been observed that some inhibitors of drug 
metabolising enzymes exert a biphasic effect in that they initially 
inhibit drug metabolism but often stimulate the rate of metabolism when 
given repeatedly. 
208 For example, chronic administration of the micro- 
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somal monooxygenase inhibitor SKF 525A to rats induces hexobarbital 
oxidation and ethylmorphine N-dealkylation, although the increased level 
of activity can still be inhibited by a further dose of SKF 525A. 209 As 
the parent compound phthalazine has been found to have an inductive 
ýý 
effect upon aldehyde oxidase, it might be expected that hydralazine 
would also have some inductive capacity. 
Consequently, in order to determine the effect of hydralazine 
treatment upon the molybdenum levels of the DEAE enzyme fractions, 
electrothermal atomic absorption spectroscopy was carried out according 
to the method described in the previous section (see page 178). 
Table 22 shows the molybdenum content and specific activity / Mo 
ratios of enzyme fractions prepared from hydralazine treated rabbits in 
comparison to those obtained using untreated rabbit liver fractions. 
The ratios of activity/Mo content were determined using the 
specific activities calculated using phthalazine as substrate, although 
similar results were obtained using those for phenanthridine or 3-methyl- 
isoquinoline. 
An examination of the results shows that the molybdenum content of 
the enzyme fractions prepared from hydralazine treated and control 
animals were not significantly different, indicating that hydralazine 
treatment has no effect upon the amount of molybdenum present within the 
enzyme fraction. The marked reduction in the activity/Mo ratio upon 
treatment with hydralazine is therefore attributable solely to the 
decrease in specific activity. 
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Table 22. Effect of Hydralazine Treatment upon Molybdenum Content and 
Activity/No Ratios of Purified Rabbit Liver Aldehyde Oxidase 
Fractions. 
0 
Treatment Mo Content % Specific Activities Activity/ 
(pg Mo/mg prot. ) Control (. pmol/min/mg prot. ) Mo ratios 
None 
(control) 
(n=3) 
Hydralazine 
10mg/kg 7 days 
(n=5) 
0.382 + 0.056 (100) 
0.428 + 0.143 112 
2.077 + 0.938 
0.499 + 0.157 
5.44 
1.17 
Values are quoted as means + S. D. 
The molybdenum content of the fractions from hydralazine treated rabbits 
was not significantly different to control. 
The activity/Mo ratios of the fractions from hydralazine treated rabbits 
were significantly different to control to p<0.01 using a two tailed 
Students t-test. 
Based upon these results, it appears that whilst hydralazine 
0 
treatment has caused a reduction in the activity of rabbit liver aldehyde 
oxidase it has not affected the amount of molybdenum containing enzyme 
present within the tissue. Similarly, the lack of increase in the 
molybdenum content following hydralazine treatment indicates that this 
compound, despite being a derivative of phthalazine, does not exert any 
apparent inductive effect upon rabbit liver aldehyde oxidase. 
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Examination of Enzyme Samples using Iso-Electric Focusing. 
The enzyme samples prepared from livers of hydralazine treated 
rabbits were further examined using iso-electric focusing as described on 
is page 174. 
The DEAE enzyme fractions from control and hydralazine treated 
rabbits were focused alongside each other to enable direct comparisons 
to be made. Each group of samples was run in duplicate and at the end 
of the focusing period the plate was divided and stained for both 
protein and aldehyde oxidase activity. 
Figure 35 shows the protein and enzyme stain for two DEAE enzyme 
fractions from control rabbits and two samples from hydralazine treated 
rabbits (10mg/kg). 
Phthalazine was used as substrate in the aldehyde oxidase stain, 
although similar results were obtained using either phenanthridine or 
3-methylisoquinoline. 
An examination of the protein stains following electrofocusing of 
both the samples from control and hydralazine treated rabbits shows that 
two or three major bands corresponding to aldehyde oxidase are present 
in each case. In contrast, although these major bands showed substrate 
activity when stained with phthalazine/nitro blue tetrazolium in the 
controls, very little activity could be detected in samples from 
hydralazine treated rabbits. I 
As all the enzyme solutions were initially diluted to give a 
protein concentration of 1mg/ml and equal volumes of each sample applied 
to the agarose plate, this effect cannot be attributed to differences in 
Figure 35. Comparison of Enzyme Fractions from Control and Hydralazine 
Treated Rabbits using Iso-Electric Focusing. 
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the amount of protein present in the sample. 
Consequently, these results appear to confirm the earlier findings 
which suggested that the reduction in liver aldehyde oxidase activity 
0 observed upon treatment of rabbits with hydralazine was due to a direct 
inhibitory effect upon pre-existing enzyme molecules in situ rather than 
by alteration of the amount of enzyme present, eg. by increasing the 
rate of degradation, decreasing the rate of synthesis or by alteration 
of the amount of demolybdo enzyme present. However, these results do 
not preclude the possibility that the decrease in enzyme activity may 
be attributed to an increase in the proportion of molybdenum containing 
desulpho enzyme present, which is another means by which enzyme activity 
may be regulated. 
Interaction of Hydralazine with the Molybdenum Hydroxylases In Vitro. 
An investigation was also undertaken to determine whether 
hydralazine interacted with the molybdenum hydroxylases in vitro. These 
studies were performed using rabbit liver aldehyde oxidase prepared to 
the ammonium sulphate stage (as described in section II) and commer- 
cially available bovine milk xanthine oxidase. 
As the results of earlier studies indicated that hydralazine was 
not stable at pH 7.0, all the in vitro work was carried out using pH 6.0 
potassium phosphate buffer (0.067M). The stability of hydralazine at 
this pH was confirmed by the observation that there was no change in the 
absorbance spectrum, over at least one hour, upon repeated scanning of a 
10-4M solution of hydralazine in pH 6.0 buffer between 200-500nm. 
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i) Interaction of Hydralazine with Aldehyde Oxidase. 
When a repeat scan was carried out between 200-350nm following 
the addition of an aliquot of aldehyde oxidase to a 10-4M solution of ® 
hydralazine hydrochloride in buffer there was no apparent change in the 
UV spectrum, indicating that hydralazine does not exhibit substrate 
activity with aldehyde oxidase. 
However, in view of the fact that hydralazine inhibits a number of 
enzymes and that 1-aminoisoquinoline has been found to be a potent 
competitive inhibitor of aldehyde oxidase in vitro, the effect of 
hydralazine upon the rate of oxidation of substrate was also examined. 
The in vitro work reported earlier in this thesis was carried out 
using the artificial electron acceptor potassium ferricyanide. However, 
when hydralazine was added to a cuvette containing 10-3M potassium 
ferricyanide in pH 6.0 buffer, non-enzymic reduction of the electron 
acceptor was found to occur. 
Similarly, 2,6-dichlorophenolindophenol, another electron 
acceptor frequently used to monitor the rate of oxidation of compounds, 
was also found to be reduced by hydralazine in the absence of enzyme. 
Consequently, as it was not possible to measure the rate of 
oxidation of substrate in the presence of hydralazine using either of 
these electron acceptors, substrates were chosen which could be 
monitored directly by following a change in absorbance at a particular 
wavelength resulting from the formation of the aldehyde oxidase 
mediated hydroxylation product. 
229 
8) 
Two substrates were chosen for this purpose: - 
Methotrexate. 
The antineoplastic drug methotrexate is an extremely good substrate 
for rabbit liver aldehyde oxidase (Km s 1Q-4 at pH 7), 
51 hydroxylation 
occurring at carbon 7 of the substituted pteridine ring. 
NH2 
N 
CH3 COOH 
Nf CHz CO-NH-CHCH2CH2000H 
I 
H 2N NN ''ý 
The rate of oxidation of this compound may be monitored by 
following the increase in absorbance at 340nm occurring upon production 
of 7-hydroxymethotrexate. 
b) Purine. 
Purine is oxidised by aldehyde oxidase to give 8-hydroxypurine, 
the Km for this reaction being 
'3 
x 10-4M at pH 6.814 
Ni N 
NF 
.NH 
0 
The rate of oxidation of purine may be determined by measuring the 
increase in absorbance at 285nm resulting from 8-hydroxypurine 
production. 
However, before these compounds could be used it was necessary to 
ensure that theyrdid not react chemically with hydralazine. Controls 
230 
® and 285nm respectively, in the absence of enzyme. As there was no 
apparent absorbance change at either wavelength over a period of ten 
minutes it was concluded that there was no non-enzymic interaction 
Figure 36 shows a representative example of the effect of 
were therefore carried out by adding hydralazine (10-5M) to cuvettes 
containing either methotrexate (5 x 10-5M) or purine (8 x 10-4M) in 
pH 6.0 phosphate buffer and monitoring any change in absorbance at 340nm 
occurring which could interfere with the measured rate of oxidation of 
either compound. 
The rate of oxidation of either methotrexate (5 x 10-5M) or purine 
(8 x 10-4M) by aldehyde oxidase was therefore monitored in the presence 
of various concentrations of hydralazine hydrochloride. All 
measurements were carried out at 37°C in pH 6.0 buffer. 
hydralazine upon the rate of oxidation 0f methotrexate by aldehyde 
oxidase. Similar results were obtained using purine as substrate. 
Figure 36. Effect of Hydralazine Hydrochloride upon the Rate of 
Oxidation of Methotrexate by Rabbit Liver Aldehyde Ozidase. 
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In the absence of hydralazine, the rate of oxidation of 
methotrexate remained linear for approximately three minutes. However, 
when the oxidation of this substrate was monitored in the presence of 
hydralazine, there was a rapid progressive reduction of the rate to 
zero. 
Although the inhibition of the oxidation of methotrexate was 
apparently immediate in the presence of 10-4M hydralazine, when lower 
concentrations of the inhibitor were added to the cell, the initial rate 
of oxidation of the substrate was the same as that observed in the 
absence of hydralazine, but subsequently curved off rapidly. Even a 
concentration as low as 10-7M hydralazine effected complete inhibition 
of the rate of oxidation of methotrexate within five minutes. 
Addition of a second aliquot of enzyme to the cuvette following 
complete inhibition of the rate of oxidation of methotrexate by 
hydralazine resulted in the recommencement of the rate which 
subsequently rapidly decreased to zero. 
Figure 37. Effect of Addition of a Second Aliquot of Enzyme to Cuvette 
following Inhibition by Hydralazine. 
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This observation confirmed that hydralazine was exerting its 
0 
In an attempt to gain some insight into the nature of the 
The rate of oxidation of methotrexate was subsequently monitored 
inhibitory effect via the enzyme rather than by chemical interaction 
with the substrate. 
Effect of Preincubation of Hydralazine with Aldehyde Oxidase. 
inhibition exhibited by hydralazine towards rabbit liver aldehyde 
oxidase, an aliquot of the enzyme was incubated with hydralazine (10-6M) 
in pH 6.0 buffer at 37°C for thirty minutes prior to the addition of 
methotrexate to the cuvette. 
and the resulting progress curve was found to be indistinguishable, from 
that obtained without preincubation of the enzyme. with hydralazine. 
Figure 38. Effect of Preincubation of Hydralazine with Aldehyde Oxidase 
upon the Rate of. Ozidation. of Hethotrezate. 
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It therefore appears that the presence of substrate is necessary 
for inhibition to occur, indicating that hydralazine exerts its 
inhibitory effect by reacting with either the enzyme - substrate complex 
41 or with 
the reduced form of the enzyme. 
ii) Interaction of Hydralazine with Xanthine Oxidase. 
When a repeat scan of a solution of hydralazine (10-4M) was 
carried out between 200 - 350nm following the addition of 0.1ml of 
xanthine oxidase to the cuvette, there was no apparent change in the UV 
spectrum over a period of ten minutes, indicating that hydralazine was 
not a substrate for xanthine oxidase. 
However, unlike the results obtained with aldehyde oxidase, the 
addition of hydralazine did not affect the rate of oxidation of 10-5M 
xanthine by xanthine oxidase when monitored at 295nm. 
Similarly, preincubation of hydralazine'with xanthine oxidase 
prior to the addition of xanthine had no effect upon the subsequent rate 
of oxidation of the substrate. 
Consequently, these results have shown that whilst hydralazine is 
a potent inhibitor of aldehyde oxidase in vitro, effective at 
concentrations as low as 10-7M, it does not appear to exert a similar 
inhibitory effect upon xanthine oxidase. 
As the initial rate of oxidation of the substrate by aldehyde 
oxidase in the presence of hydralazine was identical to that observed in 
the absence of the inhibitor it was not possible to determine a kinetic 
constant for the inhibition. However, the results indicate that 
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hydralazine is a potent progressive inhibitor of the enzyme, which, based 
upon the results of the preincubation studies, appears to react either 
with the reduced form of the enzyme or with the enzyme-substrate 
0 complex. 
Investigation of the Identity of the Species causing In Vivo Inhibition. 
The finding that hydralazineIs an inhibitor of aldehyde oxidase 
but not xanthine oxidase in vitro parallels the results of the in vivo 
study which indicated that treatment of rabbits with hydralazine 
resulted in a marked reduction in liver aldehyde oxidase activity but 
was without apparent effect upon xanthine oxidase activity. 
Hydralazine is, however, extensively metabolised by rabbits and 
although the results of the in vitro studies suggest that hydralazine 
may itself be the inhibiting species in vivo, it is possible that the 
products of metabolism may also exert an inhibitory effect upon aldehyde 
oxidase. 
In order to investigate this possibility, several compounds, 
identified as products of hydralazine metabolism, some of which are 
known to inhibit other enzymes, were tested in vitro for inhibitory 
activity towards aldehyde oxidase. 
i) Hydrazine. 
As both phthalazine and 1-hydroxyphthalazine have been reported to 
be products of hydralazine metabolism in rabbits, it might be expected 
that free hydrazine would also be present. However, there have been no 
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reports of the occurrence of this compound following hydralazine treat- 
ment until recently, when Noda et x1210 were able to demonstrate the 
presence of hydrazine in rabbit urine using a derivatisation technique. 
Hydrazine is a powerful reducing agent and is known to inhibit a 
number of enzymes211 including monoamine oxidase, 
212 the inhibition of 
which is remarkably similar to that exhibited by hydralazine towards 
aldehyde oxidase ie. a rapid progressive reduction in enzyme activity to 
zero only occurring in the presence of substrate. 
9 
Therefore, in order to determine whether hydrazine exerted any 
inhibitory effect upon aldehyde oxidase in vitro, the rate of oxidation 
of purine (8 x 10-4M) and methotrexate (5 x 10-5M) was monitored as 
described previously in the presence of 10-4M hydrazine hydrate. 
As the rate of oxidation of both substrates was unchanged 
following the addition of hydrazine to the cuvette, it was concluded 
that this compound, did not exert an inhibitory effect upon the enzyme 
and therefore was unlikely to be responsible for, or contribute to the 
reduction in the aldehyde oxidase activity observed following treatment 
with hydralazine. 
ii) 3-Methyl-s-triazolo[3,4-«]phthalazine. 
This compound is produced in vivo by the spontaneous cyclisation 
of the N-acetylated metabolite of hydralazine. 213 
N -H20 
cyclisation 
NHNHCOCH3 
\IN CHF 
N-N 
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As 3-methyl-s-triazolo[3,4-OC]phthalazine (MTP) has been reported 
0 
to be one of the major metabolites of hydralazine, this compound was 
synthesised (see Appendix 1) and tested for activity with rabbit liver 
aldehyde oxidase. 
A solution of MTP (5 x 10-5M) was scanned repeatedly between 
200-320nm following the addition of aldehyde oxidase to the cuvette. 
As there was no apparent change in the UV spectrum of the compound, it 
was concluded that MTP did not exhibit substrate activity with the 
enzyme. 
Upon monitoring the rate of oxidation of purine (5 x 10-4M) by 
aldehyde oxidase the time course of the reaction was found to be 
identical, both in the absence and presence of MTP (10-4M). 
Therefore, it appears that MTP is not an inhibitor of aldehyde 
e 
oxidase in vitro and as a 
, 
consequence is unlikely to be responsible for 
the decrease in rabbit liver aldehyde oxidase activity exhibited follow- 
ing hydralazine treatment. 
iii) Tetrazalo[5,1a ]phthalazine. 
N 
1I+ N02 º N x+ 
NHNH2 
N 
N 
NHNHNO 
cyclisation 
H2O 
N 
CQI 
N, 
N 
u N -N 
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Tetrazolo[5,10t]phthalazine has recently been identified as a 
minor product of hydralazine metabolism in humans and is believed to 
arise due to the non-enzymic reaction of hydralazine under acidic 
conditions with nitrites present in the saliva and gastro-intestinal 
tract. 214 
In view of the fact that this compound has also been found to be 
an inhibitor of monoamine oxidase in vitro, it was also synthesised 
(see Appendix 1) and tested for activity with rabbit liver aldehyde 
oxidase. 
There was no change in the absorbance spectrum of a 10-4M solution 
of tetrazolo[5,1-OC]phthalazine (the limit of solubility of the compound) 
following the addition of aldehyde oxidase to the cuvette, thus it was 
concluded that this compound was not a substrate for aldehyde oxidase. 
The effect of tetrazolo[5,1-(X]phthalazine upon the oxidation of 
substrate was investigated by monitoring the rate of oxidation of purine 
(5 x 10-4M) both in the absence and presence of this compound. However, 
as the rate of oxidation was identical in each case, it was concluded 
that tetrazolo[5,1 (X]phthalazine had no inhibitory effect upon aldehyde 
oxidase. 
s 
Interaction of other Hydrazine-Substituted N-Heterocycles with the 
0 Molybdenum Hydroxylases. 
In order to determine whether the inhibition exhibited by 
hydralazine was peculiar to phthalazine derivatives, two other 
hydrazino-substituted heterocycles were tested with both aldehyde 
oxidase and xanthine oxidase. 
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All solutions were prepared using pH 6.0 potassium phosphate 
buffer to obviate the possibility of the hydrazino-compounds undergoing 
degradation. 
0 
Substrate activity was tested for by incubating the compound in 
question with the enzyme and monitoring any changes in the UV absorption 
spectrum. 
Inhibitory activity was determined in an identical manner to that 
described for hydralazine, ie. by monitoring the change in absorbance at 
340nm of a5x 10-4M solution of methotrexate, in the presence of various 
concentrations of hydrazino derivative using aldehyde oxidase, or in the 
case of xanthine oxidase using 10-5M xanthine as substrate and following 
the-reaction at 295nm. 
i) Endralazine. 
a N, N 
CAN NHNH2 
CH3SO 
Endralazine (6-benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido- 
[4,3c] pyridazine) mesylate is a new anti hypertensive agent which has 
® similar properties to, but is pharmacologically more potent than 
hydralazine. 215 
In addition to being a hydrazine-substituted N-heterocyclic 
compound, endralazine is of interest because the pyridazine ring is 
oriented in the same way as in cinnoline (1,2-diazanaphthalene), which 
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has been found to be a substrate for aldehyde oxidase in vitro. 
6 
81 
/ N"N2 
6\I3 
Cinnoline 
54 
Cinnoline is unusual, in that unlike other N-heterocyclic 
compounds identified as substrates for aldehyde oxidase, hydroxylation 
does not. occur at the carbon Of to the ring nitrogen (ie. carbon 3) but 
at carbon 4, -which is however, the site of lowest electron density. 
In endralazine, the, hydrazine group is substituted at carbon 3 of 
the pyridazine ring, thus carbon 4 is potentially available for aldehyde 
oxidase mediated nucleophilic attack. However, this compound showed no 
substrate activity towards aldehyde oxidase. 
The effect of endralazine upon the rate of oxidation of methotrexate 
was identical to that observed in the presence of hydralazine, ie. the 
initial rate of oxidation of the substrate was unaltered but the rate 
subsequently reduced rapidly to zero. However, endralazine does not 
appear to be as potent an inhibitor as hydralazine, as the time taken 
for complete inhibition to occur was greater for the former compound, 
using equivalent concentrations of inhibitor. 
Preincubation of endralazine with the enzyme had no effect upon 
0 
the time course of the reaction and the addition of a second aliquot of 
enzyme after the rate had ceased caused it to recommence, gradually 
curving off as before. 
Consequently, it appears that whilst endralazine is not a 
substrate for aldehyde oxidase, it exerts an inhibitory effect upon the 
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enzyme similar to that exhibited by hydralazine. 
In common with hydralazine, this compound did not appear to 
0 interact with xanthine oxidase. 
ii) 1-Hydrazinoisoquinoline. 
The second compound studied was 1-hydrazinoisoquinoline, which is 
structurally very similar to hydralazine and, although not used 
clinically, is also an effective antihypertensive agent. 
207 
N 
NHNH2 
Although the parent compound isoquinoline is a substrate for 
aldehyde oxidase (Km = 1.96 x 10-4M), 
6 it seemed unlikely that 
1-hydrazinoisoquinoline , would also exhibit substrate activity towards 
the enzyme, due to the fact that carbon 1, the site at which the 
aldehyde oxidase mediated hydroxylation of isoquinoline occurs, is 
blocked by the hydrazine group and that 1-aminoisoquinoline is not a 
substrate but a competitive inhibitor of aldehyde oxidase. 206 
This was confirmed by the observation that there was no change in 
0 the absorption spectrum of the compound in the presence of aldehyde 
oxidase. 
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0 
Figure 39. Effect of 1-Hydrazinoisoquinoline Upon the Rate of Oxidation 
of Methotrexate. 
E 06 
0 
v 
co 
d 
rn 
604 
m 
V 
c 
m 
I- 0 N 
02 
C 
MTX 5x 10'5 M 
0-0+ 10'4M 1-Hyd. Isoquin. 
o -n+ 5x 10'4 M` 1- Hyd. Isoquin 
Figure 39 shows that in the presence of 1-hydrazinoisoquinoline, 
the rate of oxidation of methotrexate is rapidly reduced and ceases 
completely within five' minutes. However, unlike the effect produced by 
hydralazine and endralazine, where the initial rate of oxidation was 
unaffected by the presence of inhibitor, upon addition of 1-hydrazino- 
isoquinoline to the cuvette, the, initial rate of oxidation of substrate 
was markedly reduced. 
A similar type of inhibition was also observed when the rate of 
oxidation of a 10-3M solution of 6-methylpurine was monitored at 288nm 
in the presence of 1-hyrazinoisoquinoline. 
Furthermore, in contrast to hydralazine, an even greater reduction 
time (mins) 
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in initial rate followed by subsequent curvature was obtained when 
1-hydrazinoisoquinoline was incubated with enzyme for fifteen minutes 
prior to the addition of substrate (see Figure 40). 
0 
Figure 40. Effect of Preincubation of 1-Hydrazinoisoquinoline with 
Aldehyde Oxidase. 
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Consequently, it appears that 1-hydrazinoisoquinoline may be 
exerting its inhibitory effect upon aldehyde oxidase in two ways. 
Firstly, by interacting with the enzyme whilst it is turning over in the 
presence of substrate to cause a progressive inhibition, similar to that 
exhibited by hydralazine and also by inhibiting enzyme activity in some 
other way to cause a reduction in the initial rate of oxidation of 
substrate. 
However, as the concentration required to effect complete 
2468 10 12 
time (mins) 
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inhibition within a certain time was higher than that necessary using 
hydralazine, it appears that under identical conditions, t-hydrazino- 
isoquinoline is a less potent inhibitor than hydralazine. 
0 When the interaction of 1-hydrazinoisoquinoline with"xanthine 
oxidase was investigated, there was no apparent reduction in the rate of 
oxidation of a 10-5M solution of xanthine at 295nm, indicating that, 
like hydrazine, this compound does not exert any inhibitory effect upon 
the enzyme. However, it may also be noted that 1-aminoisoquinoline does 
not inhibit xanthine oxidase and that the parent compound isoquinoline 
is not a substrate for this enzyme. 
Whilst the results of this study show that other hydrazino- 
substituted N-heterocycles exert a similar effect to hydralazine upon 
aldehyde oxidase in vitro, it was found that isoniazid, a hydrazine 
derivative of isonicotinic acid did not exert any inhibitory effect upon 
the enzyme. 
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CONCLUSIONS. 
The work reported in this section has shown that hydralazine, a 
widely used antihypertensive agent, is a potent progressive inhibitor of 
0 
rabbit liver'aldehyde oxidase in vitro, but is without any inhibitory 
effect upon the closely related enzyme xanthine oxidase. 
Similarly, oral administration of hydralazine to rabbits resulted 
in a significant reduction in aldehyde oxidase activity, but was without 
effect upon xanthine oxidase activity. 
Whilst these results do not prove conclusively that hydralazine is 
also the active species in vivo, the lack of inhibitory activity of some 
of the metabolites of hydralazine, together with its potent effect upon 
aldehyde oxidase in vitro, suggests that hydralazine itself is probably 
responsible for the reduction in enzyme activity observed upon 
hydralazine treatment. 
Therefore, although Stubley6 reported that hydralazine exhibited 
a weak substrate activity with aldehyde oxidase and suggested that this 
enzyme may be responsible for the production of 1-hydroxyphthalazine in 
vivo as a metabolite of hydralazine, the results recorded here are 
apparently incompatible with this conclusion. 
Although the mechanism by which hydralazine exerts its inhibitory 
effect upon aldehyde oxidase in vitro is not clear, the results indicate 
that the inhibition is progressive in nature, the compound reacting with 
either the reduced form of the enzyme or with the enzyme-substrate 
complex. 
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This type of inhibition does not, however,, appear to be restricted 
solely to phthalazine derivatives, as endralazine, another hydrazine 
substituted N-heterocyclic compound exerted an identical inhibitory 
0 effect upon aldehyde oxidase in vitro. 
1-Hydrazinoisoquinoline also effected a progressive inhibition of 
the aldehyde oxidase mediated oxidation of substrate, apparently acting 
in a similar manner to hydralazine. However, as there was also a 
reduction in the initial rate of oxidation of substrate it appears that 
the inhibition exhibited by this compound may be more complex than that 
exerted by hydralazine. This could perhaps be explained if some 
impurity, eg. isoquinoline, was present in the sample of 1-hydrazino- 
isoquinoline used, although preliminary studies showed that-the compound 
had the correct melting point and ran as a single spot on a thin layer 
chromatogram. 
Hydralazine has also been found to be an effective inhibitor of a 
number of other enzymes144 and one of the ways in which it exerts its 
inhibitory effect is by chelation of metals necessary for enzyme 
activity. For example, hydralazine inhibits proline hydroxylase by 
forming labile complexes with enzyme bound Fe2+. 205 Similarly, dopamine 
ß-hydroxylase is also inhibited by this compound, which chelates Cu2+ 
necessary for the inactivation of endogenous inhibitors of the 
!r enzyme. 
216 
In view of the fact that two other commonly used metal chelating 
agents, 8-hydroxyquinoline 
15 
and 1,10-phenanthroline217 have both been 
reported to inhibit aldehyde oxidase in vitro, it is possible that the 
inhibition exhibited by hydralazine towards this enzyme may be due to 
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the chelation of enzyme bound metal, eg. Fe, Mo, necessary for catalytic 
activity. 
ýI\ 
ý N, 
OH 
8-hydroxyquinoline. 1,10-phenanthroline. 
The observation that hydralazine was only effective as an 
inhibitor of the enzyme inýthe presence of substrate could be explained 
in this context, if the metal was chelated only when in the reduced 
state. Similarly, the lack of inhibition of xanthine oxidase by this 
compound may be due to slight differences in the accessibility of the 
metal groups within the enzyme. 
If hydralazine was exerting its inhibitory effect in this way, 
forming a labile complex with the enzyme-bound metal, it might be 
expected that dialysis of the enzyme-would result in the removal of the 
chelating agent and the return of enzyme activity. 
However, assuming'that hydralazine itself is the inhibiting- 
species in vivo, the lack of activity upon purification of the aldehyde 
oxidase suggests either that the inhibitor is very tightly bound to the 
enzyme, or that -theenzyme has been permanently inactivated. in some way. 
Whilst this second option may be explained in terms of chelation, 
if the metal was completely abstracted from the enzyme molecule, the 
observation that the molybdenum content of the enzyme fractions from 
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treated and control animals was identical precludes the possibility that 
the lack of enzyme activity was due to the loss of this metal. 
It would therefore, be interesting to determine whether the 
inhibitor was firmly bound to the enzyme. This could be carried out by 
inhibiting aldehyde oxidase in vitro with 14C-labelled hydralazine and 
subsequently measuring the amount of radiolabel bound to the enzyme, or 
free in solution. 
Another means by which hydralazine is also known to exert an 
inhibitory effect upon enzymes is by hydrazone formation with available 
carbonyl groups on the enzyme molecule. 211 
N 
O=C1-1 
N 
NN 
NHNH2 NHNC 
Consequently, it is possible that when aldehyde oxidase is 
'turning over', in the presence of substrate, groups on the enzyme 
molecule may become available for this reaction to occur. 
It is also interesting to note that Antimycin A, a well-known 
inhibitor of mitochondrial electron transport,, appears to inhibit 
rabbit liver aldehyde oxidase in a similar manner to hydralazine, ie. by 
causing a rapid progressive reduction in the rate, of oxidation of 
substrate , which is unaffected by preincubation of inhibitor with the 
enzyme. Rajagopalan et a189 suggested that Antimycin A was exerting 
its inhibitory effect by attacking the reduced enzyme at a site near the 
terminal step in the electron transport sequence thus effecting a 
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conformational change to render a major portion of the electron trans- 
port chain incapable of further operation. 
However, these are only some of the ways in which hydralazine may 
0 
exert an inhibitory effect upon the enzyme and further work would be 
necessary to elucidate the mechanism of inhibition in the case of 
aldehyde oxidase. 
The fact that hydralazine is a potent inhibitor of aldehyde 
oxidase in vivo may have serious repercussions in drug therapy. As oral 
administration of hydralazine hydrochloride ( 50-100mg) to humans leads 
to circulating free hydralazine levels of 10-6M144 and in vitro 
hydralazine showed marked inhibitory activity at concentrations as low 
as 10-7M, it is possible that the metabolic profile of any compound 
whose biotransformation is mediated by aldehyde oxidase may be altered 
by the concomitant administration of hydralazine. For example, upon 
administration of methotrexate (15-45mg/kg) by bolus injection, up to 
10% of the dose is excreted as the aldehyde oxidase mediated oxidation 
product 7-hydroxymethotrexate. 
218 In view of this fact it would be 
interesting to investigate the effect of hydralazine upon the metabolism 
of methotrexate in vivo. As methotrexate is an excellent substrate for 
rabbit liver aldehyde oxidase this could be carried out by examination 
of the levels of 7-hydroxymethotrexate and methotrexate in the urine of 
a methotrexate treated rabbit following the concomitant administration 
of hydralazine and comparing with the levels obtained in the absence of 
the inhibitor. 
SECTION VII 
CONCLUSION 
Previous studies6'14 have shown that a large number of N-hetero- 
cyclic compounds are excellent substrates in vitro for aldehyde oxidase 
and xanthine oxidase. However, the relative importance of these 
enzymes, in particular aldehyde oxidase, in the metabolism, of these 
compounds in vivo has not yet been established. 
This thesis has shown that. phthalazine, which is oxidised in vitro 
to its 1-hydroxylated derivative, by both aldehyde oxidase and xanthine 
oxidase, also interacts with these enzymes in vivo. 
Metabolic studies have shown that phthalazine is readily absorbed 
from the gastro-intestinal tract, the majority of the, dose being 
excreted in the urine within twenty-four hours and in view of the fact 
that only a negligible amount of unchanged phthalazine may be detected 
in the urine it is obviously rapidly metabolised prior to excretion. 
However, the product of the aldehyde oxidase catalysed oxidation, 
1-hydroxyphthalazine, also only accounted for a small proportion of the 
total dose and when 1-hydroxyphthalazine itself was administered to 
rabbits in place of phthalazine very little unchanged compound was 
detected in the urine, indicating that this compound is subject to 
biotransformation prior to excretion. 
Therefore, although the metabolic profile of phthalazine in rabbits 
has been shown to be more complex than was initially envisaged, these 
findings suggest that the molybdenum hydroxylases may play an important 
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role in the metabolism of this compound in vivo, by first rapidly 
converting it to its 1-hydroxylated derivative, which is then further 
metabolised. 
It may be noted that when the antineoplastic drug methotrexate, 
which is an excellent substrate for rabbit liver aldehyde oxidase 
in vitro,, is administered to rabbits approximately 20-30% of the dose 
(15-45mg/kg) is excreted in the urine as the aldehyde oxidase mediated 
oxidation product, 7-hydroxymethotrexate. 
218 
However, unlike 1-hydroxyphthalazine, when 7-hydroxymethotrexate is 
administered to rabbits it is excreted unchanged, indicating that 
further biotransformation of the 7-hydroxy metabolite does not occur. 
An analogous situation also occurs in humans, where up to 10% of a 
dose of methotrexate is excreted as 7-hydroxymethotrexate and the rest 
excreted largely as unchanged methotrexate. 
Therefore, although it might be expected that phthalazine, which is 
a much simpler molecule than methotrexate, would also have a simple 
metabolic profile, this is apparently not the case. 
In addition, it appears to be less reliable to extrapolate the 
results found in one species to predict the fate of phthalazine 
0 derivatives in other species than it is with methotrexate. 
Studies170 carried out on the 1-substituted phthalazine, carbazeran, 
have shown that this compound is rapidly oxidised to its 4-hydroxylated 
derivative in vitro using aldehyde oxidase isolated from rabbit, rat and 
human liver. 
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However, in vivo the relative contributions of different drug 
metabolising enzymes differ markedly. Although 4-hydroxylation is also 
the predominant metabolic route in humans, in rabbits the situation is 
similar to that observed with phthalazine where other metabolic routes 
are also important, the major metabolite of carbazeran in rabbits being 
an N-oxide. Dogs and rats exhibit different metabolic patterns again. 
The interaction of phthalazine and its derivatives with the 
and inhibition 
molybdenum hydroxylases in vivo is further reinforced by the induct ön k 
caused by phthalazine and hydralazine respectively. 
Furthermore, there was no evidence of a change in microsomal 
activity upon-pretreatment with either of these compounds. This has 
also been found to be the case when rats were administered a similar 
concentration of hydralazine hydrochloride. 
219 
Similarly, in a recent study220 into the effect of the 1,4-diaza- 
naphthalene quinoxaline and its derivatives upon microsomal activity, it 
was found that like phthalazine, quinoxaline, did not exert any inductive 
effect. However, the methyl and phenyl derivatives of quinoxaline, 
which might be expected to have a higher lipid solubility than the 
parent compound, did increase microsomal activity. 
Upon examination of the molybdenum hydroxylases it was found that 
0 there was a significant increase in the specific activities of both 
aldehyde oxidase and xanthine oxidase following phthalazine treatment. 
In addition, administration of 1-hydroxyphthalazine to rabbits, at only 
one fifth the dose of phthalazine, resulted in at least an equivalent 
increase in enzyme activity, indicating that 1-hydroxyphthalazine itself 
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may be the true inducing agent. Whilst this theory cannot be proven 
without examination of the inductive effect of all the metabolites of 
phthalazine, it lends weight to the earlier suggestion that the 
molybdenum hydroxylases may play a significant role in the metabolism of 
phthalazine, by initially catalysing its oxidation to 1-hydroxy- 
phthalazine. 
In view of the fact that the molybdenum content of the aldehyde 
oxidase fractions increased in proportion to specific activity following 
treatment with either phthalazine or 1-hydroxyphthalazine, it may be 
postulated that true induction ie. 'de novo' synthesis of enzyme is 
occurring. However, as this observation could also be explained by a 
decreased-rate of degradation of enzyme, or due to the incorporation of 
molybdenum into pre-existing apoenzyme, further studies would be 
necessary to eliminate these possibilities. 
Although there are reports of the 'induction' of xanthine oxidase 
following treatment with substrate, it is believed that this is the 
first time that 'induction' of aldehyde oxidase activity has been 
recorded. 
Whilst phthalazine and its 1-hydroxylated derivative interact with 
both aldehyde oxidase and xanthine oxidase, substitution of a hydrazine 
group at carbon 1 of phthalazine produces an inhibitor which is specific 
0 
for aldehyde oxidase. 
Thus, hydralazine was found to be a potent progressive inhibitor of 
aldehyde oxidase in vitro, exerting its inhibitory effect by reacting 
with either the reduced form of the enzyme or with the enzyme-substrate 
complex. 
!- 
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Similarly, oral administration of hydralazine to rabbits resulted 
in a significant reduction in aldehyde oxidase activity, but was without 
effect upon xanthine oxidase activity. 
Whilst not conclusive, the lack of inhibitory activity in vitro of 
some of the metabolites of hydralazine, including hydrazine itself, 
together with the potent inhibitory effect of hydralazine upon aldehyde 
oxidase in vitro, indicates that hydralazine itself is responsible for 
the inactivation of the enzyme in vivo. 
When the inhibitory effect of two other hydrazino-substituted 
N-heterocyclic compounds, endralazine and 1-hydrazinoisoquinoline was 
investigated, it was found that these compounds also exhibited a 
progressive inhibition of aldehyde oxidase in vitro, similar to that 
observed with hydralazine. Therefore, it appears that the progressive 
inhibition exhibited by hydralazine is not peculiar to this one compound. 
In contrast, when isoniazid, a hydrazide derivative of iso- 
nicotinic acid was tested, no reduction of activity was observed, 
confirming that the presence of the hydrazine group alone is not 
sufficient to produce the inhibitory effect. 
However, it may be noted that the compounds which showed the 
progressive inhibition of aldehyde oxidase in vitro ie. hydralazine, 
endralazine and 1-hydrazinoisoquinoline all contain a hydrazine group 
substituted at the carbon atom (X to the ring nitrogen. 
1 
,N Cý I 
NHNH2 
254 
Therefore, one could speculate`that this species may be necessary 
for the inhibition to occur, although further studies on other hydrazine 
substituted N-heterocyclic compounds would be necessary to substantiate 
0 
this suggestion. 
As it appears that the first step in the metabolism of phthalazine 
may be oxidation by aldehyde oxidase to produce 1-hydroxyphthalazine, it 
would be interesting to determine the effect of hydralazine pretreatment 
on the metabolic profile of phthalazine. 
1ý 
Although isoenzymes of aldehyde oxidase have been identified in 
mouse tissues, there have been no reports of the existence of isoenzymes 
of rabbit liver aldehyde oxidase. However, iso-electric focusing 
carried out during the course of this work has indicated that the rabbit 
liver enzyme may be composed of 2 or 3 active variants. 
Moreover, it has been observed that following treatment with either 
phthalazine or 1-hydroxyphthalazine, a further band of enzyme activity 
becomes apparent upon electrofocusing, which, coupled with the 
observation that the Michaelis Menten constant for phthalazine is 
markedly reduced using enzyme isolated from pretreated rabbits, suggests 
that a form of the enzyme with a very high affinity for phthalazine may 
have been induced. 
In contrast, the electropherogram of enzyme fractions from 
hydralazine treated rabbits has shown that although 2 or 3 bands of 
protein corresponding to aldehyde oxidase are still present, none of the 
bands showed significant catalytic activity. As the in vitro results 
show that only the reduced form of the enzyme reacts with hydralazine it 
would therefore appear that aldehyde oxidase is 'turning over' in vivo. 
APPENDIX I 
SYNTHETIC METHODS 
1. Preparation of 3-Kethpl-s-triazolo[3,4 a]phthalazine. 
A mixture of hydralazine hydrochloride (1.5g, 0.0076mo1), anhydrous 
sodium acetate (1.5g, 0.018mol) and acetic anhydride (25ml) was refluxed 
for eighteen hours, cooled and the solvent removed under reduced 
pressure. The residue was titrated with chloroform (2 x 15ml), filtered 
to remove sodium acetate and the chloroform removed under reduced 
pressure. The brown oily residue was redissolved in chloroform, 
filtered, evaporated to dryness and recrystallised from ethyl acetate to 
give a white crystalline powder. 
Yield = 1.42g, 69 per cent. 
m. p. 173-174°C. Lit. 
166 
reports m. p. '174-176°C (monohydrate) 
Mass spectrum M= m/e 184 
Peak at M- 28 (loss of N2) 
2. Preparation of Tetrazolo[5,1c(]phthalazine. 
Hydralazine hydrochloride (495mg, 0.0025mo1) was dissolved, with 
warming, in 4M acetic acid (2m1). Excess of a warm concentrated 
solution of sodium nitrite (40% w/v) was''added and the-reaction product 
allowed to stand for one hour at room temperature. The solid was filtered, 
dried and recrystallised from 50% ethanol. 
Yield = 0.312g, 73 per cent 
m. p. = 208 -209°C. Lit. 
221'reports 
m. p. 209 - 210°C. 
Mass spectrum = M+ = m/e 171 
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3. Preparation of 1-Hydroxyphthalazine. 
Hydrazine hydrate (98%, 15m1) was added slowly, with stirring, to 
0-carboxybenzaldehyde (5g, 0.033mol) in water (15m1). The solution was 
allowed to stand overnight at room temperature to yield a white solid, 
which was recrystallisedifrom water. 
Yield = 3.91g, 81 per cent. 
m. p. = 183 - 1840C. Lit. 
222 reports m. p. 1840C. 
Mass spectrum M+ = m/e 146 
peaks at M- 28 (loss of CO or N2) 
m- 29 (loss of N2H) 
4. Preparation of 1-Chlorophthalazine. 
1-Hydroxyphthalazine (5g, 0.034mo1) was refluxed with phosphoryl 
chloride (15ml) for approximately two minutes, until solid began to 
separate. The mixture was shaken until precipitation was complete and 
poured with stirring into 2M sodium hydroxide (500m1) and crushed ice 
(500m1). The precipitate was filtered, washed with water and dried over 
sodium hydroxide for forty-eight hours. 
Yield = 3.6g, 64 per cent. 
M. P. = 109 - 110°C Lit. 
223 reports M. P. 109 - 111°C. 
0 
Mass spectrum M+ = m/e 165. 
5. Preparation of 1-Aminophthalazine. 
1-Chlorophthalazine (3g, 0.018mol) was heated with methanolic 
ammonia (30mis, approx. 10N) at 1600C for eight hours. The alcoholic 
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solution was evaporated under reduced pressure and the residue extracted 
into boiling water (20m1). The water was removed under reduced pressure 
and the residue dried over phosphorous pentoxide for twenty-four hours. 
0 
The solid was extracted with absolute alcohol and the extract 
evaporated to dryness. A slight excess of sodium hydroxide, dissolved 
in a minimum of hot alcohol, was added to the residue, the solution 
heated to boiling and filtered to remove sodium chloride. Evaporation 
of the ethanol gave 1-aminophthalazine which was recrystallised from 
water to give cream coloured needles. 
Yield = 3.3g, 49 per cent. 
m. p. = 209 - 210°C Lit. 
224 reports 210 - 211°C. 
Mass spectrum M+ = m/e 145. 
APPENDIX II 
MATERIALS. 
Compounds. 
Phthalazine. 
1,4-Dihydroxyphthalazine. 
Isoniazid. 
Phenanthridine. 
Xanthine. 
3-Methylisoquinoline. 
Hydralazine hydrochloride. 
14C-1-Hydralazine hydrochloride. 
Supplier. 
Aldrich Chemical Co. Ltd. 
Koch-Light Laboratories. 
ICN Pharmaceuticals Inc. (K & K) 
Sigma London Chemical, Co. Ltd. 
Amersham International. 
The following compounds were kindly donated: - 
Endralazine mesylate. by Sandoz Products Ltd. Middlesex. 
1-Hydrazinoisoquinoline. 
Methotrexate. 
by Ciba-Geigy, Basle. Switzerland. 
by The Cancer Research Unit, 
University of Bradford. 
Chromatographic Materials. 
Silica Gel. GF254 (T. L. C. Type) 
Amberlite XAD2. 
Sephadex G75. 
DEAE-Cellulose. 
Merck. 
BDH Chemicals Ltd. 
Pharmacia Fine Chemicals AB. Sweden. 
Sigma London Chemicals Ltd. 
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Biological Materials. . -"" 
Xanthine Oxidase Grade I from Buttermilk (0.5units/mg protein). 
ß -Glucuronidase. Type IX (E. -coli). 
Sulphatase. Type V (Patella Vulgata). 
Glucose-6-phosphate. (monosodium salt). 
P -NADP. (Sodium salt). 
ß -NADPH. Type X. 
all purchased from Sigma London Chemical Co. Ltd. 
0 
Electrofocusing Materials. 
Isogel Agarose. 
Ampholines. pH 4.0-6.5. 
Multiphor Gel Bond Film. 
Page Blue 83. 
Nitro blue tetrazolium Grade III. 
Phenazine Methosulphate. 
LKB Produkter. AB. Bromma Sweden. 
BDH. Chemicals Ltd. 
Sigma London Chemical Co. Ltd. 
Miscellaneous. 
Fisofluor Scintillant. Fisons. 
X-Ray Plates. Agfa-Gevaert Osray M3 (5 x 7"). 
Protein Assay Dye Reagent Concentrate. Bio-Rad Laboratories. 
Molybdenum wire (99%). Koch-Light Laboratories Ltd. 
Pyrolytically Coated graphite tubes. Pye Unicam. 
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